

**NATIONAL ADAP MONITORING PROJECT
ANNUAL REPORT
MODULE ONE**

JANUARY 2012

Prepared by

National Alliance of State & Territorial AIDS Directors (NASTAD)
Murray C. Penner
Britten Pund



ACKNOWLEDGEMENTS

The National Alliance of State & Territorial AIDS Directors (NASTAD) thanks state ADAP and AIDS program managers and staff for their time and effort in completing the National ADAP Survey, which serves as the foundation for this report, and for providing ongoing updates to inform the National ADAP Monitoring Project. NASTAD also thanks Lanny Cross, consultant, for his valuable contributions to NASTAD's ADAP Monitoring and Technical Assistance Program. Without the guidance and support from Julie Scofield, NASTAD Executive Director, this report would not be possible.

The National ADAP Monitoring Project is one component of NASTAD's National ADAP Monitoring and Technical Assistance Program which provides ongoing technical assistance to all state and territorial ADAPs. The program also serves as a resource center, providing timely information on the status of ADAPs, particularly those experiencing resource constraints or other challenges, to national coalitions and organizations, policy makers, industry members, and state and federal government agencies. NASTAD received support for the National ADAP Monitoring and Technical Assistance Program in 2011 from the following companies: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics and ViiV Healthcare. NASTAD also receives funding to provide technical assistance to ADAPs through a Training and Technical Assistance Cooperative Agreement with the Health Resources and Services Administration (HRSA).

January 2012

National Alliance of State and Territorial AIDS Directors
444 North Capitol Street, NW, Suite 339
Washington, DC 20001-1512
(202) 434-8090 (phone)
(202) 434-8092 (fax)
www.NASTAD.org

Julie M. Scofield, Executive Director
Amna Osman (Michigan), Chair

TABLE OF CONTENTS

Year in Review	3
 Detailed Findings	
ADAP Budget.....	5
ADAP Crisis.....	7
ADAP Client Enrollment and Utilization.....	7
ADAP Prescription Expenditures and Prescriptions Filled.....	8
ADAP Purchasing Models.....	9
ADAP Insurance Coordination.....	10
ADAP Eligibility Criteria.....	10
Key Dates in the History of ADAPs.....	11
Methodology.....	12
 Charts	
Chart 1: The National ADAP Budget, FY1996—FY2011.....	14
Chart 2: The National ADAP Budget, by Source, FY1996—FY2011.....	15
Chart 3: The National ADAP Budget, by Source, FY2011.....	16
Chart 4: ADAP Expenditures, FY2010.....	17
Chart 5: Number of ADAPs, by Budget Source, FY2011.....	18
Chart 6: Number of ADAPs with Funding Decreases, by Budget Source, FY2010—FY2011.....	19
Chart 7: Part B ADAP Earmark, FY1996—FY2011.....	20
Chart 8: Part B ADAP Supplemental Funding, FY2001—FY2011.....	21
Chart 9: Part B Base Contribution Directed to ADAP, FY1996—FY2011.....	22
Chart 10: Part A Contribution Directed to ADAP, FY1996—FY2011.....	23
Chart 11: State Contribution, FY1996—FY2011.....	24
Chart 12: Estimated Drug Rebates, FY1996—FY2011.....	25
Chart 13: ADAP Client Enrollment, June 2003—2011.....	26
Chart 14: ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2010.....	27
Chart 15: ADAP Client Utilization, June 1996—2011.....	28
Chart 16: ADAP Clients Served and Top Ten States, by Clients Served, June 2011.....	29
Chart 17: ADAP Clients Served, by Race/Ethnicity, June 2011.....	30
Chart 18: ADAP Clients Served, by Gender, June 2011.....	31
Chart 19: ADAP Clients Served, by Age, June 2011.....	32
Chart 20: ADAP Clients Served, by Income Level, June 2011.....	33
Chart 21: ADAP Clients Served, by Insurance Status, June 2011.....	34
Chart 22: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2011.....	35
Chart 23: ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2011.....	36
Chart 24: Percent Change in ADAP Drug Expenditures, June 1996-2011.....	37
Chart 25: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-payments), June 2011.....	38
Chart 26: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-payments), by Drug Category, June 2011.....	39
Chart 27: ADAP Average Monthly Cost Per Client, June 1996-2011.....	40
Chart 28: Clients Served and Estimated Expenditures in Insurance Purchasing and Continuation, 2011.....	41
Chart 29: ADAP Income Eligibility, as of June 30, 2011.....	42

Tables

Table 1:	The ADAP Budget, FY2010 and FY2011.....	44
Table 2:	The National ADAP Budget, by Source, FY2011.....	45
Table 3:	Major FY2011 Budget Categories Compared with FY2010.....	47
Table 4:	Growth of Federal ADAP Funding, FY2008 through FY2011.....	49
Table 5:	Growth of State Contribution to ADAP, FY2008 through FY2011.....	50
Table 6:	Growth of Estimated Drug Rebates, FY2008 through FY2011.....	51
Table 7:	Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2011.....	52
Table 8:	Total Clients Enrolled/Served and Program Expenditures, FY2010.....	53
Table 9:	Total Clients Enrolled and Served, June 2010 and June 2011.....	54
Table 10:	ADAP Clients Served, by Race/Ethnicity June 2011.....	55
Table 11:	ADAP Clients Served, by Gender, June 2011.....	56
Table 12:	ADAP Clients Served, by Age, June 2011.....	57
Table 13:	ADAP Clients Served, by Income Level, June 2011.....	58
Table 14:	ADAP Clients Served, by Insurance Status, June 2011.....	59
Table 15:	ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2011.....	60
Table 16:	ADAP Drug Expenditures (Including Purchases and Co-payments), June 2011.....	61
Table 17:	ADAP Drug Expenditures (Including Purchases and Co-payments), by Drug Category, June 2011.....	62
Table 18:	ADAP Prescriptions Filled (Including Purchases and Co-payments), June 2011.....	63
Table 19:	ADAP Prescriptions Filled (Including Purchases and Co-payments), by Drug Category, June 2011.....	64
Table 20:	ADAP Average Monthly Cost Per Client, June 2011.....	65
Table 21:	ADAP Coverage of HIV Diagnostics, June 2011.....	66
Table 22:	ADAP Drug Purchasing, June 2011.....	67
Table 23:	ADAP Prescription Distribution, June 2011.....	68
Table 24:	Federal ADAP Funds Used for and Number of Clients Served Through Insurance Purchasing and Continuation, 2011.....	69
Table 25:	ADAP Client Eligibility Requirements, as of June 30, 2011.....	70
Table 26:	ADAP Client Enrollment Processes, as of June 30, 2011.....	71
Table 27:	ADAP Management Policies in Place, as of June 30, 2011.....	72
Table 28:	HIV/AIDS Antiretroviral and Opportunistic Infection Medications	74
Glossary.....		75

MODULE ONE: YEAR IN REVIEW

ADAP's FY2011 began on April 1, 2011. Increases in ADAP client utilization and progression to more costly drug regimens, while likely resulting in important health outcomes for people living with HIV/AIDS, have led to considerable fiscal stress for many ADAPs, unable to keep pace with those demands. As a result of the nation's continued economic crisis, more Americans living with HIV are relying on public health safety net programs, including ADAP, as a vital resource for medications.

This increasing demand for services, coupled with minimal increases in federal appropriations and fluctuations in state funding, heightened national efforts focused on HIV testing and linkages into care, high drug costs, and new HIV treatment guidelines calling for earlier therapeutic treatments have caused fiscal challenges for many ADAPs as they provide services to those in need.

ADAP waiting lists reached their highest point on September 1, 2011 with 9,298 individuals eligible for ADAP in 11 states, yet unable to access services due to a waiting list. Many other ADAPs instituted other cost containment measures that impacted the provision of medications to people living with HIV/AIDS. ADAPs continue to focus on establishing program efficiencies to create long-term program sustainability, implementing effective cost-containment measures and coordinating with other payers to ensure Ryan White Program payer of last resort requirements, while still meeting the needs of people seeking services from the program.

In September 2011, ADAPs received \$40 million in emergency federal funding through the Ryan White Program to address ADAP waiting lists and other unmet ADAP needs. ADAP emergency funding allocations were made to 30 states. As a result of receipt of this funding, Alabama, Florida, Georgia, Idaho, Louisiana, Montana, North Carolina, Ohio, South Carolina, Utah, and Virginia were able to reduce the overall number of individuals on their waiting lists.

In December 2011, as part of ongoing efforts by the ADAP Crisis Task Force (ACTF) and the pharmaceutical industry to address the growing need for access to antiretroviral medicines through ADAP, the ACTF announced that it reached enhanced agreements for additional voluntary discounts and rebates on their products and/or price freezes with Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck, and ViiV Healthcare.

On World AIDS Day, President Obama announced \$35 million in new resources for ADAPs. The Health Resources and Services Administration (HRSA) is currently developing the distribution formula and mechanism for this emergency funding.

Over the course of 2011, 14 ADAPs reported an ADAP waiting list. Since that time, some ADAPs have been able to reduce the overall number of individuals on their waiting list. As states remove individuals from their waiting lists, however, they continue to add new individuals to their program. The demand for ADAP has not dwindled and ADAP waiting lists will likely plateau and grow again in the coming months. Many ADAPs are struggling, including those without any cost-containment measures currently in place, as a result of inadequate federal and state funding and are beginning to anticipate the need for cost-containment measures, and waiting lists, in the upcoming grant year (beginning April 1, 2012).

It is unclear yet how the infusion of federal funding and savings from ADAP Crisis Task Force agreements will ease the burden felt by the continued utilization increases in ADAP in 2012. It is unlikely that waiting lists and cost-containment measures will be eliminated. The need for additional state and federal funding for the program remains. Continued collaboration from all stakeholders is needed to ensure that ADAPs can thrive now, and be prepared to continue to provide necessary wrap-around services after health reform is fully implemented in 2014.

Since the Patient Protection and Affordable Care Act (PPACA) was signed into law, ADAPs have been working to implement and preparing for areas of the law that directly impact them. Portions of health reform that impact ADAPs include:

- Medicaid eligibility expansion in 2014 and the expansion of the CMS Section 1115 Waiver;
- Increase in the number of individuals covered by insurance plans, including health exchanges in 2014, and the current Pre-existing Condition Insurance Plans (PCIPs);
- ADAPs' Medicare Part D expenditures counting toward True Out Of Pocket (TrOOP) expenditures;
- Narrowing and closing of the Medicare Part D "doughnut hole;"
- An increase in the Medicaid rebate amount for purchased drugs; and
- 340B pricing transparency.

These changes will lead to increased comprehensive care for ADAP clients and should result in fiscal relief for ADAPs. ADAPs have been working to build the infrastructure necessary to implement the provisions noted above. NASTAD will provide an update on implementation of these provisions in Module Two of the National ADAP Monitoring Project *Annual Report* in Spring 2012.

MODULE ONE: DETAILED FINDINGS

AIDS Drug Assistance Programs (ADAPs) provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, Guam, the Northern Mariana Islands, Republic of Palau and the Republic of the Marshall Islands. In addition, some ADAPs provide insurance continuation and Medicare Part D and Medicaid wrap-around services to eligible individuals. ADAPs are a component of the federal Ryan White Part B Program that provides necessary medical and support services to low income, uninsured and underinsured individuals living with HIV/AIDS in all states, territories and associated jurisdictions.

The *Annual Report* of NASTAD's National ADAP Monitoring Project is based on a comprehensive survey of all ADAPs. This 17th release of the *Annual Report* updates prior findings with data from ADAP's fiscal year 2011¹ as well as provides a detailed snapshot of data from the month of June 2011. This module of the *Annual Report* reflects the latest available data and discusses recent policy and programmatic changes affecting ADAPs.

To provide interested stakeholders with more timely information, NASTAD is releasing the 2012 National ADAP Monitoring Project *Annual Report* in several modules. Detailed information related to ADAP budgets, client enrollment and utilization, client demographics, prescription distribution and payment methods, expenditures and prescriptions filled, insurance coordination, program eligibility, and program management and administration are included in this module (Module One). Module Two, to be released in spring 2012, will include detailed information on ADAP coordination with Medicare Part D, ADAP coordination with Pre-existing Condition Insurance Plans (PCIPs) and ADAP coordination with the CMS Section 1115 Waiver process. Module Three will highlight hepatitis treatments. The three modules will be combined into a final, comprehensive report.

A comprehensive survey was sent to all 58 jurisdictions² that received federal ADAP earmark funding in FY2011; 52 responded (see Methodology on page 12). Most data included in this report are from FY2011 and June 2011, unless otherwise noted. Detailed findings from the survey are included below. Tables and charts depicting the data follow the detailed findings and a glossary of key terms used throughout this report is also included.

ADAP BUDGET

The national ADAP budget grew to \$1.88 billion in FY2011, an increase of approximately \$100 million (5%) over FY2010.³ Since FY1996, the budget has grown nine-fold. While the ADAP earmark continues to represent the largest share of the budget, it no longer drives budget growth, as it did early on in the program's history (see Charts 1-12 and Tables 1-7).

- In FY2011, the ADAP earmark was \$813 million. The earmark was one-quarter of the national ADAP budget in FY1996, the year it was created, rose to more than two-thirds (68%) of the budget in FY2000 and has most recently declined as a share of the overall budget to less than half (43%) in FY2011 (see Chart 7).
- ADAP Supplemental Drug Treatment Grants (36 states in FY2011) accounted for 2% (\$42.2 million) of the overall ADAP budget, and increased by less than \$500,000 between FY2010 and FY2011 following a four-fold increase between FY2006 and FY2007 (as a result of changes in the Ryan White law, including an increase in the supplemental set-aside) (see Chart 8). This minimal increase in FY2011 and more states eligible and applying for ADAP supplemental funding resulted in smaller distributions of these grants to all eligible states. ADAP Supplemental Drug Treatment

Grants are, by law, a five percent set-aside from the ADAP earmark and represent a portion of the overall federal contribution.

- Transfers to ADAP by states from their Part B “base” awards accounted for 1% (\$27.5 million) of the overall budget in FY2011.
- Transfers to ADAP by states from their Part B Supplemental funding accounted for less than 1% (\$7.4 million) of the overall budget in FY2011.
- In September 2011, ADAPs received \$40 million to address ADAP waiting lists and other unmet ADAP needs. ADAP emergency funding awards were made to 30 states, with funding amounts ranging from \$74,324 in North Dakota to \$6.9 million in Florida.
- Transfers to ADAP from Part A jurisdictions represented \$16.4 million or 1% of the ADAP budget in FY2011.
- State contributions accounted for \$306 million, or 16% of the overall ADAP budget in FY2011, an increase of 9% over FY2010.
- Drug rebates accounted for \$618.9 million, or 33%, of the overall ADAP budget in FY2011. Drug rebates have risen from 6% of the budget in FY1996 to 33% in FY2011 (see Chart 12). ADAPs must actively seek drug rebates and, while not all ADAPs do so (because of varying state drug purchasing mechanisms), drug rebates accounted for a quarter or more of the ADAP budget in 26 states. This funding represents money that is returned to the state as a result of active filing of rebate claims with manufacturers based on past drug purchases.⁴
- ADAP budget composition varies by state. The federal earmark is provided to all eligible jurisdictions (58 in FY2011) based on a formula of living HIV (non-AIDS) and AIDS cases. The remaining federal funds are either awarded on a competitive basis or allocated as a result of demonstrated need. The breakdown of other sources of funding across the country is as follows (among 52 ADAPs reporting data) (see Chart 5 and Table 2):
 - Part B ADAP Supplemental Treatment Grants: 36 ADAPs were eligible and applied for, and received, funding;
 - Part B Base Funds: 27 ADAPs received these transfer of funds, 25 did not;
 - Part B Supplemental Funds: 27 ADAPs received transfer of these funds, 25 did not;
 - Emergency Funds: 30 ADAPs received funding, 28 did not;
 - Part A Funds: 8 ADAPs received transfer of these funds, 44 did not;
 - State Contributions: 37 ADAPs received funding, 15 did not;
 - Drug Rebates: 41 ADAPs received funding, 11 did not;
 - Other State/Federal Funds: 11 received funding, 41 did not.
- While most ADAPs had increases in their budgets between FY2010 and FY2011, some had overall decreases or reductions in specific funding streams (see Chart 6 and Tables 1 and 3)⁵:
 - Overall Budget: 40 ADAPs had increases or level funding, 12 had decreases;
 - Part B ADAP Earmark Funds: 57 ADAPs had increases or level funding, 1 had a decrease;
 - Part B ADAP Supplemental Drug Treatment Grants: 9 ADAPs had increases, 27 had decreases;
 - Part B Base Funds: 18 ADAPs had increases or level funding, 16 had decreases;
 - Part B Supplemental Funds: 7 ADAPs had increases or level funding, 26 had decreases;
 - ADAP Emergency Funding: 30 had increases, 2 had decreases;
 - Part A Funds: 6 ADAPs had increases or level funding, 7 had decreases;

- State Contributions: 24 ADAPs had increases or level funding, 14 had decreases;
 - Drug Rebates: 34 ADAPs had increases or level funding, 10 had decreases.
- While not counted as an ADAP budget category in this report (due to its high variability and significant delays in receipt of funds), “cost recovery” for medications purchased through ADAP (other than drug rebates), represented \$52 million in FY2011. Private insurance recovery, in which an ADAP receives reimbursement from insurance providers, was the largest component of all cost recovery sources (78%). Cost recovery from Medicaid represented 18% of this funding and other sources represented 4% (see Table 7).
 - In FY2010, ADAPs expended \$1.5 billion on prescription drugs, representing 82% of all ADAP expenditures. Insurance premiums, deductibles, and co-payments represented 13% of ADAP expenditures. Two percent of ADAP funds were expended for program administration costs (see Chart 4 and Table 8).

ADAP CRISIS

NASTAD continues to pursue a coordinated strategy to help save ADAPs. This three-pronged approach includes securing additional resources for ADAPs from the federal government; maintaining, restoring, and increasing resources for ADAPs from state governments; and, continuing agreements between ADAPs and pharmaceutical manufacturers to provide financial stability and augment existing agreements, when applicable (see Tables 4, 5 and 6).

- From FY2008 to FY2011, federal ADAP funding (including Part B ADAP Earmark, Part B ADAP Supplemental and ADAP Emergency Funding) increased 10%.
- From FY2008 to FY2011, state contributions to ADAP decreased 7%.
- From FY2008 to FY2011, estimated drug rebates increased 83%.

ADAP CLIENT ENROLLMENT AND UTILIZATION

ADAP client enrollment and client utilization reached their highest levels in FY2011. ADAPs primarily serve low-income, uninsured clients, most of whom are minorities. Client demographics have remained fairly constant over time, although there are significant variations by state and region.

- During FY2010, 226,419 clients were enrolled in ADAPs nationwide, including 32,522 new clients enrolled throughout the year (see Chart 14). Client enrollment ranged from 104 in North Dakota to 41,179 in California in FY2010. Typically, fewer clients are served in ADAPs than are enrolled at any given time—ADAPs served 217,905 clients in FY2010 (see Table 8).
- ADAPs provided medications to 138,173 clients across the country in June 2011. Client utilization in June 2011 increased by 2% between June 2010 and June 2011 (see Table 9).
- Mirroring the national epidemic, most ADAP clients are concentrated in states with the highest number of people living with HIV. Ten states accounted for 63% (142,031 clients) of total enrollment in FY2010; five states accounted for 47% (California, New York, Texas, Florida, and New Jersey) of total FY2010 enrollment (see Chart 14). The distribution is similar for clients served in June 2011 (see Chart 16).
- In June 2011, client demographics were as follows:
 - African Americans and Hispanics represented 59% (32% and 27%, respectively) of clients served. Non-Hispanic whites comprised 35% of clients served. Combined, Asians, Native

Hawaiian/Pacific Islanders, and Alaskan Native/American Indians represented approximately 3% of the total ADAP population. Multi-racial ADAP clients represented 1% of the total ADAP population (see Chart 17 and Table 10).

- More than three-quarters (78%) of ADAP clients were men (see Chart 18 and Table 11).
- Almost half of clients (43%) were between the ages of 25 and 44 (see Chart 19 and Table 12). For the first time since the ADAP Monitoring Project began, those between the ages of 45 and 64 represented 50% of clients served by ADAP.
- Three-quarters (78%) of clients had income levels at or below 200% of the Federal Poverty Level (FPL) (see Chart 20 and Table 13). In 2011, the FPL was \$10,830 annually (slightly higher in Alaska and Hawaii) for a family of one.
- A majority of ADAP clients (60%) were uninsured. Twenty-one percent had private insurance, 15% Medicare, 10% Medicaid, 6% were dual beneficiaries of both Medicaid and Medicare, and 2% were enrolled in a pre-existing condition insurance plan (PCIP) (see Chart 21 and Table 14). For clients with other sources of coverage, ADAPs provide wrap-around assistance, such as paying client cost-sharing requirements (i.e., premiums, deductibles, and co-payments) and/or providing additional medications for those clients who may be subject to monthly or annual prescription drug limits under their other form(s) of coverage.
- CD4 count information of clients was reported by 32 ADAPs and reflects clients enrolled in ADAPs over the last 12 months or the most recent 12 months for which data are available. Almost half of ADAP clients (43%) had CD4 counts of 350 or below (at time of enrollment or at recertification), one potential indication of more advanced HIV disease for ADAP clients (see Chart 22 and Table 15).

ADAP PRESCRIPTION EXPENDITURES AND PRESCRIPTIONS FILLED

Drug spending and utilization have increased over time, but actually decreased from FY2010 to FY2011. The distribution of drug expenditures and prescriptions varies across the country, reflecting differing formularies, drug prices and prescribing patterns. Antiretrovirals, the standard of care for HIV, account for the majority of ADAP drug expenditures and prescriptions filled.

- ADAP drug expenditures were \$135,138,130 in June 2011, ranging from a low of \$13,837 in New Mexico, which heavily relies on insurance purchasing for client coverage, to a high of \$40.3 million in California (see Table 16). Ten states accounted for 78% (\$105,980,821) of all drug spending; five states (California, New York, Texas, Puerto Rico and Florida) accounted for almost two-thirds (64%) of all drug spending (see Chart 23).
- Drug spending by ADAPs has increased more than nine-fold (806%) since 1996, almost three times the rate of client growth over this same period (341% increase between 1996 and 2011). Between June 2010 and June 2011, drug expenditures decreased 8% (see Chart 24). Reasons for this decrease likely include the impact of price reductions as a result of ADAP Crisis Task Force negotiations in May 2010, the implementation of health reform which mandated an additional 8% reduction in rebates and a shifting of expenditures to insurance premiums. In addition, data is from a one-month snapshot and may be subject to one-time only events or changes that could in turn appear to impact trends.
- The average monthly cost per client served by ADAP was \$869 in June 2011. This represents an 8% decrease in average monthly cost per client since June 2010 (\$949). Estimated annual per client expenditures were \$10,428 (see Chart 27 and Table 20).⁶ In states that purchase via a pharmacy network (rebate) model, average monthly cost per client does not include rebates on expenditures, which would reduce the cost paid for prescriptions and, therefore, the average cost per client. States must actively file for rebates with manufacturers on past drug purchases.

- In June 2011, the average expenditure per prescription was \$303, compared to \$325 in June 2010, representing a 7% decrease. Average expenditures per prescription was significantly higher for antiretrovirals (\$464) than non-antiretrovirals (\$74 for "A1" OIs and \$63 for all other drugs).
- ADAPs filled a total of 445,202 prescriptions in June 2011 (see Chart 25 and Table 18), representing a decrease of 1% compared to June 2010 (451,148 prescriptions filled). Reasons for this decrease likely include more clients utilizing combination antiretrovirals which count (in most states) as only one medication as opposed to their individual component parts. As well, data is from a one-month snapshot and may be subject to one-time only events or changes that could in turn appear to impact trends.
- Most ADAP drug spending is on FDA-approved HIV antiretrovirals⁷ (92% in June 2011). The 31 "A1" drugs highly recommended for the prevention and treatment of HIV-related opportunistic infections (OIs)^{8,9} accounted for 2% of expenditures and 7% of prescriptions filled. All other drugs (including medications for depression, hypertension and diabetes), accounted for 7% of drug expenditures, but 34% of prescriptions filled (see Chart 26 and Tables 17 and 19).
- ADAPs continue to purchase or continue insurance and pay for co-pays and deductibles on behalf of ADAP clients as a "wrap-around" of existing other payer sources. A subset of overall drug expenditures, ADAP payment of co-payments was 4% of overall drug purchases (a decrease from 5% in June 2010) (see Table 16). In June 2011, 22% of all prescriptions filled were co-payment expenditures (an increase from 21% in June 2010) (see Table 18).

ADAP PURCHASING MODELS

The federal 340B Drug Discount Program, authorized under the Veterans Health Care Act of 1992, enables ADAPs to purchase drugs at or below the statutorily defined 340B ceiling price. All ADAPs participate in the 340B program (see Table 22). ADAPs may purchase drugs directly from wholesalers at 340B (or sub-340B) prices ("direct purchase ADAPs"), through retail pharmacy networks at a higher than 340B price ("rebate ADAPs"), as a direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs ("hybrid ADAPs"), or as a combination of a direct purchase and rebate ADAP ("dual purchaser"). For rebate states, ADAPs then submit rebate requests to drug manufacturers, maintaining compliance with the 340B price requirement. Direct purchase ADAPs can also choose to participate in the HRSA Prime Vendor Program created by the federal government to negotiate pharmaceutical pricing below the 340B price.

- Nine ADAPs reported only purchasing directly from wholesalers; nine also participated in the HRSA Prime Vendor Program.
- Twenty-four ADAPs reported only purchasing through a pharmacy network and then seeking rebates.
- Five ADAPs reported purchasing through a hybrid model.
- Sixteen ADAPs reported purchasing through a dual model – both purchasing directly from wholesalers and seeking rebates.
- The District of Columbia participates in the 340B program, but is able to purchase most of its medications through the Department of Defense, allowing it to access the Federal Ceiling Price, a lower price only available to certain federal purchasers. Several other states that participate in the 340B program also have state laws regarding negotiation processes that result in lower prices.

- NASTAD's [ADAP Crisis Task Force](#) (ACTF) negotiates directly with manufacturers for pharmaceutical pricing below the 340B price on behalf of both rebate and direct purchase ADAPs. When such agreements are reached, they are provided to all states. There are currently agreements in place with all manufacturers of antiretroviral medications and with several other companies that manufacture other high-cost medications. In November 2011, recognizing the current fiscal ADAP crisis, the ACTF worked with antiretroviral manufacturers to reduce ADAPs' antiretroviral costs by an additional \$142 million from January 2012 through December 2013. Many of the agreements also include price freezes which have helped to reduce ADAP expenditures. The cumulative savings of the Task Force agreements from 2003 to 2011 is estimated at more than \$1.3 billion. NASTAD provides logistical support to the ACTF.

ADAP INSURANCE COORDINATION

The Ryan White Program allows states to use ADAP earmark dollars to purchase health insurance and pay insurance premiums, co-payments and/or deductibles for individuals eligible for ADAP, provided the insurance has comparable formulary benefits to that of the ADAP.^{10,11} States are increasingly using ADAP funds for this purpose.

- Forty-four ADAPs reported using funds for insurance purchasing/continuation in 2011 representing \$268 million in estimated expenditures in FY2011. ADAPs reported spending over \$22.6 million on insurance purchasing/continuation in June 2011 (see Table 24).
- In June 2011, 41,085 ADAP clients were served by such arrangements (see Chart 28 and Table 24). Clients served through insurance coordination increased by 20% from June 2010 (34,341 clients served).
- Spending on insurance purchasing/continuation represented an estimated \$551 per capita in June 2011, about 63% of the average monthly cost per client, based on overall drug expenditures, in that month (\$869).

ADAP ELIGIBILITY CRITERIA

The Ryan White Program requires all ADAP clients to be HIV-positive as well as low-income and uninsured or underinsured, but each ADAP determines its own income eligibility criteria. This determination is made by targeting those who may not qualify for other low-income programs, such as Medicaid, and by determining how many clients their program can serve given annual ADAP budgets. As a result of these factors, eligibility criteria vary by state, although some ADAPs set their eligibility criteria consistent with other health programs within their state (see Chart 29 and Table 25).

- All ADAPs require that individuals provide clinical documentation of HIV infection. Six ADAPs reported additional clinical eligibility criteria (e.g., specific CD4 counts or viral load levels).
- ADAP income eligibility in June 2011 ranged from 200% FPL in ten states to 500% FPL in five. Overall, 21 states set income eligibility at greater than 300% FPL. Twenty-two states were between 201% and 300% FPL (see Chart 29 and Table 25). In addition to using income to determine eligibility, 13 ADAPs reported having asset limits in place in June 2011 (see Table 25).
- All ADAPs require enrollees to be residents of the state in which they are seeking medications. Many ADAPs require documentation of residency and a few have specific residency requirements (e.g., must be a resident for 30 days) (see Table 25).

KEY DATES IN THE HISTORY OF ADAPS

- 1987:** First antiretroviral (AZT, an NRTI) approved by the FDA; Federal government provides grants to states to help them purchase AZT, marking beginning of federally funded, state-administered “AZT Assistance Programs.”
- 1990:** ADAPs incorporated into Title II of the newly created Ryan White CARE Act.
- 1995:** First protease inhibitor approved by FDA, and the highly active antiretroviral therapy (HAART) era begins.
- 1996:** First reauthorization of CARE Act—federal ADAP earmark created; first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved by FDA.
- 2000:** Second reauthorization of CARE Act. Changes for ADAPs include: allowance of insurance purchasing and maintenance; flexibility to provide other limited services (e.g., adherence support and outreach); and creation of ADAP supplemental grants program.
- 2003:** NASTAD’s ADAP Crisis Task Force formed to negotiate with pharmaceutical companies on pricing of antiretroviral medications; first fusion inhibitor approved by FDA.
- 2004:** President’s ADAP Initiative (PAI) announced, allocating \$20 million in one-time funding outside of the ADAP system to reduce ADAP waiting lists in 10 states.
- 2006:** Third reauthorization of the CARE Act, now called, “Title XXVI of the PHS Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2006” or the “Ryan White Program.” Changes for ADAP include: new formula for determining state awards, which incorporates living HIV and AIDS cases; new minimum formulary requirement; and an increase in the ADAP Supplemental set-aside and changes in eligibility and matching requirements.
- 2007:** New minimum formulary requirement effective July 1; first CCR5 antagonist and integrase inhibitor approved by FDA.
- 2009:** Fourth reauthorization of the Ryan White Program. The reauthorization was for four years and included several technical changes.
- 2010:** Patient Protection and Affordable Care Act (PPACA) signed into law. ADAP emergency funding announced by the Obama Administration, allocating \$25 million in funding to address ADAP waiting lists and cost-containment measures.
- 2011:** ADAP emergency funding continued at \$40 million. In December 2011, President Obama announced an additional \$35 million for ADAPs to address ADAP waiting lists and cost containment measures.

METHODOLOGY

Since 1996, NASTAD's National ADAP Monitoring Project has surveyed all jurisdictions receiving federal ADAP earmark funding through the Ryan White Program. In FY2011, 58 jurisdictions received earmark funding and were surveyed; 52 responded. American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Republic of Palau, and U.S. Virgin Islands did not respond; these jurisdictions represent less than one percent of estimated living HIV and AIDS cases.

The annual survey requests data and other program information for a one-month period (June), the current fiscal year, and other periods as specified. After the survey is distributed, NASTAD conducts extensive follow-up to ensure completion by as many ADAPs as possible. Data used in this report are from June 2011 and FY2011, unless otherwise noted.

All data reflect the status of ADAPs as reported by survey respondents. It is important to note that some program information may have changed between data collection and this report's release. Due to differences in data collection and availability across ADAPs, some are not able to respond to all survey questions. Where trend data are presented, only states that provided data in relevant periods are included. In some cases, ADAPs have provided revised program data from prior years and these revised data are incorporated where possible. Therefore, data from prior year reports may not be comparable for assessing trends. It is also important to note that data from a one-month snapshot may be subject to one-time only events or changes that could in turn appear to impact trends; these are noted where information is available. Data exceptions specific to a particular jurisdiction are provided in the notes section on relevant charts and tables.

CHARTS AND TABLES

Charts for each major finding and tables, with data provided by state, are included in the full report.

¹ FY2011 refers to ADAP fiscal year 2011 and encompasses data from April 1, 2011 through March 31, 2012.

² For the purposes of this *Report*, "jurisdiction" or "state" refers to all entities that receive a federal ADAP earmark award.

³ For purposes of determining the overall ADAP budget, federal, state and drug rebate funds are counted.

⁴ The Ryan White Program requires that rebate funds, once received, remain in the Ryan White Part B program. This funding is considered a part of the national ADAP budget as it facilitates additional drug purchases and thus drives overall program expenditures.

⁵ This section contains all jurisdictions that received an increase in funding (either new funding or an increase in existing funding), level funding, or a decrease in existing funding (either eliminating a funding category or a reduction in the amount of funding received from a source) in FY2011.

⁶ This estimate is based on annualizing June 2010 average monthly cost per client. It is important to note that June 2010 expenditures may not be representative of monthly expenditures overall.

⁷ U.S. Food and Drug Administration, "Drugs Used in the Treatment of HIV Infection." Available at: <http://www.fda.gov/oashi/aids/virals.html> (accessed April 15, 2011).

⁸ Centers for Disease Control and Prevention, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." *MMWR* 2002; 51(RR08): 1-46. Available at: <http://www.aidsinfo.nih.gov/> (accessed April 15, 2011).


⁹ Centers for Disease Control and Prevention, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." *MMWR* 2004; 53(RR15): 1-112. Available at: <http://www.aidsinfo.nih.gov/> (accessed April 15, 2011).

¹⁰ Health Resources and Services Administration, HIV/AIDS Bureau, Policy Notice 07-05, "The Use of Ryan White HIV/AIDS Program Part B ADAP Funds to Purchase Health Insurance."

¹¹ Health Resources and Services Administration, HIV/AIDS Bureau, DSS Program Policy Guidance No. 2, "Allowable Uses of Funds for Discretely Defined Categories of Services," Formerly Policy No. 97-02, First Issued: February 1, 1997, June 1, 2000.

MODULE ONE: CHARTS

Chart 1: The National ADAP Budget, FY1996-FY2011



Note: The total FY2010 budget includes federal and state allocations as well as drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget. Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 2: The National ADAP Budget, by Source, FY1996-FY2011






Chart 3: The National ADAP Budget, by Source, FY2011



Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. The total FY2010 budget does not include cost recovery funds, with the exception of drug rebate dollars.


Chart 4: ADAP Expenditures, FY2010



Total = \$1.86 billion


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 5: Number of ADAPs, by Budget Source, FY2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Chart 6: Number of ADAPs with Funding Decreases, by Budget Source, FY2010-FY2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Chart 7: Part B ADAP Earmark, FY1996-FY2011




Note: ADAP earmark does not include ADAP Supplemental Fund set-aside from FY2001-2011. Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 8: Part B ADAP Supplemental Funding, FY2001-FY2011




Note: All Part B ADAP supplemental funds are reported. Percentages represent changes between the two years indicated, not aggregate changes since FY2001. The 2006 reauthorization of the Ryan White Program raised the percentage allocated to the ADAP supplemental from three percent to five percent of the ADAP Earmark, beginning in FY2007.

Chart 9: Part B Base Contribution Directed to ADAP, FY1996-FY2011




Note: Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 10: Part A Contribution Directed to ADAP, FY1996-FY2011




Note: Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 11: State Contribution, FY1996-FY2011




Note: Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 12: Estimated Drug Rebates, FY1996-FY2011




Note: Percentages represent changes between the two years indicated, not aggregate changes since FY1996.

Chart 13: ADAP Client Enrollment, June 2003-2011



Note: Includes clients enrolled by ADAPs reporting data for June in a given year. Data on client enrollment in ADAP is not available prior to June 2003. Percentages represent changes between the two years indicated, not aggregate since 2003.

Chart 14: ADAP Clients Enrolled and Top Ten States, by Clients Enrolled, FY2010



State	Clients Enrolled, FY2010
California	41,179
New York	23,965
Texas	17,015
Florida	15,975
New Jersey	8,259
Illinois	7,792
Massachusetts	7,527
Maryland	7,075
Pennsylvania	6,653
North Carolina	6,591
Total	142,031

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 15: ADAP Client Utilization, June 1996-2011






Chart 16: ADAP Clients Served and Top Ten States, by Clients Served, June 2011



State	Clients Served, June 2011
California	26,586
New York	15,811
Texas	10,959
Florida	8,396
New Jersey	6,086
Puerto Rico	4,617
Pennsylvania	4,299
Massachusetts	4,285
Illinois	4,097
Maryland	4,071
Total	85,136


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 17: ADAP Clients Served, by Race/Ethnicity, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. Percentages may not total 100% due to rounding.

Chart 18: ADAP Clients Served, by Gender, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. Percentages may not total 100% due to rounding.

Chart 19: ADAP Clients Served, by Age, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. Percentages may not total 100% due to rounding.

Chart 20: ADAP Clients Served, by Income Level, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. Percentages may not total 100% due to rounding. The 2010 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one.

Chart 21: ADAP Clients Served, by Insurance Status, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. The overall percentage of clients in each category is calculated separately based on reported data.

**Chart 22: ADAP Clients by CD4 Count,
Enrolled During 12-Month Period, June 2011**



Note: 32 ADAPs reported data.


Chart 23: ADAP Drug Expenditures and Top 10 States, by Drug Expenditures, June 2011



State	Drug Expenditures, June 2011
California	\$40,300,136
New York	\$22,785,301
Texas	\$8,607,353
New Jersey	\$7,833,884
Florida	\$6,904,709
Pennsylvania	\$6,621,533
Illinois	\$4,090,859
Georgia	\$3,208,840
North Carolina	\$2,882,508
Maryland	\$2,745,698
Total	\$105,980,821


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 24: Percent Change in ADAP Drug Expenditures, June 1996-2011




Note: Percentages represent changes between the two years indicated, not aggregate since 1996.

Chart 25: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-Payments), June 2011




Total = \$135.1 million



Total = 445,202 prescriptions (Rx) filled


Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 26: ADAP Drug Expenditures and Prescriptions Filled (Including Drug Purchases and Co-Payments), by Drug Category, June 2011




Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data.

Chart 27: ADAP Average Monthly Cost Per Client, June 1996-2011




Note: Includes average monthly cost per client based on drug expenditures and clients served by ADAPs reporting data for June in a given year.

Chart 28: Clients Served and Estimated Expenditures in Insurance Purchasing and Continuation, 2011



Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data. Health insurance programs include purchasing health insurance and paying insurance premiums, co-payments, and/or deductibles. Client data for June 2002 and 2003 represent clients enrolled; June 2004-2011 data represent clients served. All ADAPs that have reported having insurance purchasing/maintenance programs since 2002 are included.

Chart 29: ADAP Income Eligibility, as of June 30, 2011



Note: 52 ADAPs reported data. American Samoa, Federated States Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report data. The 2011 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one.

MODULE ONE: TABLES

Table 1: The ADAP Budget, FY2010 and FY2011

State/Territory	ADAP FY2010 Total Budget	ADAP FY2011 Total Budget	% Change
Alabama	\$16,222,907	\$17,725,286	9%
Alaska	\$740,249	\$645,578	-13%
American Samoa	\$2,663	\$2,663	0%
Arizona	\$14,617,786	\$15,794,695	8%
Arkansas	\$5,181,690	\$8,368,433	62%
California	\$436,930,287	\$452,181,453	3%
Colorado	\$16,360,124	\$23,380,197	43%
Connecticut	\$21,609,270	\$23,567,283	9%
Delaware	\$3,983,575	\$6,562,038	65%
District of Columbia	\$15,702,218	\$16,432,779	5%
Federated States of Micronesia	\$8,186	\$8,186	0%
Florida	\$103,943,567	\$114,427,754	10%
Georgia	\$49,898,649	\$49,349,266	-1%
Guam	\$86,530	\$86,530	0%
Hawaii	\$3,600,388	\$3,758,420	4%
Idaho	\$3,433,951	\$3,571,340	4%
Illinois	\$55,128,599	\$52,198,030	-5%
Indiana	\$18,217,385	\$21,091,935	16%
Iowa	\$3,483,963	\$3,584,364	3%
Kansas	\$6,939,308	\$9,858,934	42%
Kentucky	\$12,546,932	\$10,222,985	-19%
Louisiana	\$23,535,439	\$20,012,105	-15%
Maine	\$1,303,839	\$1,636,209	25%
Marshall Islands	\$0	\$0	--
Maryland	\$56,428,342	\$59,338,057	5%
Massachusetts	\$19,801,813	\$25,546,195	29%
Michigan	\$32,704,231	\$32,843,704	0%
Minnesota	\$12,072,941	\$12,165,439	1%
Mississippi	\$7,533,479	\$6,507,264	-14%
Missouri	\$24,825,045	\$28,280,709	14%
Montana	\$968,851	\$1,099,162	13%
Nebraska	\$2,700,188	\$2,579,023	-4%
Nevada	\$11,530,315	\$12,857,572	12%
New Hampshire	\$2,986,545	\$3,603,521	21%
New Jersey	\$85,852,566	\$82,498,782	-4%
New Mexico	\$2,150,993	\$2,199,786	2%
New York	\$276,605,700	\$283,500,000	2%
North Carolina	\$53,945,002	\$57,516,959	7%
North Dakota	\$289,092	\$603,816	109%
Northern Mariana Islands	\$7,276	\$8,845	22%
Ohio	\$23,584,068	\$28,280,821	20%
Oklahoma	\$9,251,755	\$10,321,074	12%
Oregon	\$18,724,367	\$11,240,296	-40%
Pennsylvania	\$74,130,521	\$70,193,736	-5%
Puerto Rico	\$27,479,715	\$32,034,454	17%
Republic of Palau	\$0	\$2,654	--
Rhode Island	\$6,627,964	\$9,986,489	51%
South Carolina	\$23,719,514	\$27,856,243	17%
South Dakota	\$545,055	\$429,263	-21%
Tennessee	\$27,659,608	\$30,430,298	10%
Texas	\$91,990,332	\$102,383,814	11%
Utah	\$5,136,619	\$7,182,640	40%
Vermont	\$1,032,356	\$1,162,356	13%
Virgin Islands (U.S.)	\$1,418,387	\$821,138	-42%
Virginia	\$25,392,593	\$29,297,638	15%
Washington	\$28,971,114	\$35,327,625	22%
West Virginia	\$3,806,301	\$3,879,033	2%
Wisconsin	\$14,365,086	\$17,370,799	21%
Wyoming	\$1,277,312	\$1,948,952	53%
Total	\$1,788,992,551	\$1,885,764,620	
Comparison Total¹	\$1,788,992,551	\$1,885,761,966	5%

¹ *Comparison Totals* are based on only those states that reported data for both time periods.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. The total FY2011 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget.

Table 2: The National

State/Territory	Part B ADAP Earmark	% of Total Budget	Part B ADAP Supplemental ¹	% of Total Budget	Part B Base Contribution Directed to ADAP	% of Total Budget	Part B Supplemental Directed to ADAP	% of Total Budget
Alabama	\$9,677,468	55%	\$745,200	4%	\$1,500,000	8%	\$82,000	0%
Alaska	\$589,363	91%	\$44,817	7%	\$5,699	1%	\$5,699	1%
American Samoa	\$2,663	100%	\$0	0%	--	--	--	--
Arizona	\$10,674,315	68%	\$821,961	5%	\$0	0%	\$0	0%
Arkansas	\$4,415,494	53%	\$340,009	4%	\$3,569,175	43%	\$0	0%
California	\$103,750,158	23%	\$8,028,154	2%	\$0	0%	\$1,376,784	0%
Colorado	\$9,731,767	42%	\$747,312	3%	\$0	0%	\$104,962	0%
Connecticut	\$10,972,770	47%	\$0	0%	\$0	0%	\$0	0%
Delaware	\$3,146,550	48%	\$0	0%	\$0	0%	\$0	0%
District of Columbia	\$15,257,867	93%	\$1,174,912	7%	\$0	0%	\$0	0%
Federated States of Micronesia	\$8,186	100%	\$0	0%	--	--	--	--
Florida	\$86,207,390	75%	\$6,638,284	6%	\$3,024,805	3%	\$1,077,279	1%
Georgia	\$30,721,825	62%	\$2,365,693	5%	\$1,500,000	3%	\$382,700	1%
Guam	\$86,530	100%	\$0	0%	\$0	0%	\$0	0%
Hawaii	\$2,049,128	55%	\$151,751	4%	\$274,000	7%	\$0	0%
Idaho	\$689,921	19%	\$53,126	1%	\$50,918	1%	\$8,202	0%
Illinois	\$29,557,287	57%	\$2,201,478	4%	\$0	0%	\$344,830	1%
Indiana	\$7,685,542	36%	\$591,815	3%	\$2,096,044	10%	\$0	0%
Iowa	\$1,555,860	43%	\$119,807	3%	\$0	0%	\$0	0%
Kansas	\$2,498,752	25%	\$0	0%	\$0	0%	\$60,182	1%
Kentucky	\$4,225,323	41%	\$325,365	3%	\$0	0%	\$0	0%
Louisiana	\$15,606,365	78%	\$1,201,747	6%	\$0	0%	\$203,993	1%
Maine	\$958,813	59%	\$0	0%	\$127,396	8%	\$0	0%
Marshall Islands	\$0	0%	\$0	0%	--	--	--	--
Maryland	\$30,408,708	51%	\$0	0%	\$0	0%	\$0	0%
Massachusetts	\$15,013,298	59%	\$0	0%	\$0	0%	\$0	0%
Michigan	\$12,574,251	38%	\$0	0%	\$269,453	1%	\$0	0%
Minnesota	\$5,738,727	47%	\$0	0%	\$0	0%	\$71,908	1%
Mississippi	\$6,507,264	100%	\$0	0%	\$0	0%	\$0	0%
Missouri	\$10,246,210	36%	\$0	0%	\$0	0%	\$126,843	0%
Montana	\$330,808	30%	\$25,473	2%	\$213,494	19%	\$3,562	0%
Nebraska	\$1,423,183	55%	\$109,590	4%	\$21,305	1%	\$0	0%
Nevada	\$6,212,826	48%	\$0	0%	\$2,189,758	17%	\$57,198	0%
New Hampshire	\$1,007,461	28%	\$0	0%	\$0	0%	\$0	0%
New Jersey	\$31,615,321	38%	\$2,415,686	3%	\$352,764	0%	\$367,128	0%
New Mexico	\$2,199,786	100%	\$0	0%	\$0	0%	\$0	0%
New York	\$119,859,704	42%	\$0	0%	\$1,190,357	0%	\$1,401,646	0%
North Carolina	\$21,500,767	37%	\$1,655,638	3%	\$0	0%	\$177,406	0%
North Dakota	\$165,404	27%	\$12,737	2%	\$50,029	8%	\$1,322	0%
Northern Mariana Islands	\$8,845	--	\$0	0%	--	--	--	--
Ohio	\$15,066,049	53%	\$1,157,679	4%	\$0	0%	\$0	0%
Oklahoma	\$4,281,048	41%	\$329,656	3%	\$228,070	2%	\$0	0%
Oregon	\$4,566,746	41%	\$351,656	3%	\$0	0%	\$0	0%
Pennsylvania	\$30,028,414	43%	\$0	0%	\$0	0%	\$0	0%
Puerto Rico	\$19,811,944	62%	\$1,237,710	4%	\$3,956,224	12%	\$199,352	1%
Republic of Palau	\$2,654	100%	\$0	0%	--	--	--	--
Rhode Island	\$2,259,933	23%	\$174,023	0%	\$2,259,933	0%	\$26,795	0%
South Carolina	\$13,043,044	47%	\$1,004,362	4%	\$0	0%	\$149,981	1%
South Dakota	\$356,459	83%	\$27,449	6%	\$45,355	11%	\$0	0%
Tennessee	\$13,778,959	45%	\$1,061,030	3%	\$400,000	1%	\$168,479	1%
Texas	\$58,379,694	57%	\$4,495,450	4%	\$0	0%	\$584,119	1%
Utah	\$2,066,225	29%	\$0	0%	\$1,709,161	24%	\$26,006	0%
Vermont	\$392,356	34%	\$0	0%	\$0	0%	\$0	0%
Virgin Islands (U.S.)	\$613,013	75%	\$38,687	5%	--	--	--	--
Virginia	\$18,197,991	62%	\$1,401,312	5%	\$626,227	2%	\$230,895	1%
Washington	\$9,494,373	27%	\$731,101	2%	\$614,143	2%	\$121,213	0%
West Virginia	\$1,370,633	35%	\$103,120	3%	\$460,000	12%	\$0	0%
Wisconsin	\$4,538,441	26%	\$349,477	2%	\$450,795	3%	\$0	0%
Wyoming	\$212,283	11%	\$16,347	1%	\$300,000	15%	\$16,347	1%
Total	\$813,342,159	43%	\$42,249,614	2%	\$27,485,105	1%	\$7,376,831	0%

¹ Part B ADAP supplemental awards were provided to 36 states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report total FY2011 budget includes federal, state, and drug rebate dollars. Cost recovery funds, with the exception of drug rebate dollars, are not included in the total budget.

ADAP Budget, by Source, FY2011

ADAP Emergency Funding	% of Total Budget	Part A Contribution Directed to ADAP	% of Total Budget	State Contribution	% of Total Budget	Estimated Drug Rebates	% of Total Budget	Other State or Federal	% of Total Budget	Total FY 2011 Budget
\$1,054,365	6%	\$0	0%	\$4,426,253	25%	\$240,000	1%	\$0	0%	\$17,725,286
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$645,578
\$0	0%	--	--	--	--	--	--	--	--	\$2,663
\$455,866	3%	\$0	0%	\$875,000	6%	\$2,514,280	16%	\$453,273	3%	\$15,794,695
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$43,755	1%	\$8,368,433
\$2,574,357	1%	\$0	0%	\$82,625,000	18%	\$253,827,000	56%	\$0	0%	\$452,181,453
\$285,430	1%	\$200,000	1%	\$4,652,179	20%	\$7,658,547	33%	\$0	0%	\$23,380,197
\$0	0%	\$0	0%	\$0	0%	\$12,594,513	53%	\$0	0%	\$23,567,283
\$0	0%	\$0	0%	\$0	0%	\$3,415,488	52%	\$0	0%	\$6,562,038
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$16,432,779
\$0	0%	--	--	--	--	--	--	--	--	\$8,186
\$6,979,996	6%	\$0	0%	\$10,500,000	9%	\$0	0%	\$0	0%	\$114,427,754
\$3,000,000	6%	\$0	0%	\$11,379,048	23%	\$0	0%	\$0	0%	\$49,349,266
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$86,530
\$243,541	6%	\$0	0%	\$440,000	12%	\$600,000	16%	\$0	0%	\$3,758,420
\$467,373	13%	\$0	0%	\$801,800	22%	\$1,500,000	42%	\$0	0%	\$3,571,340
\$722,935	1%	\$0	0%	\$18,571,500	36%	\$800,000	2%	\$0	0%	\$52,198,030
\$0	0%	\$320,534	2%	\$0	0%	\$10,398,000	49%	\$0	0%	\$21,091,935
\$709,751	20%	\$0	0%	\$498,946	14%	\$700,000	20%	\$0	0%	\$3,584,364
\$0	0%	\$0	0%	\$800,000	8%	\$6,500,000	66%	\$0	0%	\$9,858,934
\$2,090,956	20%	\$0	0%	\$81,341	1%	\$3,500,000	34%	\$0	0%	\$10,222,985
\$3,000,000	15%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$20,012,105
\$0	0%	\$0	0%	\$50,000	3%	\$500,000	31%	\$0	0%	\$1,636,209
\$0	0%	--	--	--	--	--	--	--	--	\$0
\$0	0%	\$0	0%	\$0	0%	\$28,929,349	49%	\$0	0%	\$59,338,057
\$0	0%	\$1,139,522	4%	\$1,893,375	7%	\$7,500,000	29%	\$0	0%	\$25,546,195
\$0	0%	\$0	0%	\$0	0%	\$20,000,000	61%	--	--	\$32,843,704
\$0	0%	\$0	0%	\$0	0%	\$6,354,804	52%	\$0	0%	\$12,165,439
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$6,507,264
\$307,656	1%	\$0	0%	\$4,200,000	15%	\$13,400,000	47%	\$0	0%	\$2,280,709
\$348,241	32%	\$0	0%	\$164,036	15%	\$13,548	1%	\$0	0%	\$1,099,162
\$0	0%	\$0	0%	\$900,000	35%	\$124,945	5%	\$0	0%	\$2,579,023
\$0	0%	\$0	0%	\$1,840,198	14%	\$2,557,592	20%	\$0	0%	\$12,857,572
\$0	0%	\$516,060	14%	\$180,000	5%	\$1,900,000	53%	\$0	0%	\$3,603,521
\$736,383	1%	\$187,500	0%	\$6,509,000	8%	\$40,000,000	48%	\$315,000	0%	\$82,498,782
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$2,199,786
\$0	0%	\$13,186,324	5%	\$42,300,000	15%	\$104,152,679	37%	\$1,409,290	0%	\$283,500,000
\$3,000,000	5%	\$0	0%	\$28,617,246	50%	\$0	0%	\$2,565,902	4%	\$5,516,959
\$74,324	12%	\$0	0%	\$0	0%	\$300,000	50%	\$0	0%	\$603,816
\$0	0%	--	--	--	--	--	--	--	--	\$8,845
\$1,237,528	4%	\$395,000	1%	\$5,424,565	19%	\$5,000,000	18%	\$0	0%	\$28,280,821
\$0	0%	\$0	0%	\$1,482,300	14%	\$4,000,000	39%	\$0	0%	\$10,321,074
\$321,920	3%	\$0	0%	\$1,725,000	15%	\$4,026,664	36%	\$248,310	2%	\$11,240,296
\$0	0%	\$0	0%	\$10,267,000	15%	\$29,000,000	41%	\$898,322	1%	\$70,193,736
\$2,069,536	6%	\$0	0%	\$0	0%	\$0	0%	\$4,759,688	15%	\$32,034,454
\$0	0%	--	--	--	--	--	--	--	--	\$2,654
\$427,606	4%	\$0	0%	\$2,134,715	21%	\$1,036,923	10%	\$1,666,561	0%	\$9,986,489
\$3,000,000	11%	\$0	0%	\$4,658,856	17%	\$6,000,000	22%	\$0	0%	\$27,856,243
\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$0	0%	\$429,263
\$1,021,830	3%	\$0	0%	\$7,000,000	23%	\$7,000,000	23%	\$0	0%	\$30,430,298
\$786,424	1%	\$0	0%	\$32,138,127	31%	\$6,000,000	6%	\$0	0%	\$102,383,814
\$931,936	13%	\$0	0%	\$427,220	6%	\$1,000,000	14%	\$1,022,092	14%	\$7,182,640
\$0	0%	\$0	0%	\$70,000	6%	\$700,000	60%	\$0	0%	\$1,162,356
\$169,438	21%	--	--	--	--	--	--	--	--	\$821,138
\$3,000,000	10%	\$0	0%	\$4,899,336	17%	\$750,000	3%	\$191,877	1%	\$9,297,638
\$660,158	2%	\$491,635	1%	\$11,825,586	33%	\$11,389,416	32%	\$0	0%	\$35,327,625
\$0	0%	\$0	0%	\$25,780	1%	\$1,919,500	49%	\$0	0%	\$3,879,033
\$180,263	1%	\$0	0%	\$1,306,220	8%	\$10,545,603	61%	\$0	0%	\$17,370,799
\$142,187	7%	\$0	0%	\$735,000	38%	\$526,788	27%	\$0	0%	\$1,948,952
\$40,000,000	2%	\$16,436,575	1%	\$306,424,627	16%	\$618,875,639	33%	\$13,574,070	1%	\$1,885,764,620

t or receive a waiver.

: FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. The

Table 3: Major FY2011 Budget Categories Co

State/Territory	2010 Part B ADAP Earmark	2011 Part B ADAP Earmark	% Change	2010 Part B ADAP Supplemental ¹	2011 Part B ADAP Supplemental ¹	% Change	2010 Part B Base Contribution Directed to ADAP	2011 Part B Base Contribution Directed to ADAP	% Change	2010 Part B Supplemental Directed to ADAP	2011 Part B Supplemental Directed to ADAP	% Change
Alabama	\$9,515,304	\$9,677,468	2%	\$1,451,221	\$745,200	-49%	\$298,260	\$1,500,000	403%	\$233,065	\$82,000	-65%
Alaska	\$589,363	\$589,363	0%	\$89,886	\$44,817	-50%	\$0	\$5,699	--	\$11,889	\$5,699	-52%
American Samoa	\$2,663	\$2,663	0%	\$0	\$0	--	--	--	--	--	--	--
Arizona	\$10,671,292	\$10,674,315	0%	\$1,627,526	\$821,961	-49%	\$0	\$0	--	\$288,200	\$0	-100%
Arkansas	\$4,352,010	\$4,415,494	1%	\$663,744	\$340,009	-49%	\$0	\$3,569,175	--	\$165,936	\$0	-100%
California	\$98,809,674	\$103,750,158	5%	\$0	\$8,028,154	--	\$0	\$0	--	\$2,659,865	\$1,376,784	-48%
Colorado	\$9,731,767	\$9,731,767	0%	\$0	\$747,312	--	\$714,363	\$0	-100%	\$240,552	\$104,962	-56%
Connecticut	\$10,972,770	\$10,972,770	0%	\$0	\$0	--	\$541,375	\$0	-100%	\$0	\$0	--
Delaware	\$2,289,869	\$3,146,550	37%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
District of Columbia	\$14,631,303	\$15,257,867	4%	\$0	\$1,174,912	--	\$0	\$0	--	\$365,413	\$0	--
Federated States of Micronesia	\$8,186	\$8,186	0%	--	\$0	--	--	--	--	--	--	--
Florida	\$85,188,435	\$86,207,390	1%	\$0	\$6,638,284	--	\$2,275,136	\$3,024,805	33%	\$0	\$1,077,279	--
Georgia	\$29,280,796	\$30,721,825	5%	\$4,465,744	\$2,365,693	-47%	\$2,222,156	\$1,500,000	-32%	\$711,303	\$382,700	-46%
Guam	\$86,530	\$86,530	0%	\$0	\$0	--	\$17,187	\$0	-100%	\$0	\$0	--
Hawaii	\$2,049,128	\$2,049,128	0%	\$312,522	\$151,751	-51%	\$274,420	\$274,000	0%	\$50,033	\$0	-100%
Idaho	\$676,676	\$689,921	2%	\$103,203	\$53,126	-49%	\$115,103	\$50,918	-56%	\$16,526	\$8,202	-50%
Illinois	\$29,557,287	\$29,557,287	0%	\$4,507,912	\$2,201,478	-51%	\$0	\$0	--	\$476,355	\$344,830	-28%
Indiana	\$7,532,570	\$7,685,542	2%	\$1,148,826	\$591,815	-48%	\$2,160,873	\$2,096,044	-3%	\$0	\$0	--
Iowa	\$1,487,050	\$1,555,860	5%	\$226,797	\$119,807	-47%	\$169,139	\$0	-100%	\$37,181	\$0	-100%
Kansas	\$2,439,308	\$2,498,752	2%	\$0	\$0	--	\$0	\$0	--	\$0	\$60,182	--
Kentucky	\$4,146,461	\$4,225,323	2%	\$632,395	\$325,365	-49%	\$0	\$0	--	\$0	\$0	--
Louisiana	\$15,342,541	\$15,606,365	2%	\$2,339,959	\$1,201,747	-49%	\$747,862	\$0	-100%	\$403,580	\$203,993	-49%
Maine	\$898,597	\$958,813	7%	\$0	\$0	--	\$75,242	\$127,396	69%	\$0	\$0	--
Marshall Islands	\$0	\$0	--	\$0	\$0	--	--	--	--	--	--	--
Maryland	\$29,262,549	\$30,408,708	4%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Massachusetts	\$15,013,298	\$15,013,298	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Michigan	\$12,433,924	\$12,574,251	1%	\$0	\$0	--	\$370,307	\$269,453	-27%	\$0	\$0	--
Minnesota	\$5,548,017	\$5,738,727	3%	\$0	\$0	--	\$0	\$0	--	\$125,838	\$71,908	-43%
Mississippi	\$7,533,479	\$6,507,264	-14%	\$0	\$0	--	--	\$0	--	--	\$0	--
Missouri	\$10,136,500	\$10,246,210	1%	\$0	\$0	--	\$0	\$0	--	\$261,850	\$126,843	--
Montana	\$324,695	\$330,808	2%	\$49,521	\$25,473	-49%	\$205,460	\$213,494	4%	\$7,095	\$7,095	0%
Nebraska	\$1,397,918	\$1,423,183	2%	\$213,203	\$109,590	-49%	\$0	\$21,305	--	\$0	\$0	--
Nevada	\$6,101,000	\$6,212,826	2%	\$0	\$0	--	\$2,189,758	\$2,189,758	0%	\$144,931	\$57,198	-61%
New Hampshire	\$1,002,281	\$1,007,461	1%	\$0	\$0	--	\$111,015	\$0	-100%	\$0	\$0	--
New Jersey	\$31,615,321	\$31,615,321	0%	\$0	\$2,415,686	--	\$0	\$352,764	--	\$705,518	\$367,128	-48%
New Mexico	\$2,150,993	\$2,199,786	2%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
New York	\$119,859,704	\$119,859,704	0%	\$0	\$0	--	\$1,030,197	\$1,190,357	16%	\$2,977,598	\$1,401,646	-53%
North Carolina	\$21,023,346	\$21,500,767	2%	\$3,206,363	\$1,655,638	-48%	\$300,000	\$0	-100%	\$392,261	\$177,406	-55%
North Dakota	\$158,255	\$165,404	5%	\$0	\$12,737	--	\$61,822	\$50,029	-19%	\$3,512	\$1,322	-62%
Northern Mariana Islands	\$7,276	\$8,845	22%	\$0	\$0	--	--	--	--	--	--	--
Ohio	\$15,066,049	\$15,066,049	0%	\$0	\$1,157,679	--	\$0	\$0	--	\$372,557	\$0	-100%
Oklahoma	\$4,268,335	\$4,281,048	0%	\$650,983	\$329,656	-49%	\$1,272,773	\$228,070	-82%	\$0	\$0	--
Oregon	\$4,423,861	\$4,566,746	3%	\$674,703	\$351,656	-48%	\$0	\$0	--	\$0	\$0	--
Pennsylvania	\$30,028,414	\$30,028,414	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Puerto Rico	\$19,811,944	\$19,811,944	0%	\$2,572,304	\$1,237,710	-52%	\$2,922,183	\$3,956,224	35%	\$434,317	\$199,352	-54%
Republic of Palau	\$0	\$2,654	--	\$0	\$0	--	\$0	\$0	--	\$0	--	--
Rhode Island	\$2,207,221	\$2,259,933	2%	\$0	\$0	--	\$0	\$0	--	\$47,379	\$26,795	-43%
South Carolina	\$12,987,817	\$13,043,044	0%	\$1,980,829	\$1,004,362	-49%	\$0	\$0	--	\$302,439	\$149,981	-50%
South Dakota	\$348,343	\$356,459	2%	\$0	\$27,449	--	\$80,131	\$45,355	-43%	\$6,746	\$0	-100%
Tennessee	\$13,416,196	\$13,778,959	3%	\$2,046,163	\$1,061,030	-48%	\$0	\$400,000	--	\$350,209	\$168,479	-52%
Texas	\$57,315,562	\$58,379,694	2%	\$8,741,447	\$4,495,450	-49%	\$0	\$0	--	\$350,000	\$584,119	67%
Utah	\$2,020,024	\$2,066,224	2%	\$308,083	\$0	-100%	\$842,988	\$1,709,161	103%	\$50,547	\$26,006	-49%
Vermont	\$392,356	\$392,356	0%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Virgin Islands (U.S.)	\$613,013	\$613,013	0%	\$79,067	\$38,687	-51%	\$500,000	--	--	\$11,867	--	--
Virginia	\$17,981,032	\$18,197,991	1%	\$2,742,367	\$1,401,312	-49%	\$400,385	\$921,479	130%	\$447,658	\$230,895	-48%
Washington	\$9,324,306	\$9,494,373	2%	\$0	\$731,101	--	\$165,044	\$614,143	272%	\$106,740	\$121,213	14%
West Virginia	\$1,370,633	\$1,370,633	0%	\$209,041	\$103,120	-51%	\$474,367	\$460,000	-3%	\$0	\$0	--
Wisconsin	\$4,426,590	\$4,538,441	3%	\$675,119	\$349,477	-48%	\$0	\$450,795	--	\$0	\$0	--
Wyoming	\$203,730	\$212,283	4%	\$31,072	\$16,347	-47%	\$325,000	\$325,000	0%	\$3,958	\$3,958	0%
Total	\$800,033,562	\$813,342,159	2%	\$41,750,000	\$42,075,591	1%	\$20,862,546	\$25,545,424	22%	\$12,762,918	\$7,367,975	-42%

¹ Part B ADAP Supplemental awards were provided to states that met federal eligibility criteria, applied for funding, and were able to meet the mandated matching requirement or receive a waiver.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Island

mpared with FY2010

2010 ADAP Emergency Funding	2011 ADAP Emergency Funding	% Change	2010 Part A Contribution Directed to ADAP	2011 Part A Contribution Directed to ADAP	% Change	2010 State Contribution	2011 State Contribution	% Change	2010 Estimated Drug Rebates	2011 Estimated Drug Rebates	% Change
\$0	\$1,054,365	--	\$0	\$0	--	\$4,465,057	\$4,426,253	-1%	\$260,000	\$240,000	-8%
\$38,111	\$0	-100%	\$0	\$0	--	\$0	\$0	--	\$11,000	\$0	-100%
\$0	\$0	--	--	--	--	--	--	--	--	--	--
\$262,550	\$455,866	74%	\$768,218	\$0	-100%	\$1,000,000	\$875,000	-13%	\$0	\$2,514,280	--
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$2,423,137	\$2,574,357	6%	\$0	\$0	--	\$54,406,000	\$82,625,000	52%	\$226,091,000	\$253,827,000	12%
\$221,356	\$285,430	29%	\$200,000	\$200,000	0%	\$3,945,265	\$4,652,179	18%	\$112,000	\$7,658,547	6738%
\$0	\$0	--	\$0	\$0	--	\$606,678	\$0	--	\$9,488,447	\$12,594,513	33%
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$1,693,706	\$3,415,488	102%
\$332,891	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	\$0	--	--	--	--	--	--	--	--	--	--
\$6,979,996	\$6,979,996	0%	\$0	\$0	--	\$9,500,000	\$10,500,000	11%	\$0	\$0	--
\$731,614	\$3,000,000	310%	\$0	\$0	--	\$12,487,036	\$11,379,048	-9%	\$0	\$0	--
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$148,165	\$243,541	64%	\$0	\$0	--	\$440,535	\$440,000	0%	\$150,000	\$600,000	300%
\$301,143	\$467,373	55%	\$0	\$0	--	\$721,300	\$801,800	11%	\$1,500,000	\$1,500,000	0%
\$0	\$722,935	--	\$0	\$0	--	\$20,587,045	\$18,571,500	-10%	\$0	\$800,000	--
\$0	\$0	--	\$415,116	\$320,534	-23%	\$0	\$0	--	\$6,960,000	\$10,398,000	49%
\$664,928	\$709,751	7%	\$0	\$0	--	\$498,868	\$498,946	0%	\$400,000	\$700,000	75%
\$0	\$0	--	\$0	\$0	--	\$500,000	\$800,000	60%	\$4,000,000	\$6,500,000	63%
\$1,768,076	\$2,090,956	18%	\$0	\$0	--	\$0	\$81,341	--	\$6,000,000	\$3,500,000	-42%
\$1,066,761	\$3,000,000	181%	\$0	\$0	--	\$0	\$0	--	\$3,634,736	\$0	-100%
\$0	\$0	--	\$0	\$0	--	\$50,000	\$50,000	0%	\$280,000	\$500,000	79%
\$0	\$0	--	--	--	--	--	--	--	--	--	--
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$2,596,739	\$2,596,739	0%
\$0	\$0	--	\$1,564,373	\$1,139,522	-27%	\$2,076,147	\$1,893,375	-9%	\$1,500,000	\$7,500,000	400%
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$19,900,000	\$20,000,000	1%
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$6,399,086	\$6,354,804	-1%
\$0	\$0	--	--	--	--	--	--	--	--	\$0	--
\$238,545	\$307,656	29%	\$0	\$0	--	\$4,200,000	\$4,200,000	0%	\$10,250,000	\$13,400,000	31%
\$131,566	\$348,241	165%	\$0	\$0	--	\$164,036	\$164,036	0%	\$10,217	\$10,217	0%
\$0	\$0	--	\$0	\$0	--	\$954,794	\$900,000	-6%	\$134,273	\$124,945	-7%
\$0	\$0	--	\$0	\$0	--	\$1,900,000	\$1,840,198	-3%	\$2,543,176	\$2,557,592	1%
\$0	\$0	--	\$493,249	\$516,060	5%	\$180,000	\$180,000	0%	\$1,200,000	\$1,900,000	58%
\$642,727	\$736,383	15%	\$0	\$187,500	--	\$17,220,000	\$6,509,000	-62%	\$35,000,000	\$40,000,000	14%
\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	\$0	--	\$10,245,548	\$13,186,324	29%	\$42,300,000	\$42,300,000	0%	\$100,192,653	\$104,152,679	4%
\$2,242,421	\$3,000,000	34%	\$0	\$0	--	\$25,543,127	\$28,617,246	12%	\$785,687	\$0	-100%
\$65,503	\$74,324	13%	\$0	\$0	--	\$0	\$0	--	\$0	\$300,000	--
\$0	\$0	--	--	--	--	--	--	--	--	--	--
\$1,238,314	\$1,237,528	0%	\$395,000	\$395,000	0%	\$1,512,148	\$5,424,565	259%	\$5,000,000	\$5,000,000	0%
\$0	\$0	--	\$0	\$0	--	\$1,559,664	\$1,482,300	-5%	\$1,500,000	\$4,000,000	167%
\$273,790	\$321,920	18%	\$0	\$0	--	\$1,149,000	\$1,725,000	50%	\$11,903,707	\$4,026,664	-66%
\$0	\$0	--	\$0	\$0	--	\$16,227,000	\$10,267,000	-37%	\$27,875,107	\$29,000,000	4%
\$1,738,967	\$2,069,536	19%	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
\$0	\$0	--	\$0	\$0	--	\$0	--	--	\$0	--	--
\$79,016	\$427,606	441%	\$0	\$0	--	\$1,500,000	\$2,134,715	42%	\$1,088,091	\$1,036,923	-5%
\$1,549,180	\$3,000,000	94%	\$329,000	\$0	-100%	\$1,870,249	\$4,658,856	149%	\$4,700,000	\$6,000,000	28%
\$29,835	\$0	-100%	\$0	\$0	--	\$0	\$0	--	\$80,000	\$0	-100%
\$319,040	\$1,021,830	220%	\$28,000	\$0	-100%	\$7,000,000	\$7,000,000	0%	\$4,500,000	\$7,000,000	56%
\$0	\$786,424	--	\$583,323	\$0	-100%	\$25,000,000	\$32,138,127	29%	\$0	\$6,000,000	--
\$724,806	\$931,936	29%	\$0	\$0	--	\$44,500	\$427,220	860%	\$1,113,150	\$1,000,000	-10%
\$0	\$0	--	\$0	\$0	--	\$140,000	\$70,000	-50%	\$500,000	\$700,000	40%
\$38,133	\$169,438	344%	\$0	--	--	\$150,000	--	--	\$0	--	--
\$407,816	\$3,000,000	636%	\$500,000	\$90,000	-82%	\$3,182,217	\$4,899,336	54%	\$0	\$750,000	--
\$192,677	\$660,158	243%	\$435,836	\$491,635	13%	\$8,957,681	\$11,825,586	32%	\$9,788,830	\$11,389,416	16%
\$0	\$0	--	\$0	\$0	--	\$52,260	\$25,780	-51%	\$1,700,000	\$1,919,500	13%
\$102,197	\$180,263	76%	\$0	\$0	--	\$2,200,800	\$1,306,220	-41%	\$6,960,380	\$10,545,603	52%
\$46,052	\$142,187	209%	\$0	\$0	--	\$367,500	\$735,000	100%	\$300,000	\$526,788	76%
\$24,999,313	\$40,000,000	60%	\$15,957,663	\$16,526,575	4%	\$274,658,907	\$306,424,627	12%	\$518,101,985	\$592,539,698	14%

ds did not receive a federal ADAP earmark award in FY2011. This table does not include the "Other State or Federal" category (\$13,574,070), which is reported in the total budget in Tables 1 and :

Table 4: Growth of Federal ADAP Funding, FY2008 through FY2011

State/Territory	2008 Federal Contribution	2009 Federal Contribution	% Change	2009 Federal Contribution	2010 Federal Contribution	% Change	2010 Federal Contribution	2011 Federal Contribution	% Change	2008 Federal Contribution	2011 Federal Contribution	% Change
Alabama	\$11,238,171	\$10,961,499	-2%	\$10,961,499	\$10,966,525	0%	\$10,966,525	\$11,477,033	5%	\$11,238,171	\$11,477,033	2%
Alaska	\$633,064	\$686,621	8%	\$686,621	\$717,360	4%	\$717,360	\$634,180	-12%	\$633,064	\$634,180	0%
American Samoa	\$1,978	\$2,803	42%	\$2,803	\$2,663	-5%	\$2,663	\$2,663	0%	\$1,978	\$2,663	35%
Arizona	\$9,610,361	\$11,624,545	21%	\$11,624,545	\$12,561,368	8%	\$12,561,368	\$11,952,142	-5%	\$9,610,361	\$11,952,142	24%
Arkansas	\$4,245,310	\$4,174,689	-2%	\$4,174,689	\$5,015,754	20%	\$5,015,754	\$4,755,503	-5%	\$4,245,310	\$4,755,503	12%
California	\$89,623,287	\$94,104,451	5%	\$94,104,451	\$101,232,811	8%	\$101,232,811	\$114,352,669	13%	\$89,623,287	\$114,352,669	28%
Colorado	\$9,527,197	\$9,612,191	1%	\$9,612,191	\$9,953,123	4%	\$9,953,123	\$10,764,509	8%	\$9,527,197	\$10,764,509	13%
Connecticut	\$11,471,742	\$11,550,284	1%	\$11,550,284	\$10,972,770	-5%	\$10,972,770	\$10,972,770	0%	\$11,471,742	\$10,972,770	-4%
Delaware	\$3,291,545	\$2,664,690	-19%	\$2,664,690	\$2,289,869	-14%	\$2,289,869	\$3,146,550	37%	\$3,291,545	\$3,146,550	-4%
District of Columbia	\$14,392,258	\$14,429,241	0%	\$14,429,241	\$14,964,194	4%	\$14,964,194	\$16,432,779	10%	\$14,392,258	\$16,432,779	14%
Federated States of Micronesia	\$4,934	\$7,475	51%	\$7,475	\$8,186	10%	\$8,186	\$8,186	0%	\$4,934	\$8,186	66%
Florida	\$83,509,558	\$83,621,697	0%	\$83,621,697	\$92,168,431	10%	\$92,168,431	\$99,825,670	8%	\$83,509,558	\$99,825,670	20%
Georgia	\$31,004,376	\$31,475,700	2%	\$31,475,700	\$34,478,154	10%	\$34,478,154	\$36,087,518	5%	\$31,004,376	\$36,087,518	16%
Guam	\$91,055	\$91,084	0%	\$91,084	\$86,530	-5%	\$86,530	\$86,530	0%	\$91,055	\$86,530	-5%
Hawaii	\$2,057,066	\$2,427,295	18%	\$2,427,295	\$2,509,815	3%	\$2,509,815	\$2,444,420	-3%	\$2,057,066	\$2,444,420	19%
Idaho	\$731,554	\$741,062	1%	\$741,062	\$1,081,022	46%	\$1,081,022	\$1,210,420	12%	\$731,554	\$1,210,420	65%
Illinois	\$27,628,149	\$29,009,556	5%	\$29,009,556	\$34,065,199	17%	\$34,065,199	\$32,481,700	-5%	\$27,628,149	\$32,481,700	18%
Indiana	\$9,279,327	\$9,078,290	-2%	\$9,078,290	\$8,681,396	-4%	\$8,681,396	\$8,277,357	-5%	\$9,279,327	\$8,277,357	-11%
Iowa	\$1,694,654	\$1,720,997	2%	\$1,720,997	\$2,378,775	38%	\$2,378,775	\$2,385,418	0%	\$1,694,654	\$2,385,418	41%
Kansas	\$2,265,222	\$2,456,542	8%	\$2,456,542	\$2,439,308	-1%	\$2,439,308	\$2,498,752	2%	\$2,265,222	\$2,498,752	10%
Kentucky	\$4,307,876	\$4,562,107	6%	\$4,562,107	\$6,546,932	44%	\$6,546,932	\$6,641,644	1%	\$4,307,876	\$6,641,644	54%
Louisiana	\$18,748,508	\$18,750,876	0%	\$18,750,876	\$18,749,261	0%	\$18,749,261	\$19,808,112	6%	\$18,748,508	\$19,808,112	6%
Maine	\$871,574	\$866,121	-1%	\$866,121	\$898,597	4%	\$898,597	\$958,813	7%	\$871,574	\$958,813	10%
Marshall Islands	\$2,893	\$2,968	3%	\$2,968	\$0	-100%	\$0	\$0	--	\$2,893	\$0	-100%
Maryland	\$26,541,994	\$27,869,094	5%	\$27,869,094	\$29,262,549	5%	\$29,262,549	\$30,408,708	4%	\$26,541,994	\$30,408,708	15%
Massachusetts	\$14,782,288	\$14,865,398	1%	\$14,865,398	\$15,013,298	1%	\$15,013,298	\$15,013,298	0%	\$14,782,288	\$15,013,298	2%
Michigan	\$11,681,534	\$12,219,172	5%	\$12,219,172	\$12,433,924	2%	\$12,433,924	\$12,574,251	1%	\$11,681,534	\$12,574,251	8%
Minnesota	\$5,143,281	\$5,444,759	6%	\$5,444,759	\$5,548,017	2%	\$5,548,017	\$5,738,727	3%	\$5,143,281	\$5,738,727	12%
Mississippi	\$7,277,816	\$7,610,703	5%	\$7,610,703	\$7,533,479	-1%	\$7,533,479	\$6,507,264	-14%	\$7,277,816	\$6,507,264	-11%
Missouri	\$9,789,559	\$10,102,752	3%	\$10,102,752	\$10,375,045	3%	\$10,375,045	\$10,553,866	2%	\$9,789,559	\$10,553,866	8%
Montana	\$364,893	\$361,090	-1%	\$361,090	\$505,782	40%	\$505,782	\$704,522	39%	\$364,893	\$704,522	93%
Nebraska	\$1,256,366	\$1,626,559	29%	\$1,626,559	\$1,611,121	-1%	\$1,611,121	\$1,532,773	-5%	\$1,256,366	\$1,532,773	22%
Nevada	\$5,784,830	\$6,224,050	8%	\$6,224,050	\$6,101,000	-2%	\$6,101,000	\$6,212,826	2%	\$5,784,830	\$6,212,826	7%
New Hampshire	\$998,421	\$999,945	0%	\$999,945	\$1,002,281	0%	\$1,002,281	\$1,007,461	1%	\$998,421	\$1,007,461	1%
New Jersey	\$33,221,747	\$33,279,285	0%	\$33,279,285	\$32,258,048	-3%	\$32,258,048	\$34,767,390	8%	\$33,221,747	\$34,767,390	5%
New Mexico	\$2,238,552	\$2,243,691	0%	\$2,243,691	\$2,150,993	-4%	\$2,150,993	\$2,199,786	2%	\$2,238,552	\$2,199,786	-2%
New York	\$125,611,598	\$126,168,109	0%	\$126,168,109	\$119,859,704	-5%	\$119,859,704	\$119,859,704	0%	\$125,611,598	\$119,859,704	-5%
North Carolina	\$18,587,094	\$23,920,644	29%	\$23,920,644	\$26,472,130	11%	\$26,472,130	\$26,156,405	-1%	\$18,587,094	\$26,156,405	41%
North Dakota	\$143,526	\$150,440	5%	\$150,440	\$223,758	49%	\$223,758	\$252,465	13%	\$143,526	\$252,465	76%
Northern Mariana Islands	\$3,958	\$5,606	42%	\$5,606	\$7,276	30%	\$7,276	\$8,845	22%	\$3,958	\$8,845	123%
Ohio	\$14,529,892	\$13,805,298	-5%	\$13,805,298	\$16,304,363	18%	\$16,304,363	\$17,461,256	7%	\$14,529,892	\$17,461,256	20%
Oklahoma	\$5,277,945	\$5,101,885	-3%	\$5,101,885	\$4,919,318	-4%	\$4,919,318	\$4,610,704	-6%	\$5,277,945	\$4,610,704	-13%
Oregon	\$5,214,754	\$5,204,101	0%	\$5,204,101	\$5,372,354	3%	\$5,372,354	\$5,240,322	-2%	\$5,214,754	\$5,240,322	0%
Pennsylvania	\$28,159,902	\$16,341,059	-42%	\$16,341,059	\$30,028,414	84%	\$30,028,414	\$30,028,414	0%	\$28,159,902	\$30,028,414	7%
Puerto Rico	\$22,287,304	\$24,008,337	8%	\$24,008,337	\$24,123,215	0%	\$24,123,215	\$23,119,190	-4%	\$22,287,304	\$23,119,190	4%
Republic of Palau	\$0	\$0	--	\$0	\$0	--	\$0	\$2,654	--	\$0	\$2,654	--
Rhode Island	\$2,002,014	\$2,102,115	5%	\$2,102,115	\$2,286,237	9%	\$2,286,237	\$2,861,562	25%	\$2,002,014	\$2,861,562	43%
South Carolina	\$16,520,224	\$15,922,450	-4%	\$15,922,450	\$16,517,826	4%	\$16,517,826	\$17,047,406	3%	\$16,520,224	\$17,047,406	3%
South Dakota	\$305,924	\$329,844	8%	\$329,844	\$378,178	15%	\$378,178	\$383,908	2%	\$305,924	\$383,908	25%
Tennessee	\$12,597,325	\$12,945,202	3%	\$12,945,202	\$15,781,399	22%	\$15,781,399	\$15,861,819	1%	\$12,597,325	\$15,861,819	26%
Texas	\$67,228,159	\$67,359,999	0%	\$67,359,999	\$66,057,009	-2%	\$66,057,009	\$63,661,568	-4%	\$67,228,159	\$63,661,568	-5%
Utah	\$2,583,743	\$2,492,188	-4%	\$2,492,188	\$3,052,913	22%	\$3,052,913	\$2,998,161	-2%	\$2,583,743	\$2,998,161	16%
Vermont	\$402,212	\$413,006	3%	\$413,006	\$392,356	-5%	\$392,356	\$392,356	0%	\$402,212	\$392,356	-2%
Virgin Islands (U.S.)	\$640,973	\$517,680	-19%	\$517,680	\$730,213	41%	\$730,213	\$821,138	12%	\$640,973	\$821,138	28%
Virginia	\$20,865,729	\$20,737,520	-1%	\$20,737,520	\$21,131,215	2%	\$21,131,215	\$22,599,303	7%	\$20,865,729	\$22,599,303	8%
Washington	\$8,694,418	\$9,487,916	9%	\$9,487,916	\$9,516,983	0%	\$9,516,983	\$10,885,632	14%	\$8,694,418	\$10,885,632	25%
West Virginia	\$1,373,538	\$1,374,271	0%	\$1,374,271	\$1,579,674	15%	\$1,579,674	\$1,473,753	-7%	\$1,373,538	\$1,473,753	7%
Wisconsin	\$5,334,671	\$5,222,988	-2%	\$5,222,988	\$5,203,906	0%	\$5,203,906	\$5,068,181	-3%	\$5,334,671	\$5,068,181	-5%
Wyoming	\$180,188	\$193,421	7%	\$193,421	\$280,854	45%	\$280,854	\$370,817	32%	\$180,188	\$370,817	106%
Total	\$ 813,858,031	\$ 821,273,361	1%	\$ 821,273,361	\$ 866,782,875	6%	\$ 866,782,875	\$ 895,591,773	3%	\$ 813,858,031	\$ 895,591,773	10%

Note: Federal funding to ADAP includes only funding distributed directly to states from HRSA (ADAP Earmark, ADAP Supplemental and ADAP Emergency Relief Funding, when applicable).

Table 5: Growth of State Contribution to ADAP, FY2008 through FY2011

State/Territory	2008 State Contribution	2009 State Contribution	% Change	2009 State Contribution	2010 State Contribution	% Change	2010 State Contribution	2011 State Contribution	% Change	2008 State Contribution	2011 State Contribution	% Change
Alabama	\$5,075,403	\$2,225,000	-56%	\$2,225,000	\$4,465,057	101%	\$4,465,057	\$4,426,253	-1%	\$5,075,403	\$4,426,253	-13%
Alaska	\$31,221	\$0	-100%	\$0	\$0	--	\$0	\$0	--	\$31,221	\$0	-100%
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	\$1,000,000	\$1,000,000	0%	\$1,000,000	\$1,000,000	0%	\$1,000,000	\$875,000	-13%	\$1,000,000	\$875,000	-13%
Arkansas	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
California	\$96,349,000	\$70,849,000	-26%	\$70,849,000	\$126,019,004	78%	\$54,406,000	\$82,625,000	52%	\$96,349,000	\$82,625,000	-14%
Colorado	\$5,083,028	\$3,732,915	-27%	\$3,732,915	\$3,945,265	6%	\$3,945,265	\$4,652,179	18%	\$5,083,028	\$4,652,179	-8%
Connecticut	\$606,678	\$606,678	0%	\$606,678	\$606,678	0%	\$606,678	\$0	-100%	\$606,678	\$0	-100%
Delaware	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
District of Columbia	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--
Florida	\$10,500,000	\$9,500,000	-10%	\$9,500,000	\$9,500,000	0%	\$9,500,000	\$10,500,000	11%	\$10,500,000	\$10,500,000	0%
Georgia	\$9,500,000	\$10,000,000	5%	\$10,000,000	\$12,487,036	25%	\$12,487,036	\$11,379,048	-9%	\$9,500,000	\$11,379,048	20%
Guam	\$0	\$0	--	\$0	--	--	\$0	\$0	--	\$0	\$0	--
Hawaii	\$440,535	\$440,535	0%	\$440,535	\$440,535	0%	\$440,535	\$440,000	0%	\$440,535	\$440,000	0%
Idaho	\$779,300	\$801,300	3%	\$801,300	\$721,300	-10%	\$721,300	\$801,800	11%	\$779,300	\$801,800	3%
Illinois	\$13,814,074	\$14,504,778	5%	\$14,504,778	\$20,587,045	42%	\$20,587,045	\$18,571,500	-10%	\$13,814,074	\$18,571,500	34%
Indiana	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Iowa	\$555,000	\$526,078	-5%	\$526,078	\$498,868	-5%	\$498,868	\$498,946	0%	\$555,000	\$498,946	-10%
Kansas	\$0	\$500,000	--	\$500,000	\$500,000	0%	\$500,000	\$800,000	60%	\$0	\$800,000	--
Kentucky	\$0	\$0	--	\$0	\$0	--	\$0	\$81,341	--	\$0	\$81,341	--
Louisiana	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Maine	\$66,550	\$50,000	-25%	\$50,000	\$50,000	0%	\$50,000	\$50,000	0%	\$66,550	\$50,000	-25%
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	\$17,372,828	\$0	-100%	\$0	\$0	--	\$0	\$0	--	\$17,372,828	\$0	-100%
Massachusetts	\$1,958,523	\$1,893,375	-3%	\$1,893,375	\$1,893,375	0%	\$2,076,147	\$1,893,375	-9%	\$1,958,523	\$1,893,375	-3%
Michigan	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Minnesota	\$0	\$4,525,577	--	\$4,525,577	\$0	-100%	\$0	\$0	--	\$0	\$0	--
Mississippi	\$0	--	--	--	--	--	--	\$0	--	\$0	\$0	--
Missouri	\$3,649,634	\$4,390,000	20%	\$4,390,000	\$4,200,000	-4%	\$4,200,000	\$4,200,000	0%	\$3,649,634	\$4,200,000	15%
Montana	\$147,018	\$58,154	-60%	\$58,154	\$164,036	182%	\$164,036	\$164,036	0%	\$147,018	\$164,036	12%
Nebraska	\$900,000	\$900,000	0%	\$900,000	\$954,794	6%	\$954,794	\$900,000	-6%	\$900,000	\$900,000	0%
Nevada	\$1,633,261	\$0	-100%	\$0	\$1,900,000	--	\$1,900,000	\$1,840,198	-3%	\$1,633,261	\$1,840,198	13%
New Hampshire	\$500,000	\$0	-100%	\$0	\$180,000	--	\$180,000	\$180,000	0%	\$500,000	\$180,000	-64%
New Jersey	\$4,700,000	\$8,600,000	83%	\$8,600,000	\$17,220,000	100%	\$17,220,000	\$6,509,000	-62%	\$4,700,000	\$6,509,000	38%
New Mexico	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
New York	\$55,000,000	\$3,302,461	-94%	\$3,302,461	\$42,300,000	1181%	\$42,300,000	\$42,300,000	0%	\$55,000,000	\$42,300,000	-23%
North Carolina	\$14,551,663	\$10,695,504	-26%	\$10,695,504	\$25,543,127	139%	\$25,543,127	\$28,617,246	12%	\$14,551,663	\$28,617,246	97%
North Dakota	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	\$3,000,000	\$693,100	-77%	\$693,100	\$1,512,148	118%	\$1,512,148	\$5,424,565	259%	\$3,000,000	\$5,424,565	81%
Oklahoma	\$1,646,179	\$1,620,000	-2%	\$1,620,000	\$1,559,664	-4%	\$1,559,664	\$1,482,300	-5%	\$1,646,179	\$1,482,300	-10%
Oregon	\$1,157,157	\$1,643,278	42%	\$1,643,278	\$1,149,000	-30%	\$1,149,000	\$1,725,000	50%	\$1,157,157	\$1,725,000	49%
Pennsylvania	\$16,267,000	\$16,150,699	-1%	\$16,150,699	\$16,227,000	0%	\$16,227,000	\$10,267,000	-37%	\$16,267,000	\$10,267,000	-37%
Puerto Rico	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Republic of Palau	--	--	--	--	--	--	\$0	--	--	--	--	--
Rhode Island	\$1,700,000	\$549,911	-68%	\$549,911	\$1,500,000	173%	\$1,500,000	\$2,134,715	42%	\$1,700,000	\$2,134,715	26%
South Carolina	\$5,900,000	\$4,634,467	-21%	\$4,634,467	\$1,870,249	-60%	\$1,870,249	\$4,658,856	149%	\$5,900,000	\$4,658,856	-21%
South Dakota	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Tennessee	\$7,300,000	\$7,200,000	-1%	\$7,200,000	\$7,000,000	-3%	\$7,000,000	\$7,000,000	0%	\$7,300,000	\$7,000,000	-4%
Texas	\$35,475,307	\$26,887,609	-24%	\$26,887,609	\$25,000,000	-7%	\$25,000,000	\$32,138,127	29%	\$35,475,307	\$32,138,127	-9%
Utah	\$0	\$94,412	--	\$94,412	\$77,021	-18%	\$44,500	\$427,220	860%	\$0	\$427,220	--
Vermont	\$0	\$140,000	--	\$140,000	\$140,000	0%	\$140,000	\$70,000	-50%	\$0	\$70,000	--
Virgin Islands (U.S.)	\$0	\$0	--	\$0	\$150,000	--	\$150,000	--	--	\$0	--	--
Virginia	\$2,612,200	\$1,611,172	-38%	\$1,611,172	\$3,223,646	100%	\$3,182,217	\$4,899,336	54%	\$2,612,200	\$4,899,336	88%
Washington	\$8,809,064	\$8,944,861	2%	\$8,944,861	\$8,957,681	0%	\$8,957,681	\$11,825,586	32%	\$8,809,064	\$11,825,586	34%
West Virginia	\$0	\$0	--	\$0	\$52,260	--	\$52,260	\$25,780	-51%	\$0	\$25,780	--
Wisconsin	\$464,000	\$926,200	100%	\$926,200	\$2,200,800	138%	\$2,200,800	\$1,306,220	-41%	\$464,000	\$1,306,220	182%
Wyoming	\$0	\$367,500	--	\$367,500	\$367,500	0%	\$367,500	\$735,000	100%	\$0	\$735,000	--
Total	\$328,544,623	\$220,564,564	-33%	\$220,564,564	\$346,163,089	57%	\$274,658,907	\$306,424,627	12%	\$328,544,623	\$306,424,627	-7%

Table 6: Growth of Estimated Drug Rebates, FY2008 through FY2011

State/Territory	2008 Estimated Drug Rebates	2009 Estimated Drug Rebates	% Change	2009 Estimated Drug Rebates	2010 Estimated Drug Rebates	% Change	2010 Estimated Drug Rebates	2011 Estimated Drug Rebates	% Change	2008 Estimated Drug Rebates	2011 Estimated Drug Rebates	% Change
Alabama	\$0	\$320,000	--	\$320,000	\$260,000	-19%	\$260,000	\$240,000	-8%	\$0	\$240,000	--
Alaska	\$10,000	\$10,000	0%	\$10,000	\$11,000	10%	\$11,000	\$0	-100%	\$10,000	\$0	-100%
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	\$0	\$0	--	\$0	\$0	--	\$0	\$2,514,280	--	\$0	\$2,514,280	--
Arkansas	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
California	\$135,915,000	\$248,257,000	83%	\$248,257,000	\$207,018,607	-17%	\$207,018,607	\$253,827,000	23%	\$135,915,000	\$253,827,000	87%
Colorado	\$20,000	\$0	-100%	\$0	\$112,000	--	\$112,000	\$7,658,547	6738%	\$20,000	\$7,658,547	38193%
Connecticut	\$7,500,000	\$8,100,000	8%	\$8,100,000	\$9,488,447	17%	\$9,488,447	\$12,594,513	33%	\$7,500,000	\$12,594,513	68%
Delaware	\$281,775	\$691,483	145%	\$691,483	\$1,693,706	145%	\$1,693,706	\$3,415,488	102%	\$281,775	\$3,415,488	1112%
District of Columbia	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--
Florida	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Georgia	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Guam	\$0	\$0	--	\$0	--	--	--	\$0	--	\$0	\$0	--
Hawaii	\$21,000	\$100,000	376%	\$100,000	\$150,000	50%	\$150,000	\$600,000	300%	\$21,000	\$600,000	2757%
Idaho	\$700,000	\$875,000	25%	\$875,000	\$1,500,000	71%	\$1,500,000	\$1,500,000	0%	\$700,000	\$1,500,000	114%
Illinois	\$0	\$0	--	\$0	\$0	--	\$0	\$800,000	--	\$0	\$800,000	--
Indiana	\$205,000	\$5,360,000	2515%	\$5,360,000	\$6,960,000	30%	\$6,960,000	\$10,398,000	49%	\$205,000	\$10,398,000	4972%
Iowa	\$20,000	\$34,000	70%	\$34,000	\$400,000	1076%	\$400,000	\$700,000	75%	\$20,000	\$700,000	3400%
Kansas	\$3,200,000	\$4,000,000	25%	\$4,000,000	\$4,000,000	0%	\$4,000,000	\$6,500,000	63%	\$3,200,000	\$6,500,000	103%
Kentucky	\$2,500,000	\$0	-100%	\$0	\$6,000,000	--	\$6,000,000	\$3,500,000	-42%	\$2,500,000	\$3,500,000	40%
Louisiana	\$500,000	\$620,000	24%	\$620,000	\$3,634,736	486%	\$3,634,736	\$0	-100%	\$500,000	\$0	-100%
Maine	\$150,000	\$0	-100%	\$0	\$280,000	--	\$280,000	\$500,000	79%	\$150,000	\$500,000	233%
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	\$20,000,000	\$2,607,544	-87%	\$2,607,544	\$2,596,739	0%	\$2,596,739	\$2,596,739	0%	\$20,000,000	\$2,596,739	-87%
Massachusetts	\$1,500,000	\$1,500,000	0%	\$1,500,000	\$1,500,000	0%	\$1,500,000	\$7,500,000	400%	\$1,500,000	\$7,500,000	400%
Michigan	\$9,000,000	\$11,200,000	24%	\$11,200,000	\$19,900,000	78%	\$19,900,000	\$20,000,000	1%	\$9,000,000	\$20,000,000	122%
Minnesota	\$3,928,270	\$3,529,075	-10%	\$3,529,075	\$6,399,086	81%	\$6,399,086	\$6,354,804	-1%	\$3,928,270	\$6,354,804	62%
Mississippi	\$208,000	--	--	--	--	--	--	\$0	--	\$208,000	\$0	-100%
Missouri	\$3,200,000	\$4,685,000	46%	\$4,685,000	\$10,250,000	119%	\$10,250,000	\$13,400,000	31%	\$3,200,000	\$13,400,000	319%
Montana	\$12,500	\$10,679	-15%	\$10,679	\$10,217	-4%	\$10,217	\$10,217	0%	\$12,500	\$10,217	-18%
Nebraska	\$28,000	\$54,400	94%	\$54,400	\$134,273	147%	\$134,273	\$124,945	-7%	\$28,000	\$124,945	346%
Nevada	\$110,000	\$500,000	355%	\$500,000	\$1,194,626	139%	\$1,194,626	\$2,557,592	114%	\$110,000	\$2,557,592	2225%
New Hampshire	\$100,000	\$1,400,000	1300%	\$1,400,000	\$1,200,000	-14%	\$1,200,000	\$1,900,000	58%	\$100,000	\$1,900,000	1800%
New Jersey	\$31,549,324	\$30,000,000	-5%	\$30,000,000	\$35,000,000	17%	\$35,000,000	\$40,000,000	14%	\$31,549,324	\$40,000,000	27%
New Mexico	\$0	\$5,000	--	\$5,000	\$0	-100%	\$0	\$0	--	\$0	\$0	--
New York	\$69,344,600	\$111,490,965	61%	\$111,490,965	\$100,192,653	-10%	\$100,192,653	\$104,152,679	4%	\$69,344,600	\$104,152,679	50%
North Carolina	\$0	\$0	--	\$0	\$785,687	--	\$785,687	\$0	-100%	\$0	\$0	--
North Dakota	\$150,000	\$180,000	20%	\$180,000	\$0	-100%	\$0	\$300,000	--	\$150,000	\$300,000	100%
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	\$250,000	\$0	-100%	\$0	\$5,000,000	--	\$5,000,000	\$5,000,000	0%	\$250,000	\$5,000,000	1900%
Oklahoma	\$960,000	\$900,000	-6%	\$900,000	\$1,500,000	67%	\$1,500,000	\$4,000,000	167%	\$960,000	\$4,000,000	317%
Oregon	\$5,076,000	\$4,866,722	-4%	\$4,866,722	\$11,903,707	145%	\$11,903,707	\$4,026,664	-66%	\$5,076,000	\$4,026,664	-21%
Pennsylvania	\$13,560,000	\$21,244,084	57%	\$21,244,084	\$27,875,107	31%	\$27,875,107	\$29,000,000	4%	\$13,560,000	\$29,000,000	114%
Puerto Rico	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--	\$0	\$0	--
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--	--
Rhode Island	\$582,000	\$2,315,347	298%	\$2,315,347	\$1,088,091	-53%	\$1,088,091	\$1,036,923	-5%	\$582,000	\$1,036,923	78%
South Carolina	\$3,400,000	\$3,000,000	-12%	\$3,000,000	\$4,700,000	57%	\$4,700,000	\$6,000,000	28%	\$3,400,000	\$6,000,000	76%
South Dakota	\$116,160	\$189,000	63%	\$189,000	\$80,000	-58%	\$80,000	\$0	-100%	\$116,160	\$0	-100%
Tennessee	\$1,500,000	\$3,000,000	100%	\$3,000,000	\$4,500,000	50%	\$4,500,000	\$7,000,000	56%	\$1,500,000	\$7,000,000	367%
Texas	\$0	\$0	--	\$0	\$0	--	\$0	\$6,000,000	--	\$0	\$6,000,000	--
Utah	\$1,056,926	\$1,471,486	39%	\$1,471,486	\$1,113,150	-24%	\$1,113,150	\$1,000,000	-10%	\$1,056,926	\$1,000,000	-5%
Vermont	\$600,000	\$500,000	-17%	\$500,000	\$500,000	0%	\$500,000	\$700,000	40%	\$600,000	\$700,000	17%
Virgin Islands (U.S.)	\$0	\$0	--	\$0	\$0	--	\$0	--	--	\$0	--	--
Virginia	\$500,000	\$454,419	-9%	\$454,419	\$338,702	-25%	\$338,702	\$750,000	121%	\$500,000	\$750,000	50%
Washington	\$4,310,546	\$8,047,200	87%	\$8,047,200	\$9,788,830	22%	\$9,788,830	\$11,389,416	16%	\$4,310,546	\$11,389,416	164%
West Virginia	\$945,000	\$1,100,000	16%	\$1,100,000	\$1,700,000	55%	\$1,700,000	\$1,919,500	13%	\$945,000	\$1,919,500	103%
Wisconsin	\$3,994,154	\$4,763,723	19%	\$4,763,723	\$6,960,380	46%	\$6,960,380	\$10,545,603	52%	\$3,994,154	\$10,545,603	164%
Wyoming	\$100,000	\$240,000	140%	\$240,000	\$300,000	25%	\$300,000	\$526,788	76%	\$100,000	\$526,788	427%
Total	\$ 327,104,255	\$487,622,127	49%	\$487,622,127	\$498,019,744	2%	\$498,019,744	\$598,973,290	20%	\$327,104,255	\$598,973,290	83%

Table 7: Cost Recovery and Other Cost-Saving Mechanisms (Excluding Drug Rebates), FY2011

State/Territory	Private Insurance	Medicaid	Other	Total
Alabama	\$0	\$0	\$0	\$0
Alaska	\$750,000	\$0	\$0	\$750,000
American Samoa	--	--	--	--
Arizona	\$0	\$0	\$0	\$0
Arkansas	\$0	\$0	\$0	\$0
California	\$0	\$0	\$0	\$0
Colorado	\$0	\$0	\$0	\$0
Connecticut	\$3,173,520	\$0	\$0	\$3,173,520
Delaware	\$0	\$0	\$0	\$0
District of Columbia	\$0	\$0	\$0	\$0
Federated States of Micronesia	--	--	--	--
Florida	\$0	\$0	\$0	\$0
Georgia	\$0	\$0	\$0	\$0
Guam	--	--	--	--
Hawaii	\$0	\$0	\$0	\$0
Idaho	\$0	\$0	\$0	\$0
Illinois	\$0	\$89,713	\$0	\$89,713
Indiana	\$0	\$0	\$0	\$0
Iowa	\$112,000	\$20,000	\$0	\$132,000
Kansas	\$0	\$0	\$0	\$0
Kentucky	\$0	\$0	\$0	\$0
Louisiana	\$2,000,000	\$0	\$0	\$2,000,000
Maine	\$0	\$0	\$0	\$0
Marshall Islands	--	--	--	--
Maryland	\$0	\$0	\$0	\$0
Massachusetts	\$0	\$0	\$0	\$0
Michigan	\$0	\$650,000	\$0	\$650,000
Minnesota	\$0	\$0	\$0	\$0
Mississippi	--	--	--	--
Missouri	\$25,000	\$2,400,000	\$0	\$2,425,000
Montana	\$0	\$0	\$0	\$0
Nebraska	\$3,370	\$6,521	\$39,967	\$49,858
Nevada	\$0	\$0	\$0	\$0
New Hampshire	\$0	\$0	\$0	\$0
New Jersey	\$6,000,000	\$3,900,000	\$2,000,000	\$11,900,000
New Mexico	\$0	\$0	\$0	\$0
New York	\$16,000,000	\$1,500,000	\$0	\$17,500,000
North Carolina	\$0	\$0	\$0	\$0
North Dakota	\$0	\$0	\$0	\$0
Northern Mariana Islands	--	--	--	--
Ohio	\$0	\$0	\$0	\$0
Oklahoma	\$120,000	\$30,000	\$0	\$150,000
Oregon	\$10,202,444	\$0	\$0	\$10,202,444
Pennsylvania	\$2,000,000	\$0	\$0	\$2,000,000
Puerto Rico	\$0	\$0	\$0	\$0
Republic of Palau	--	--	--	--
Rhode Island	\$0	\$0	\$0	\$0
South Carolina	\$0	\$0	\$0	\$0
South Dakota	\$0	\$0	\$0	\$0
Tennessee	\$0	\$0	\$0	\$0
Texas	\$0	\$0	\$0	\$0
Utah	\$0	\$40,000	\$0	\$40,000
Vermont	\$15,000	\$0	\$0	\$15,000
Virgin Islands (U.S.)	\$0	\$0	\$0	\$0
Virginia	\$0	\$650,000	\$0	\$650,000
Washington	\$0	\$0	\$0	\$0
West Virginia	\$0	\$0	\$0	\$0
Wisconsin	\$60,049	\$201,732	\$0	\$261,781
Wyoming	\$0	\$0	\$0	\$0
Totals	\$40,461,383	\$9,487,966	\$2,039,967	\$51,989,316
Total # of ADAPs	13	11	2	17

Note: 16 ADAPs reported data. A zero (\$0) indicates a response of zero (\$0) from the ADAP.

Table 8: Total Clients Enrolled/Served and Program Expenditures, FY2010¹

State/Territory	FY2010 Clients Enrolled ²	FY2010 New Clients Enrolled	FY2010 Clients Served ²	FY2010 ADAP Expenditures										Total Expenditures
				Prescription Drugs	Prescription Dispensing Costs	Insurance Premiums	Insurance Co-payments and Deductibles	Client Outreach	Adherence and Monitoring	Quality Management	Program Administration	Client Enrollment Costs	Other ³	
Alabama	2,015	685	1,763	\$18,423,430	\$449,583	\$16,497	\$132,147	\$0	\$1,405,673	\$180,786	\$877,536	\$0	\$0	\$21,485,652
Alaska	144	34	121	\$815,157	\$70,019	\$125,896	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$1,011,071
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Arizona	1,683	437	1,622	\$12,674,790	\$330,892	\$65,275	\$0	\$0	\$0	\$11,880	\$528,109	\$0	\$0	\$13,610,946
Arkansas	565	240	565	\$5,382,557	\$128,962	\$0	\$14,002	\$0	\$0	\$0	\$0	\$0	\$0	\$5,525,521
California	41,179	4,274	39,481	\$386,856,487	\$2,708,250	\$357,671	\$42,281,819	\$0	\$0	\$2,338,560	\$795,584	\$7,027,512	\$0	\$442,365,881
Colorado	3,586	423	2,983	\$13,232,382	\$468,025	\$2,885,110	\$0	\$0	\$0	\$0	\$204,109	\$0	\$0	\$16,789,626
Connecticut	2,604	406	2,414	\$22,474,501	\$156,073	\$21,437	\$1,018,835	\$0	\$442,503	\$486,870	\$349,324	\$0	\$0	\$24,949,543
Delaware	1,657	185	1,200	\$1,128,571	\$27,862	\$106,046	\$0	\$0	\$807,462	\$83,129	\$289,976	\$0	\$0	\$2,443,046
District of Columbia	3,336	788	2,740	\$12,960,717	\$721,806	\$143,722	\$540,222	\$0	\$750,000	\$439,397	\$1,448,568	\$0	\$0	\$17,004,432
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Florida	15,975	1,064	14,305	\$94,952,280	\$0	\$2,186,684	\$197,617	\$0	\$0	\$0	\$4,607,178	\$0	\$0	\$101,943,759
Georgia	5,919	523	5,919	\$45,700,440	\$1,523,338	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$47,223,778
Guam	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Hawaii	405	80	386	\$3,335,121	\$89,440	\$162,211	\$159,320	\$0	\$4,163	\$0	\$0	\$0	\$0	\$3,750,255
Idaho	205	62	188	\$3,079,705	\$0	\$0	\$0	\$0	\$23,232	\$0	\$0	\$0	\$11,616	\$3,114,553
Illinois	7,792	1,422	6,447	\$46,055,583	\$1,592,799	\$0	\$1,402,148	\$0	\$0	\$0	\$0	\$0	\$0	\$49,050,531
Indiana	2,096	694	2,061	\$847,080	\$7,725	\$4,682,094	\$5,490,531	\$0	\$0	\$116,706	\$1,071,821	\$0	\$0	\$12,215,957
Iowa	658	212	578	\$2,390,748	\$91,481	\$139,425	\$198,628	\$0	\$0	\$0	\$125,357	\$0	\$0	\$2,945,639
Kansas	1,418	248	1,206	\$11,491,262	\$56,587	\$204,481	\$0	\$164,899	\$134,275	\$227,804	\$0	\$0	\$0	\$12,279,308
Kentucky	1,806	349	1,457	\$9,265,589	\$319,155	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$9,584,744
Louisiana	3,557	508	3,557	\$20,728,914	\$456,399	\$0	\$1,274,247	\$0	\$0	\$0	\$0	\$0	\$0	\$22,459,560
Maine	698	124	454	\$806,984	\$22,118	\$150,026	\$55,238	--	\$10,114	\$19,568	\$107,709	\$0	\$0	\$1,171,757
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Maryland	7,075	1,084	6,238	\$25,965,339	\$536,923	\$14,129,850	\$6,011,518	\$0	\$1,463,127	\$511,769	\$1,057,650	\$0	\$0	\$49,676,176
Massachusetts	7,527	880	6,519	\$4,284,711	\$18,996	\$10,976,162	\$3,042,679	\$0	\$1,263,045	\$0	\$828,139	\$0	\$0	\$20,413,732
Michigan	3,175	917	2,690	\$26,865,735	\$116,349	\$971,362	\$4,427,921	\$0	\$0	\$26,113	\$404,262	\$0	\$0	\$32,811,742
Minnesota	2,429	390	1,316	\$2,619,932	\$0	\$2,905,780	\$0	\$0	\$1,567	\$0	\$20,739	\$0	\$0	\$5,548,018
Mississippi	1,496	379	14,483	\$7,699,496	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$7,699,496
Missouri	4,129	383	3,302	\$21,811,626	\$1,764,719	\$44,893	\$1,236,364	\$0	\$0	\$15,751	\$79,779	\$0	\$0	\$24,953,132
Montana	149	49	146	\$779,333	\$12,925	\$0	\$96,303	\$0	\$0	\$0	\$0	\$0	\$0	\$888,561
Nebraska	640	140	563	\$2,726,106	\$0	\$6,238	\$34,138	\$0	\$0	\$0	\$162,812	\$0	\$0	\$2,929,294
Nevada	1,589	358	1,192	\$7,077,828	\$253,803	\$222,359	\$1,020,293	\$33,585	\$190,212	\$199,666	\$513,866	\$296,732	\$382,336	\$10,190,680
New Hampshire	451	74	451	\$1,590,658	\$14,690	\$265,880	\$458,600	--	--	\$56,300	\$216,309	\$0	\$0	\$2,602,437
New Jersey	8,259	306	7,235	\$87,869,590	\$1,181,942	\$3,794,648	\$2,020,000	\$69,128	\$712,480	\$767,652	\$581,827	\$0	\$0	\$96,997,267
New Mexico	811	98	804	\$252,302	\$0	\$2,176,333	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$2,428,635
New York	23,965	3,040	21,691	\$256,514,208	\$2,185,540	\$28,201,000	\$0	\$602,550	\$3,135,695	\$787,950	\$324,450	\$2,920,050	\$0	\$294,671,443
North Carolina	6,591	775	5,586	\$43,701,757	\$1,485,718	\$0	\$100,739	\$0	\$0	\$0	\$187,000	\$0	\$0	\$45,475,214
North Dakota	104	17	104	\$599,329	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$599,329
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Ohio	4,871	365	3,464	\$14,247,464	\$593,548	\$2,402,926	\$2,590,520	\$0	\$0	\$0	\$2,121,845	\$0	\$0	\$21,956,302
Oklahoma	1,640	325	1,535	\$7,112,163	\$292,734	\$706,008	\$930,619	\$0	\$86,108	\$160,221	\$139,990	\$131,026	\$0	\$9,698,859
Oregon	3,165	369	3,098	\$3,539,821	\$0	\$8,569,541	\$2,279,343	\$0	\$0	\$55,591	\$1,138,056	\$0	\$0	\$15,582,352
Pennsylvania	6,653	2,005	6,125	\$71,916,418	\$904,868	\$200,503	\$42,149,014	\$0	\$0	\$11,000	\$653,381	\$498,971	\$261,652	\$116,595,806
Puerto Rico	5,279	882	5,279	\$25,829,815	\$46,644	\$0	\$0	\$0	\$12,460	\$33,673	\$776,324	\$0	\$0	\$26,698,916
Republic of Palau	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Rhode Island	611	157	850	\$6,206,838	\$28,723	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$6,235,561
South Carolina	4,126	300	3,697	\$25,416,979	\$881,116	\$610,733	\$1,291,509	\$0	\$0	\$0	\$1,369,854	\$0	\$0	\$29,570,191
South Dakota	142	7	142	\$678,800	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$678,800
Tennessee	4,626	1,067	4,176	\$20,470,534	\$723,322	\$5,317,301	\$2,415,747	\$0	\$0	\$0	\$0	\$0	\$0	\$28,926,904
Texas	17,015	3,381	16,501	\$93,009,334	\$0	\$0	\$5,805,624	\$0	\$0	\$0	\$8,000,000	\$0	\$0	\$106,814,957
Utah	514	166	461	\$2,802,173	\$70,190	\$503,291	\$194,842	\$0	\$0	\$28,613	\$235,890	\$0	\$0	\$3,834,999
Vermont	353	70	253	\$327,520	\$18,021	\$84,312	\$358,849	\$0	\$0	\$9,256	\$4,344	\$0	\$0	\$802,302
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Virginia	4,373	763	4,059	\$28,021,256	\$633,204	\$16,012	\$238,485	\$0	\$428,540	\$28,293	\$979,511	\$0	\$0	\$30,345,301
Washington	4,721	613	4,287	\$11,610,485	\$74,409	\$18,982,744	\$2,413,749	\$0	\$0	\$324,533	\$1,086,667	\$0	\$0	\$34,492,587
West Virginia	515	98	348	\$2,886,028	\$32,232	\$0	\$631,356	\$0	\$0	\$0	\$0	\$0	\$0	\$3,549,616
Wisconsin	1,977	280	1,754	\$9,411,761	\$0	\$3,683,569	\$3,694,492	\$0	\$0	\$0	\$178,400	\$0	\$0	\$16,968,222
Wyoming	150	26	109	\$1,008,283	\$12,875	\$0	\$38,212	\$0	\$0	\$0	\$0	\$0	\$0	\$1,059,370
Total	226,419	32,522	217,905	\$1,527,455,918	\$21,104,004	\$116,018,021	\$136,245,670	\$870,162	\$10,870,655	\$4,582,521	\$32,805,234	\$4,855,436	\$7,814,142	\$1,862,621,761

¹ This table represents ADAP program expenditures in FY2010 (April 1, 2010-March 31, 2011). Only expenditure categories requested in the National ADAP Monitoring Survey are represented in this table.

² For some states, enrolled clients reported may be a snapshot in time rather than a cumulative unduplicated client count. In this instance, some ADAPs may report a higher number of clients served throughout the fiscal year compared to the number of clients enrolled in the program at the end of the fiscal year.

³ "Other" includes, but is not limited to, contract services to dispense medications, determine eligibility, and manage enrollment; pharmacy charges, dispensing and shipping fees, central pharmacy fees; as well as medical, dental, lab, and nutritional services.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 9: Total Clients Enrolled and Served, June 2010 and June 2011

State/Territory	June 2010 Clients Enrolled	June 2011 Clients Enrolled	% Change	June 2010 Clients Served	June 2011 Clients Served	% Change
Alabama	1,618	1,875	16%	1,468	1,534	4%
Alaska	96	90	-6%	93	79	-15%
American Samoa	--	--	--	--	--	--
Arizona	1,100	1,122	2%	1,071	1,114	4%
Arkansas	552	407	-26%	552	389	-30%
California	34,963	36,738	5%	25,128	26,586	6%
Colorado	2,883	3,067	6%	1,822	1,775	-3%
Connecticut	2,042	2,053	1%	1,558	1,678	8%
Delaware	1,107	1,460	32%	590	677	15%
District of Columbia	2,457	1,458	-41%	1,507	861	-43%
Federated States of Micronesia	--	--	--	--	--	--
Florida	13,832	9,819	-29%	11,636	8,396	-28%
Georgia	5,883	4,004	-32%	5,398	3,958	-27%
Guam	--	--	--	--	--	--
Hawaii	288	315	9%	264	266	1%
Idaho	130	146	12%	130	123	-5%
Illinois	5,919	5,604	-5%	4,346	4,097	-6%
Indiana	1,669	1,913	15%	1,669	1,885	13%
Iowa	362	617	70%	289	471	63%
Kansas	1,128	1,153	2%	735	778	6%
Kentucky	1,526	1,745	14%	996	1,424	43%
Louisiana	2,346	1,938	-17%	2,346	1,938	-17%
Maine	696	726	4%	216	285	32%
Marshall Islands	--	--	--	--	--	--
Maryland	5,298	5,672	7%	3,344	4,071	22%
Massachusetts	5,579	6,059	9%	4,099	4,285	5%
Michigan	2,878	2,825	-2%	2,321	2,205	-5%
Minnesota	1,200	2,004	67%	678	653	-4%
Mississippi	--	886	--	--	886	--
Missouri	2,287	2,519	10%	1,372	1,727	26%
Montana ¹	105	113	8%	83	92	11%
Nebraska	349	552	58%	227	377	66%
Nevada	1,122	1,113	-1%	872	845	-3%
New Hampshire	315	319	1%	193	177	-8%
New Jersey	6,521	7,005	7%	4,949	6,086	23%
New Mexico ²	655	624	-5%	654	623	-5%
New York	19,051	19,462	2%	15,294	15,811	3%
North Carolina	4,605	5,463	19%	3,428	3,465	1%
North Dakota	100	67	-33%	57	60	5%
Northern Mariana Islands	--	--	--	--	--	--
Ohio	4,367	3,415	-22%	2,581	1,786	-31%
Oklahoma	1,264	1,275	1%	1,054	1,035	-2%
Oregon	2,688	2,903	8%	2,630	2,831	8%
Pennsylvania	5,066	5,550	10%	4,019	4,299	7%
Puerto Rico	4,633	4,617	0%	4,328	4,617	7%
Republic of Palau	--	--	--	--	--	--
Rhode Island	717	660	-8%	508	524	3%
South Carolina	3,180	3,022	-5%	2,780	2,455	-12%
South Dakota	77	95	23%	77	95	23%
Tennessee	3,682	3,931	7%	2,535	2,886	14%
Texas	12,716	14,123	11%	8,862	10,959	24%
Utah	275	510	85%	250	405	62%
Vermont	--	312	--	--	106	--
Virgin Islands (U.S.)	131	--	--	131	--	--
Virginia	3,453	2,824	-18%	2,144	1,992	-7%
Washington	3,854	3,393	-12%	3,140	3,115	-1%
West Virginia	511	529	4%	283	318	12%
Wisconsin	1,597	1,761	10%	824	1,003	22%
Wyoming	136	135	-1%	65	70	8%
Total	179,009	179,988		135,596	138,173	
Comparison Total¹	180,404	179,102	-1%	134,731	137,287	2%

¹ Comparison Totals are based on only those ADAPs that reported data in both time periods.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 10: ADAP Clients Served, by Race/Ethnicity, June 2011

State/Territory	June 2011 Clients Served	Non-Hispanic Black/African American	Non-Hispanic White	Hispanic	Asian	Native Hawaiian/Pacific Islander	American Indian/Alaskan Native	Multi-Racial	Other	Unknown
Alabama	1,534	63%	33%	4%	0.5%	0%	0.1%	0%	0%	0%
Alaska	79	11%	53%	19%	11%	0%	5%	0%	0%	0%
American Samoa	--	--	--	--	--	--	--	--	--	--
Arizona	1,114	8%	46%	41%	1%	0%	2%	1%	0.2%	1%
Arkansas	389	35%	53%	7%	0%	0%	0.3%	3%	1%	1%
California	26,586	12%	38%	41%	4%	0.3%	0.3%	4%	0%	1%
Colorado	1,775	14%	52%	28%	1%	0.1%	1%	2%	2%	0%
Connecticut	1,678	35%	38%	25%	1%	0.1%	0.4%	0%	0%	0%
Delaware	677	64%	29%	5%	0.3%	0%	0.1%	1%	0%	0.1%
District of Columbia	861	64%	16%	17%	1%	0%	0.2%	1%	0%	2%
Federated States of Micronesia	--	--	--	--	--	--	--	--	--	--
Florida	8,396	38%	29%	31%	1%	0.1%	0.1%	0.2%	0.3%	0%
Georgia	3,958	64%	23%	10%	1%	0.1%	0.2%	1%	0.5%	0.03%
Guam	--	--	--	--	--	--	--	--	--	--
Hawaii	266	5%	51%	8%	17%	9%	1%	9%	0%	0%
Idaho	123	4%	76%	18%	1%	0%	2%	0%	0%	0%
Illinois	4,097	39%	27%	27%	1%	0.1%	0.1%	3%	0%	2%
Indiana	1,885	27%	63%	6%	1%	0%	0.1%	1%	2%	0%
Iowa	471	19%	64%	12%	3%	0.2%	1%	1%	0%	0.2%
Kansas	778	25%	57%	16%	1%	1%	1%	0%	0%	0%
Kentucky	1,424	30%	63%	5%	0%	0%	0%	0%	1%	1%
Louisiana	1,938	62%	33%	3%	0.3%	0.1%	0.3%	1%	0.4%	0%
Maine	285	9%	71%	6%	0.4%	0%	2%	7%	0%	5%
Marshall Islands	--	--	--	--	--	--	--	--	--	--
Maryland	4,071	69%	21%	0.3%	1%	0.1%	0.2%	0.1%	9%	1%
Massachusetts	4,285	29%	41%	26%	2%	0.05%	0.1%	1%	1%	1%
Michigan	2,205	43%	46%	5%	1%	0.2%	1%	0%	1%	4%
Minnesota	653	26%	53%	17%	1%	0.3%	0.3%	0.3%	0%	19%
Mississippi	886	26%	17%	0.3%	0%	19%	0%	0%	0%	0%
Missouri	1,727	47%	48%	2%	1%	0.1%	0.2%	0.3%	0%	1%
Montana	92	1%	87%	2%	0%	1%	8%	0%	0%	1%
Nebraska	377	26%	51%	19%	0%	0%	1%	0%	3%	0%
Nevada	845	20%	48%	30%	0.5%	0.5%	0.2%	0.1%	0%	1%
New Hampshire	177	12%	71%	10%	1%	0%	0%	4%	1%	2%
New Jersey	6,086	48%	20%	28%	1%	1%	2%	0%	0%	0%
New Mexico	623	5%	42%	48%	0%	0.3%	4%	0%	1%	0%
New York	15,811	34%	28%	30%	2%	0.3%	0.3%	0%	0%	5%
North Carolina	3,465	61%	29%	7%	0%	0.2%	1%	1%	0%	0%
North Dakota	60	10%	85%	0%	0%	0%	5%	0%	0%	0%
Northern Mariana Islands	--	--	--	--	--	--	--	--	--	--
Ohio	1,786	36%	56%	5%	1%	0.1%	0.2%	0%	2%	0%
Oklahoma	1,035	20%	64%	7%	1%	0.4%	8%	0.1%	0.1%	0%
Oregon	2,831	7%	72%	15%	1%	0.5%	2%	2%	0.5%	0.04%
Pennsylvania	4,299	43%	40%	10%	1%	0%	0%	0%	1%	4%
Puerto Rico	4,617	0%	0%	100%	0%	0%	0%	0%	0%	0%
Republic of Palau	--	--	--	--	--	--	--	--	--	--
Rhode Island	524	23%	50%	23%	1%	0.2%	1%	1%	0.4%	0%
South Carolina	2,455	65%	27%	5%	0.4%	0.1%	0.1%	2%	0%	0.2%
South Dakota	95	29%	56%	4%	0%	0%	11%	0%	0%	0%
Tennessee	2,886	55%	40%	4%	1%	0.03%	0.03%	0%	1%	0.2%
Texas	10,959	30%	28%	38%	1%	0%	0.3%	0%	1%	1%
Utah	405	10%	52%	35%	0.5%	1%	1%	0%	0%	0%
Vermont	106	8%	87%	0%	0%	0%	1%	2%	0%	3%
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--	--	--
Virginia	1,992	50%	29%	10%	1%	0%	0.3%	0%	0.3%	9%
Washington	3,115	12%	58%	17%	2%	1%	1%	6%	2%	1%
West Virginia	318	14%	83%	2%	1%	0.3%	0.3%	0%	0%	0%
Wisconsin	1,003	32%	48%	16%	2%	0.1%	1%	0%	1%	1%
Wyoming	70	6%	83%	4%	1%	0%	6%	1%	0%	0%
Total	138,173	32%	35%	27%	2%	0.2%	0.5%	1%	0.6%	1%

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. A dash (--) indicates no data available from the ADAP. A zero (0%) indicates a response of zero (0%) from the ADAP.

Table 11: ADAP Clients Served, by Gender, June 2011

State/Territory	June 2011 Clients Served	Male	Female	Transgender	Unknown
Alabama	1,534	71%	29%	0%	0%
Alaska	79	78%	22%	0%	0%
American Samoa	--	--	--	--	--
Arizona	1,114	84%	15%	1%	0%
Arkansas	389	79%	21%	0%	0%
California	26,586	91%	8%	0.5%	0%
Colorado	1,775	86%	13%	0.5%	0.1%
Connecticut	1,678	72%	28%	0%	0%
Delaware	677	62%	38%	0.1%	0%
District of Columbia	861	76%	24%	0.1%	0.3%
Federated States of Micronesia	--	--	--	--	--
Florida	8,396	74%	26%	0.2%	0%
Georgia	3,958	74%	25%	0.5%	0%
Guam	--	--	--	--	--
Hawaii	266	89%	10%	1%	0%
Idaho	123	80%	20%	0%	0%
Illinois	4,097	83%	16%	0.4%	0.1%
Indiana	1,885	84%	16%	0%	0%
Iowa	471	78%	21%	1%	0%
Kansas	778	78%	22%	0.4%	0%
Kentucky	1,424	81%	18%	1%	0%
Louisiana	1,938	70%	30%	0.1%	0%
Maine	285	85%	15%	0.4%	0.4%
Marshall Islands	--	--	--	--	--
Maryland	4,071	64%	36%	0.05%	0%
Massachusetts	4,285	68%	32%	0.2%	0%
Michigan	2,205	83%	17%	0%	0%
Minnesota	653	78%	22%	0%	0%
Mississippi	886	73%	27%	0%	0%
Missouri	1,727	82%	18%	0%	0%
Montana	92	90%	10%	0%	0%
Nebraska	377	73%	27%	0%	0%
Nevada	845	81%	18%	0.2%	0%
New Hampshire	177	75%	25%	0%	0%
New Jersey	6,086	68%	32%	0%	0%
New Mexico	623	91%	9%	0.2%	0%
New York	15,811	76%	24%	0.2%	0%
North Carolina	3,465	70%	29%	0.2%	0%
North Dakota	60	87%	13%	0%	0%
Northern Mariana Islands	--	--	--	--	--
Ohio	1,786	83%	17%	0.4%	0%
Oklahoma	1,035	84%	15%	0.2%	0.1%
Oregon	2,831	84%	15%	0.3%	0%
Pennsylvania	4,299	76%	24%	0.05%	0%
Puerto Rico	4,617	63%	37%	0%	0%
Republic of Palau	--	--	--	--	--
Rhode Island	524	78%	22%	1%	0%
South Carolina	2,455	70%	30%	0.2%	0%
South Dakota	95	71%	29%	0%	0%
Tennessee	2,886	76%	23%	0.1%	0.03%
Texas	10,959	78%	22%	0.3%	0%
Utah	405	83%	17%	0%	0%
Vermont	106	83%	17%	0%	0%
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	1,992	68%	28%	0.1%	3%
Washington	3,115	87%	13%	0.5%	0%
West Virginia	318	85%	15%	0%	0%
Wisconsin	1,003	85%	14%	1%	0%
Wyoming	70	80%	20%	0%	0%
Total	138,173	78%	21%	0.3%	0.1%

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. A dash (--) indicates no data available from the ADAP. A zero (0%) indicates a response of zero (0%) from the ADAP.

Table 12: ADAP Clients Served, by Age, June 2011

State/Territory	June 2011 Clients Served	≤12 Years	13-24 Years	25-44 Years	45-64 Years	>64 Years	Age Unknown
Alabama	1,534	0%	7%	53%	39%	1%	0%
Alaska	79	0%	3%	48%	47%	3%	0%
American Samoa	--	--	--	--	--	--	--
Arizona	1,114	0.1%	2%	41%	52%	5%	0%
Arkansas	389	0%	5%	50%	43%	2%	0%
California	26,586	0%	2%	44%	50%	4%	0%
Colorado	1,775	0.2%	2%	43%	50%	3%	0%
Connecticut	1,678	0.1%	1%	34%	59%	5%	0%
Delaware	677	0%	2%	35%	60%	3%	0%
District of Columbia	861	0%	3%	47%	47%	4%	0%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	8,396	0.1%	2%	40%	55%	3%	0%
Georgia	3,958	0.03%	3%	48%	47%	2%	0%
Guam	--	--	--	--	--	--	--
Hawaii	266	0%	2%	26%	65%	8%	0%
Idaho	123	0%	5%	54%	41%	1%	0%
Illinois	4,097	0.1%	6%	51%	42%	1%	0%
Indiana	1,885	0.1%	5%	49%	44%	2%	0%
Iowa	471	0%	3%	51%	44%	2%	0%
Kansas	778	1%	5%	44%	48%	3%	0%
Kentucky	1,424	0%	3%	43%	51%	3%	0%
Louisiana	1,938	0%	4%	48%	46%	3%	0%
Maine	285	0%	1%	29%	60%	5%	5%
Marshall Islands	--	--	--	--	--	--	--
Maryland	4,071	0.1%	2%	39%	55%	4%	0%
Massachusetts	4,285	0.05%	1%	32%	62%	4%	0%
Michigan	2,205	0.2%	4%	41%	51%	3%	0%
Minnesota	653	1%	3%	48%	45%	3%	0%
Mississippi	886	0.1%	9%	54%	36%	1%	0%
Missouri	1,727	0.2%	6%	54%	39%	0.1%	0%
Montana	92	0%	0%	50%	49%	0%	1%
Nebraska	377	1%	3%	50%	45%	2%	0%
Nevada	845	0.1%	4%	46%	47%	3%	0%
New Hampshire	177	0%	2%	27%	67%	4%	0%
New Jersey	6,086	0.2%	4%	40%	53%	2%	0%
New Mexico	623	0%	3%	37%	59%	1%	0%
New York	15,811	0.1%	2%	39%	53%	5%	0%
North Carolina	3,465	0%	5%	47%	45%	3%	0%
North Dakota	60	0%	3%	70%	23%	3%	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	1,786	0%	2%	40%	55%	3%	0%
Oklahoma	1,035	0%	4%	46%	48%	2%	0%
Oregon	2,831	0%	3%	44%	50%	3%	0%
Pennsylvania	4,299	0.05%	3%	37%	56%	4%	0%
Puerto Rico	4,617	0.3%	3%	34%	60%	2%	0%
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	524	0.4%	3%	38%	54%	5%	0%
South Carolina	2,455	0.1%	3%	41%	54%	2%	0%
South Dakota	95	0%	3%	45%	49%	2%	0%
Tennessee	2,886	0.1%	6%	52%	42%	0.5%	0%
Texas	10,959	0.1%	4%	49%	45%	2%	0%
Utah	405	0%	0.2%	55%	42%	3%	0%
Vermont	106	0%	1%	31%	63%	5%	0%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	1,992	0.2%	6%	51%	39%	2%	2%
Washington	3,115	0.03%	2%	42%	52%	3%	0%
West Virginia	318	0%	1%	43%	51%	5%	0%
Wisconsin	1,003	0.1%	6%	46%	46%	2%	0%
Wyoming	70	0%	0%	43%	54%	3%	0%
Total	138,173	0.1%	3%	43%	50%	3%	0.03%

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. A dash (--) indicates no data available from the ADAP. A zero (0%) indicates a response of zero (0%) from the ADAP.

Table 13: ADAP Clients Served, by Income Level, June 2011

State/Territory	June 2011 Clients Served	≤100% FPL	101-133% FPL	134-200% FPL	201-300% FPL	301-400% FPL	>400% FPL	Unknown
Alabama	1,534	70%	11%	14%	4%	0.1%	0.1%	0%
Alaska	79	34%	15%	25%	25%	0%	0%	0%
American Samoa	--	--	--	--	--	--	--	--
Arizona	1,114	23%	17%	34%	25%	0%	0%	0%
Arkansas	389	47%	17%	35%	0%	0%	0%	0%
California	26,586	43%	10%	20%	17%	9%	1%	0.3%
Colorado	1,775	44%	11%	23%	16%	7%	0%	0%
Connecticut	1,678	30%	24%	20%	19%	6%	1%	0%
Delaware	677	46%	11%	18%	11%	6%	2%	7%
District of Columbia	861	49%	7%	16%	17%	9%	0%	0%
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	8,396	46%	16%	21%	14%	3%	0%	0%
Georgia	3,958	50%	22%	16%	17%	9%	0%	0%
Guam	--	--	--	--	--	--	--	--
Hawaii	266	32%	13%	37%	17%	2%	0%	0%
Idaho	123	64%	18%	18%	0%	0%	0%	0%
Illinois	4,097	53%	25%	4%	13%	4%	1%	0%
Indiana	1,885	47%	14%	24%	15%	0%	0%	0%
Iowa	471	44%	15%	24%	11%	1%	0%	5%
Kansas	778	49%	12%	18%	20%	1%	0%	0%
Kentucky	1,424	51%	14%	19%	14%	1%	0%	0%
Louisiana	1,938	--	--	--	--	--	0%	--
Maine	285	45%	11%	22%	17%	4%	1%	0%
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	4,071	24%	11%	23%	22%	14%	0%	0%
Massachusetts	4,285	48%	8%	15%	14%	9%	7%	0%
Michigan	2,205	26%	14%	24%	19%	8%	5%	4%
Minnesota	653	19%	6%	28%	47%	0%	0%	0%
Mississippi	886	58%	14%	20%	7%	1%	0%	0%
Missouri	1,727	50%	20%	14%	16%	0%	0%	0%
Montana	92	35%	20%	12%	25%	5%	1%	2%
Nebraska	377	0%	0%	100%	0%	0%	0%	0%
Nevada	845	47%	14%	22%	12%	5%	0%	0%
New Hampshire	177	31%	13%	32%	24%	1%	0%	0%
New Jersey	6,086	32%	11%	11%	19%	13%	15%	0%
New Mexico	623	52%	13%	23%	13%	0%	0%	0%
New York	15,811	33%	10%	24%	19%	12%	1%	0%
North Carolina	3,465	57%	26%	13%	4%	0%	0%	0%
North Dakota	60	50%	12%	12%	15%	10%	2%	0%
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	1,786	44%	11%	25%	20%	0%	0%	0%
Oklahoma	1,035	43%	56%	0%	2%	0%	0%	0%
Oregon	2,831	56%	17%	18%	9%	0%	0%	0%
Pennsylvania	4,299	13%	11%	21%	24%	12%	6%	11%
Puerto Rico	4,617	95%	0%	5%	0%	0%	0%	0%
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	524	50%	21%	14%	14%	2%	0%	0%
South Carolina	2,455	42%	10%	22%	19%	5%	2%	0%
South Dakota	95	44%	18%	17%	21%	0%	0%	0%
Tennessee	2,886	51%	11%	18%	20%	0%	0%	0%
Texas	10,959	55%	10%	35%	0%	0%	0%	0%
Utah	405	55%	10%	20%	15%	0%	0%	0%
Vermont	106	31%	34%	35%	0%	0%	0%	0%
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--
Virginia	1,992	63%	11%	14%	9%	1%	0%	3%
Washington	3,115	36%	14%	25%	22%	3%	0%	0%
West Virginia	318	54%	33%	8%	4%	1%	0%	0%
Wisconsin	1,003	48%	12%	19%	21%	0%	0%	0.5%
Wyoming	70	43%	21%	17%	17%	1%	0%	6%
Total	138,173	44%	12%	20%	14%	6%	2%	1%

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. A dash (--) indicates no data available from the ADAP. A zero (0%) indicates a response of zero (0%) from the ADAP. The 2010 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one.

Table 14: ADAP Clients Served, by Insurance Status, June 2011

State/Territory	June 2011 Clients Served	Medicaid	Medicare	Dually Eligible ¹	Private Insurance	PCIPs	Uninsured
Alabama	1,534	0%	5%	0%	0%	0%	95%
Alaska	79	0%	5%	0%	68%	0%	32%
American Samoa	--	--	--	--	--	--	--
Arizona	1,114	0%	28%	0%	0.2%	15%	61%
Arkansas	389	0%	19%	0%	0%	0%	96%
California	26,586	1%	15%	7%	17%	0%	67%
Colorado	1,775	0%	19%	6%	15%	0%	71%
Connecticut	1,678	0.4%	28%	0%	32%	0%	63%
Delaware	677	89%	10%	8%	25%	0%	17%
District of Columbia	861	0%	26%	0%	0%	0%	0%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	8,396	1%	7%	0.5%	6%	0%	100%
Georgia	3,958	0%	5%	0%	0%	0%	0%
Guam	--	--	--	--	--	--	--
Hawaii	266	0%	26%	0%	21%	0%	53%
Idaho	123	0%	0%	0%	0%	0%	100%
Illinois	4,097	0%	3%	0.1%	7%	0.4%	100%
Indiana	1,885	0%	22%	0%	0%	0%	79%
Iowa	471	4%	14%	0%	18%	0%	64%
Kansas	778	19%	16%	6%	25%	0%	48%
Kentucky	1,424	--	--	--	--	--	--
Louisiana	1,938	0%	11%	0%	12%	0%	0%
Maine	285	78%	2%	8%	5%	0%	6%
Marshall Islands	--	--	--	--	--	--	--
Maryland	4,071	0%	34%	0%	71%	0.2%	35%
Massachusetts	4,285	28%	3%	16%	11%	0%	4%
Michigan	2,205	0%	23%	0%	39%	3%	66%
Minnesota	653	0%	28%	28%	0%	0%	0%
Mississippi	886	0%	5%	0%	0%	0%	95%
Missouri	1,727	10%	0.1%	0%	30%	5%	55%
Montana	92	0%	0%	0%	24%	0%	76%
Nebraska	377	1%	0%	0%	27%	0%	73%
Nevada	845	4%	21%	8%	18%	0%	81%
New Hampshire	177	29%	38%	18%	32%	1%	24%
New Jersey	6,086	0%	5%	0%	25%	0%	0%
New Mexico	623	0%	18%	0%	90%	7%	2%
New York	15,811	2%	20%	0%	32%	2%	46%
North Carolina	3,465	0%	0%	0%	0%	0%	0%
North Dakota	60	0%	0%	0%	0%	0%	0%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	1,786	18%	54%	0%	29%	0.4%	62%
Oklahoma	1,035	1%	15%	1%	33%	0%	52%
Oregon	2,831	17%	27%	8%	41%	6%	2%
Pennsylvania	4,299	14%	20%	1%	29%	0%	68%
Puerto Rico	4,617	95%	0%	0%	2%	0%	3%
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	524	0%	11%	12%	24%	0%	53%
South Carolina	2,455	0%	0%	0%	29%	0.2%	71%
South Dakota	95	16%	12%	4%	28%	0%	41%
Tennessee	2,886	0%	0%	0%	0%	1%	100%
Texas	10,959	2%	12%	0%	1%	0%	85%
Utah	405	0%	2%	0%	0%	0%	0%
Vermont	106	51%	37%	19%	18%	0%	6%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	1,992	1%	8%	0%	1%	0%	81%
Washington	3,115	6%	29%	6%	67%	5%	5%
West Virginia	318	3%	36%	2%	3%	1%	61%
Wisconsin	1,003	6%	12%	4%	14%	1%	55%
Wyoming	70	6%	21%	1%	9%	9%	56%
Total	138,173	10%	15%	6%	21%	2%	60%
Comparison Total²		95,743	124,098	65,366	121,068	50,012	120,747

¹ Eligible for both Medicare and Medicaid.

² Comparison Totals are used to calculate the overall category percentages.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011. A dash (--) indicates no data available from the ADAP. A zero (0%) indicates a response of zero (0%) from the ADAP. Insurance categories are not mutually exclusive. Insurance status percentages by category are based on the number of clients from ADAPs that reported data for that category.

Table 15: ADAP Clients by CD4 Count, Enrolled During 12-Month Period, June 2011

State/Territory	Number of Clients ¹	CD4 ≤200	CD4 between 201-350	CD4 between 351-500	CD4 > 500
Alabama	1,534	12%	18%	20%	50%
Alaska	--	--	--	--	--
American Samoa	--	--	--	--	--
Arizona	433	26%	22%	21%	31%
Arkansas	157	26%	21%	0%	0%
California	3,950	23%	20%	23%	34%
Colorado	--	--	--	--	--
Connecticut	--	--	--	--	--
Delaware	186	40%	19%	18%	23%
District of Columbia	307	25%	20%	20%	35%
Federated States of Micronesia	--	--	--	--	--
Florida	999	23%	20%	21%	36%
Georgia	416	28%	29%	20%	22%
Guam	--	--	--	--	--
Hawaii	59	19%	19%	31%	32%
Idaho	56	25%	18%	25%	32%
Illinois	6,447	15%	23%	23%	39%
Indiana	694	70%	7%	7%	16%
Iowa	212	21%	24%	27%	28%
Kansas	245	16%	18%	20%	46%
Kentucky	--	--	--	--	--
Louisiana	--	--	--	--	--
Maine	--	--	--	--	--
Marshall Islands	--	--	--	--	--
Maryland	1,084	27%	21%	21%	30%
Massachusetts	880	19%	19%	20%	43%
Michigan	--	--	--	--	--
Minnesota	1,993	13%	17%	23%	47%
Mississippi	--	--	--	--	--
Missouri	--	--	--	--	--
Montana	49	8%	22%	31%	39%
Nebraska	--	--	--	--	--
Nevada	165	42%	1%	0%	58%
New Hampshire	451	10%	13%	21%	57%
New Jersey	1,096	36%	19%	18%	27%
New Mexico	--	--	--	--	--
New York	2,411	25%	20%	21%	35%
North Carolina	3,465	23%	21%	19%	37%
North Dakota	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--
Ohio	93	31%	16%	20%	32%
Oklahoma	1,270	16%	21%	24%	39%
Oregon	343	29%	26%	32%	13%
Pennsylvania	--	--	--	--	--
Puerto Rico	--	--	--	--	--
Republic of Palau	--	--	--	--	--
Rhode Island	--	--	--	--	--
South Carolina	300	33%	28%	23%	15%
South Dakota	--	--	--	--	--
Tennessee	930	18%	22%	24%	36%
Texas	3,377	34%	27%	21%	18%
Utah	--	--	--	--	--
Vermont	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	1,824	14%	18%	22%	46%
Washington	--	--	--	--	--
West Virginia	98	24%	44%	23%	8%
Wisconsin	233	23%	23%	22%	32%
Wyoming	--	--	--	--	--
Total	35,757	22%	21%	21%	35%

¹This number reflects only the number of clients for which CD4 count was reported.

Note: 32 ADAPs reported data. Data reflect clients enrolled in ADAPs over the past 12 months or the most recent 12 months for which data are available.

Table 16: ADAP Drug Expenditures (Including Purchases and Co-payments), June 2011

State/Territory	June 2011 Drug Purchases	Drug Purchases % of Total Expenditures	June 2011 Co-Payment Expenditures	Co-Payment % of Total Expenditures	June 2011 Total Drug Expenditures (Including Purchases and Co-payments)
Alabama	\$1,437,733	99%	\$11,518	1%	\$1,449,251
Alaska	\$60,649	100%	\$0	0%	\$60,649
American Samoa	--	--	--	--	--
Arizona	\$667,285	82%	\$145,390	18%	\$812,675
Arkansas	--	--	--	--	--
California	\$40,300,136	100%	\$0	0%	\$40,300,136
Colorado	\$1,258,723	92%	\$105,528	8%	\$1,364,251
Connecticut	\$1,985,668	94%	\$135,427	6%	\$2,121,095
Delaware	\$221,681	100%	\$0	0%	\$221,681
District of Columbia	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--
Florida	\$6,904,709	100%	\$0	0%	\$6,904,709
Georgia	\$3,208,840	100%	\$0	0%	\$3,208,840
Guam	--	--	--	--	--
Hawaii	\$173,369	95%	\$10,082	5%	\$183,451
Idaho	\$321,098	100%	\$0	0%	\$321,098
Illinois	\$4,016,627	98%	\$74,232	2%	\$4,090,859
Indiana	\$109,089	31%	\$242,175	69%	\$351,264
Iowa	\$257,401	91%	\$25,274	9%	\$282,675
Kansas	\$878,858	77%	\$255,326	23%	\$1,134,184
Kentucky	\$886,305	92%	\$76,849	8%	\$963,154
Louisiana	\$1,391,835	91%	\$130,997	9%	\$1,522,832
Maine	\$67,874	96%	\$2,657	4%	\$70,530
Marshall Islands	--	--	--	--	--
Maryland	\$2,313,678	84%	\$432,020	16%	\$2,745,698
Massachusetts	\$365,210	57%	\$280,863	43%	\$646,073
Michigan	\$2,194,341	87%	\$332,874	13%	\$2,527,215
Minnesota	\$248,608	69%	\$114,068	31%	\$362,676
Mississippi	\$851,086	100%	\$0	0%	\$851,086
Missouri	\$1,882,667	100%	\$178,477	9%	\$2,061,144
Montana	\$86,066	93%	\$6,137	7%	\$92,203
Nebraska	\$284,531	94%	\$16,710	6%	\$301,241
Nevada	\$580,380	90%	\$62,190	10%	\$642,570
New Hampshire	\$127,472	84%	\$24,959	16%	\$152,431
New Jersey	\$7,833,884	100%	\$0	0%	\$7,833,884
New Mexico	\$13,837	100%	\$0	0%	\$13,837
New York	\$22,785,301	100%	\$0	0%	\$22,785,301
North Carolina	\$2,704,771	94%	\$177,737	6%	\$2,882,508
North Dakota	\$63,217	100%	\$0	0%	\$63,217
Northern Mariana Islands	--	--	--	--	--
Ohio	\$969,250	65%	\$530,736	35%	\$1,499,986
Oklahoma	\$716,541	92%	\$65,932	8%	\$782,473
Oregon ¹	\$27,739	11%	\$225,378	89%	\$253,117
Pennsylvania	\$6,062,615	92%	\$558,917	8%	\$6,621,533
Puerto Rico	--	--	--	--	--
Republic of Palau	--	--	--	--	--
Rhode Island	\$582,412	100%	\$0	0%	\$582,412
South Carolina	\$1,010,386	89%	\$121,826	11%	\$1,132,211
South Dakota	\$85,324	100%	\$0	0%	\$85,324
Tennessee	\$1,786,758	100%	\$0	0%	\$1,786,758
Texas	\$8,363,516	97%	\$243,837	3%	\$8,607,353
Utah	\$294,218	91%	\$28,877	9%	\$323,095
Vermont	\$23,485	79%	\$6,130	21%	\$29,615
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	\$1,752,487	97%	\$49,003	3%	\$1,801,490
Washington	\$214,145	44%	\$273,943	56%	\$488,088
West Virginia	\$323,350	100%	\$0	0%	\$323,350
Wisconsin	\$1,405,118	100%	\$0	0%	\$1,405,118
Wyoming	\$87,422	95%	\$4,365	5%	\$91,787
Total	\$130,187,695	96%	\$4,950,434	4%	\$135,138,130

¹ Oregon expenditure data changes dramatically when comparing June 2010 and June 2011 due to a change in purchasing mechanism.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 17: ADAP Drug Expenditures (Including Purchases and Co-payments), by Drug Category, June 2011

State/Territory	June 2011 Total Expenditures	June 2011 ARV Total Expenditures ¹	ARV % of Total Expenditures ¹	June 2011 "A1" OI Total Expenditures ²	"A1" OI % of Total Expenditures ²	June 2011 All Other Total Expenditures	All Other % of Total Expenditures
Alabama	\$1,449,251	\$1,359,338	94%	\$26,021	2%	\$63,892	4%
Alaska	\$60,649	\$59,234	99%	\$1,091	0%	\$324	1%
American Samoa	--	--	--	--	--	--	--
Arizona	\$812,675	\$795,253	98%	\$2,511	0%	\$14,911	2%
Arkansas	--	\$357,230	--	\$8,927	--	\$20,115	--
California	\$40,300,136	\$36,833,333	91%	\$797,716	2%	\$2,669,088	7%
Colorado	\$1,364,251	\$1,304,616	96%	\$58,655	4%	\$980	0%
Connecticut	\$2,121,095	\$1,949,372	92%	\$29,799	1%	\$141,924	7%
Delaware	\$221,681	\$199,744	90%	\$764	0%	\$21,173	10%
District of Columbia	--	--	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	\$6,904,709	\$6,847,310	99%	\$57,400	1%	\$0	0%
Georgia	\$3,208,840	\$3,208,840	0%	\$0	0%	\$0	0%
Guam	--	--	--	--	--	--	--
Hawaii	\$183,451	\$170,268	93%	\$1,767	1%	\$11,416	6%
Idaho	\$321,098	\$317,705	99%	\$3,392	1%	\$0	0%
Illinois	\$4,090,859	\$3,551,872	87%	\$44,311	1%	\$494,676	12%
Indiana	\$351,264	\$176,024	50%	\$6,667	2%	\$168,573	48%
Iowa	\$282,675	\$277,973	98%	\$3,633	1%	\$1,069	0%
Kansas	\$1,134,184	\$1,068,843	94%	\$9,406	1%	\$55,935	5%
Kentucky	\$963,154	\$963,154	100%	\$0	0%	\$0	0%
Louisiana	\$1,522,832	\$1,481,188	97%	\$6,816	0%	\$34,828	2%
Maine	\$70,530	\$61,829	88%	\$526	1%	\$8,176	12%
Marshall Islands	--	--	--	--	--	--	--
Maryland	\$2,745,698	\$2,629,402	96%	\$17,870	1%	\$98,426	4%
Massachusetts	\$646,073	\$523,686	81%	\$21,910	3%	\$100,478	16%
Michigan	\$2,527,215	\$2,376,218	94%	\$37,867	1%	\$113,129	4%
Minnesota	\$362,676	\$344,845	95%	\$8,847	2%	\$8,984	2%
Mississippi	\$851,086	\$805,408	95%	\$24,361	3%	\$21,317	3%
Missouri	\$2,061,144	\$1,948,917	95%	\$20,368	1%	\$91,859	4%
Montana	\$92,203	\$92,008	100%	\$92	0%	\$103	0%
Nebraska	\$301,241	\$292,735	97%	\$3,246	1%	\$5,260	2%
Nevada ³	\$642,570	\$624,762	97%	\$17,808	3%	\$0	0%
New Hampshire	\$152,431	\$140,915	92%	\$526	0%	\$10,990	7%
New Jersey	\$7,833,884	\$5,498,668	70%	\$69,916	1%	\$2,265,300	29%
New Mexico	\$13,837	\$13,637	99%	\$123	1%	\$77	1%
New York	\$22,785,301	\$20,342,761	89%	\$2443,076	2%	\$1,999,465	9%
North Carolina	\$2,882,508	\$2,782,402	97%	\$60,419	2%	\$39,687	1%
North Dakota	\$63,217	\$60,843	96%	\$0	0%	\$2,374	4%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	\$1,499,986	\$1,479,748	99%	\$10,708	1%	\$9,530	1%
Oklahoma	\$782,473	\$729,704	93%	\$7,277	1%	\$45,492	6%
Oregon ³	\$253,117	\$141,444	56%	\$11,833	5%	\$99,840	39%
Pennsylvania	\$6,621,533	\$5,863,706	89%	\$101,321	2%	\$656,506	10%
Puerto Rico	--	--	--	--	--	--	--
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	\$582,412	\$572,544	98%	\$6,096	1%	\$3,772	1%
South Carolina	\$1,132,211	\$1,044,681	92%	\$4,640	0%	\$82,890	7%
South Dakota	\$85,324	\$78,807	92%	\$2,487	3%	\$4,030	5%
Tennessee	\$1,786,758	\$1,741,859	97%	\$42,046	2%	\$2,853	0%
Texas	\$8,607,353	\$8,452,871	98%	\$98,295	1%	\$56,187	1%
Utah	\$323,095	\$318,560	99%	\$4,535	1%	\$0	0%
Vermont	\$29,615	\$28,724	97%	\$364	1%	\$527	2%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	\$1,801,490	\$1,758,865	98%	\$40,910	2%	\$1,715	0%
Washington	\$488,088	\$460,723	94%	\$2,957	1%	\$24,407	5%
West Virginia	\$323,350	\$309,166	96%	\$6,349	2%	\$7,835	2%
Wisconsin	\$1,405,118	\$1,351,799	96%	\$33,415	2%	\$19,904	1%
Wyoming	\$91,787	\$88,688	97%	\$143	0%	\$2,956	3%
Total	\$135,138,130	\$123,882,222	92%	\$2,159,208	2%	\$9,482,972	7%

¹ ARV=Antiretrovirals.

² "A1" OI=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).

³ Oregon expenditure data changes dramatically when comparing June 2010 and June 2011 due to a change in purchasing mechanism.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 18: ADAP Prescriptions Filled (Including Purchases and Co-payments), June 2011

State/Territory	June 2011 Drug Purchases Rx ¹	Drug Purchases Rx % of Total Rx	June 2011 Co-Payment Rx	Co-Payment Rx % of Total Rx	June 2011 Total Rx
Alabama	4,319	94%	272	6%	4,591
Alaska	216	100%	0	0%	216
American Samoa	--	--	--	--	--
Arizona	1,952	46%	2,257	54%	4,209
Arkansas	--	--	--	--	--
California	100,987	100%	0	0%	100,987
Colorado	3,414	59%	2,342	41%	5,756
Connecticut	4,707	82%	1,001	18%	5,708
Delaware	2,999	100%	0	0%	2,999
District of Columbia	1,770	100%	0	0%	1,770
Federated States of Micronesia	--	--	--	--	--
Florida	18,840	100%	0	0%	18,840
Georgia	9,343	100%	0	0%	9,343
Guam	--	--	--	--	--
Hawaii	556	74%	194	26%	750
Idaho	354	100%	0	0%	354
Illinois	10,390	94%	665	6%	11,055
Indiana	264	2%	11,157	98%	11,421
Iowa	696	58%	514	42%	1,210
Kansas	273	26%	796	74%	1,069
Kentucky	4,118	88%	556	12%	4,674
Louisiana	3,395	55%	2,745	45%	6,140
Maine	806	71%	328	29%	1,134
Marshall Islands	--	--	--	--	--
Maryland	3,550	34%	7,001	66%	10,551
Massachusetts	1,138	6%	16,448	94%	17,586
Michigan	4,281	47%	4,844	53%	9,125
Minnesota	569	32%	1,225	68%	1,794
Mississippi	2,828	100%	0	0%	2,828
Missouri	3,294	100%	1,625	0%	4,919
Montana	212	79%	55	21%	267
Nebraska	867	71%	357	29%	1,224
Nevada	1,731	66%	906	34%	2,637
New Hampshire	199	22%	707	78%	906
New Jersey	20,212	100%	0	0%	20,212
New Mexico	37	100%	0	0%	37
New York	69,484	100%	0	0%	69,484
North Carolina	7,711	87%	1,111	13%	8,822
North Dakota	123	100%	0	0%	123
Northern Mariana Islands	--	--	--	--	--
Ohio	2,665	52%	2,486	48%	5,151
Oklahoma	1,950	55%	1,585	45%	3,535
Oregon	179	2%	8,510	98%	8,689
Pennsylvania	12,272	58%	8,871	42%	21,143
Puerto Rico	--	--	--	--	--
Republic of Palau	--	--	--	--	--
Rhode Island	1,213	100%	0	0%	1,213
South Carolina	4,933	72%	1,895	28%	6,828
South Dakota	208	100%	0	0%	208
Tennessee	5,460	100%	0	0%	5,460
Texas	23,457	73%	8,841	27%	32,298
Utah	684	82%	149	18%	833
Vermont	24	8%	283	92%	307
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	4,746	73%	1,762	27%	6,508
Washington	676	11%	5,603	89%	6,279
West Virginia	831	100%	0	0%	831
Wisconsin	2,962	100%	0	0%	2,962
Wyoming	172	80%	44	20%	216
Total	348,067	78%	97,135	22%	445,202

¹Rx=Prescription

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 19: ADAP Prescriptions Filled (Including Purchases and Co-payments), by Drug Category, June 2011

State/Territory	June 2011 Total Rx ¹	June 2011 ARV Total Rx ²	ARV % of Total Rx ²	June 2011 "A1" OI Total Rx ³	"A1" OI % of Total Rx ³	June 2011 All Other Total Rx	All Other Rx % of Total Rx
Alabama	4,591	3,159	69%	504	11%	928	20%
Alaska	216	173	80%	22	10%	21	10%
American Samoa	--	--	--	--	--	--	--
Arizona	4,209	2,634	63%	566	13%	1,009	24%
Arkansas	--	875	--	171	--	377	--
California	100,987	59,279	59%	8,891	9%	32,817	32%
Colorado	5,756	4,520	79%	550	10%	686	12%
Connecticut	5,708	2,856	50%	376	7%	2,476	43%
Delaware	2,999	1,518	51%	104	3%	1,377	46%
District of Columbia	1,770	1,394	79%	78	4%	298	17%
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	18,840	18,016	96%	824	4%	0	0%
Georgia	9,343	9,343	100%	0	0%	0	0%
Guam	--	--	--	--	--	--	--
Hawaii	750	519	69%	74	10%	157	21%
Idaho	354	322	91%	32	9%	0	0%
Illinois	11,055	7,731	70%	621	6%	2,703	24%
Indiana	11,421	2,347	21%	400	4%	8,674	76%
Iowa	1,210	979	81%	122	10%	109	9%
Kansas	1,069	722	68%	152	14%	195	18%
Kentucky	4,674	4,674	100%	0	0%	0	0%
Louisiana	6,140	4,125	67%	406	7%	1,609	26%
Maine	1,134	476	42%	57	5%	601	53%
Marshall Islands	--	--	--	--	--	--	--
Maryland	10,551	6,639	63%	676	6%	3,236	31%
Massachusetts	17,586	6,582	37%	440	3%	10,564	60%
Michigan	9,125	4,991	55%	586	6%	3,548	39%
Minnesota	1,794	1,223	68%	131	7%	440	25%
Mississippi	2,828	2,434	86%	209	7%	185	7%
Missouri	4,919	2,970	60%	229	5%	1,720	35%
Montana	267	249	93%	4	1%	14	5%
Nebraska	1,224	861	70%	97	8%	266	22%
Nevada ⁴	2,637	1,998	76%	639	24%	0	0%
New Hampshire	906	378	42%	37	4%	491	54%
New Jersey	20,212	7,109	35%	962	5%	12,141	60%
New Mexico	37	29	78%	5	14%	3	8%
New York	69,484	31,390	45%	3,524	5%	34,570	50%
North Carolina	8,822	7,232	82%	1,193	14%	397	5%
North Dakota	123	96	78%	0	0%	27	22%
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	5,151	4,311	84%	376	7%	464	9%
Oklahoma	3,535	1,897	54%	229	6%	1,409	40%
Oregon	8,689	3,012	35%	520	6%	5,257	61%
Pennsylvania	21,143	8,760	41%	1,118	5%	11,265	53%
Puerto Rico	--	--	--	--	--	--	--
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	1,213	932	77%	103	8%	178	15%
South Carolina	6,828	5,432	80%	288	4%	1,108	16%
South Dakota	208	169	81%	24	12%	15	7%
Tennessee	5,460	3,616	66%	912	17%	932	17%
Texas	32,298	25,184	78%	1,470	5%	5,644	17%
Utah	833	749	90%	84	10%	0	0%
Vermont	307	208	68%	36	12%	63	21%
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	6,508	5,878	90%	608	9%	22	0%
Washington	6,279	4,070	65%	339	5%	1,870	30%
West Virginia	831	584	70%	129	16%	118	14%
Wisconsin	2,962	2,362	80%	338	11%	262	9%
Wyoming	216	117	54%	8	4%	91	42%
Total	445,202	267,124	60%	29,264	7%	150,337	34%

¹Rx=Prescription.

²ARV=Antiretrovirals.

³"A1" OI=Drugs recommended ("A1") for the prevention and treatment of opportunistic infections (OIs).

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 20: ADAP Average Monthly Cost Per Client, June 2011

State/Territory	June 2011 Clients Served	June 2011 Total Drug Expenditures	June 2011 Average Monthly Cost Per Client ¹
Alabama	1,534	\$1,449,251	\$945
Alaska	79	\$60,649	\$768
American Samoa	--	--	--
Arizona	1,114	\$812,675	\$730
Arkansas	389	--	--
California	26,586	\$40,300,136	\$1,516
Colorado	1,775	\$1,364,251	\$769
Connecticut	1,678	\$2,121,095	\$1,264
Delaware	677	\$221,681	\$327
District of Columbia	861	--	--
Federated States of Micronesia	--	--	--
Florida	8,396	\$6,904,709	\$822
Georgia	3,958	\$3,208,840	\$811
Guam	--	--	--
Hawaii	266	\$183,451	\$690
Idaho	123	\$321,098	\$2,611
Illinois	4,097	\$4,090,859	\$999
Indiana	1,885	\$351,264	\$186
Iowa	471	\$282,675	\$600
Kansas	778	\$1,134,184	\$1,458
Kentucky	1,424	\$963,154	\$676
Louisiana	1,938	\$1,522,832	\$786
Maine	285	\$70,530	\$247
Marshall Islands	--	--	--
Maryland	4,071	\$2,745,698	\$674
Massachusetts	4,285	\$646,073	\$151
Michigan	2,205	\$2,527,215	\$1,146
Minnesota	653	\$362,676	\$555
Mississippi	886	\$851,086	--
Missouri	1,727	\$2,061,144	\$1,193
Montana	92	\$92,203	\$1,002
Nebraska	377	\$301,241	\$799
Nevada	845	\$642,570	\$760
New Hampshire	177	\$152,431	\$861
New Jersey	6,086	\$7,833,884	\$1,287
New Mexico	623	\$13,837	\$22
New York	15,811	\$22,785,301	\$1,441
North Carolina	3,465	\$2,882,508	\$832
North Dakota	60	\$63,217	\$1,054
Northern Mariana Islands	--	--	--
Ohio	1,786	\$1,499,986	\$840
Oklahoma	1,035	\$782,473	\$756
Oregon ²	2,831	\$253,117	--
Pennsylvania	4,299	\$6,621,533	\$1,540
Puerto Rico	4,617	--	--
Republic of Palau	--	--	--
Rhode Island	524	\$582,412	\$1,111
South Carolina	2,455	\$1,132,211	\$461
South Dakota	95	\$85,324	\$898
Tennessee	2,886	\$1,786,758	\$619
Texas	10,959	\$8,607,353	\$785
Utah	405	\$323,095	\$798
Vermont	106	\$29,615	\$279
Virgin Islands (U.S.)	--	--	--
Virginia	1,992	\$1,801,490	\$904
Washington	3,115	\$488,088	\$157
West Virginia	318	\$323,350	\$1,017
Wisconsin	1,003	\$1,405,118	\$1,401
Wyoming	70	\$91,787	\$1,311
Total	138,173	\$135,138,130	\$869

¹ In ADAPs that purchase via a pharmacy network (rebate) model, average monthly cost per client does not include rebates on expenditures, which would reduce the cost paid for prescriptions and, therefore, the average cost per client.

² Oregon expenditure data changes dramatically when comparing June 2010 and June 2011 due to a change in purchasing mechanism, therefore no average cost per client has been calculated.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 21: ADAP Coverage of HIV Diagnostics, June 2011

State/Territory	CD4 Count Testing	Viral Load Testing	Resistance Testing	Tropism Testing	Other Laboratory Testing
Alabama	Yes	Yes	Yes	--	--
Alaska	--	--	--	Yes	--
American Samoa	--	--	--	--	--
Arizona	--	--	--	--	--
Arkansas	Yes	Yes	Yes	Yes	--
California	--	--	--	--	--
Colorado	--	--	--	--	--
Connecticut	--	--	--	--	--
Delaware	Yes	Yes	Yes	Yes	--
District of Columbia	--	--	--	--	--
Federated States of Micronesia	--	--	--	--	--
Florida	Yes	Yes	Yes	--	--
Georgia	--	--	--	--	--
Guam	--	--	--	--	--
Hawaii	Yes	Yes	Yes	--	Yes
Idaho	--	--	--	--	--
Illinois	--	--	--	--	--
Indiana	Yes	Yes	Yes	Yes	Yes
Iowa	--	--	--	Yes	--
Kansas	Yes	Yes	Yes	Yes	Yes
Kentucky	--	--	--	--	--
Louisiana	--	--	--	--	--
Maine	Yes	Yes	Yes	Yes	--
Marshall Islands	--	--	--	--	--
Maryland	--	--	--	--	--
Massachusetts	--	--	Yes	Yes	--
Michigan	Yes	Yes	Yes	--	--
Minnesota	--	--	Yes	Yes	--
Mississippi	--	--	--	--	--
Missouri	--	--	--	--	--
Montana ¹	--	--	--	--	--
Nebraska	--	--	--	--	--
Nevada	Yes	Yes	--	--	--
New Hampshire	--	--	--	--	--
New Jersey	--	--	--	--	--
New Mexico ²	--	--	--	--	--
New York	Yes	Yes	Yes	Yes	Yes
North Carolina	--	--	--	--	--
North Dakota	--	--	--	--	--
Northern Mariana Islands	--	--	--	--	--
Ohio	Yes	Yes	Yes	Yes	Yes
Oklahoma	--	--	--	--	--
Oregon	Yes	Yes	Yes	Yes	Yes
Pennsylvania	Yes	Yes	Yes	--	Yes
Puerto Rico	--	--	Yes	Yes	Yes
Republic of Palau	--	--	--	--	--
Rhode Island	--	--	--	--	--
South Carolina	--	--	--	--	--
South Dakota	--	--	--	--	--
Tennessee	--	--	--	--	--
Texas	--	--	--	--	--
Utah	--	--	--	--	--
Vermont	--	--	--	--	--
Virgin Islands (U.S.)	--	--	--	--	--
Virginia	--	--	--	--	--
Washington	Yes	Yes	Yes	Yes	Yes
West Virginia	--	--	--	--	--
Wisconsin	--	--	--	--	--
Wyoming	--	--	--	Yes	--
Total	15	15	17	15	9

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 22: ADAP Drug Purchasing, June 2011

State/Territory	Direct Purchase	Pharmacy Network (Rebate)	Hybrid	Dual	Participates in 340B Drug Discount Program	Participates in HRSA Prime Vendor Program	Dispensing Fee per Prescription
Alabama	Yes	--	--	--	Yes	Yes	\$7
Alaska	Yes	--	--	--	Yes	Yes	\$25
American Samoa	--	--	--	--	--	--	--
Arizona	--	--	--	Yes	Yes	--	\$10
Arkansas	Yes	--	--	--	Yes	Yes	\$7
California	--	Yes	--	--	Yes	--	\$4
Colorado	--	--	--	Yes	Yes	--	\$6
Connecticut	--	Yes	--	--	Yes	--	\$2
Delaware	--	--	Yes	--	Yes	--	\$5
District of Columbia	Yes	--	--	--	--	--	\$21
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	Yes	--	--	--	Yes	Yes	\$0
Georgia	Yes	--	--	--	Yes	Yes	\$12
Guam	--	--	--	--	--	--	--
Hawaii	--	--	--	Yes	Yes	--	\$13
Idaho	--	Yes	--	--	Yes	--	\$0
Illinois	--	--	--	Yes	Yes	--	\$13
Indiana	--	Yes	--	--	Yes	--	\$2
Iowa	--	--	--	Yes	Yes	--	\$13
Kansas	--	Yes	--	--	Yes	--	\$3
Kentucky	--	--	Yes	--	Yes	--	\$15
Louisiana	--	--	--	Yes	Yes	--	\$9
Maine	--	Yes	--	--	Yes	--	\$2
Marshall Islands	--	--	--	--	--	--	--
Maryland	--	Yes	--	--	Yes	--	\$3
Massachusetts	--	Yes	--	--	Yes	--	\$3
Michigan	--	Yes	--	--	Yes	--	\$2
Minnesota	--	Yes	--	--	Yes	--	\$3
Mississippi	--	--	--	Yes	Yes	Yes	\$0
Missouri	--	Yes	--	--	Yes	--	\$2
Montana	Yes	--	--	Yes	Yes	Yes	\$5
Nebraska	--	--	--	Yes	Yes	--	\$5
Nevada	--	--	Yes	--	Yes	--	\$14
New Hampshire	--	Yes	--	--	Yes	--	\$2
New Jersey	--	Yes	--	--	Yes	--	\$4
New Mexico	Yes	--	--	--	Yes	Yes	\$0
New York	--	Yes	--	--	Yes	--	\$3
North Carolina	--	--	--	Yes	Yes	--	\$14
North Dakota	--	Yes	--	--	Yes	--	\$5
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	Yes	Yes	--	--	Yes	Yes	\$13
Oklahoma	--	--	--	Yes	Yes	--	\$9
Oregon	--	--	Yes	--	Yes	--	\$20
Pennsylvania	--	Yes	--	--	Yes	--	\$4
Puerto Rico	--	--	--	Yes	Yes	--	\$3
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	--	Yes	--	--	Yes	--	\$0
South Carolina	--	--	--	Yes	Yes	--	\$13
South Dakota	--	Yes	--	--	--	--	\$0
Tennessee	--	--	--	Yes	Yes	--	\$13
Texas	--	--	--	Yes	Yes	--	\$0
Utah	--	--	Yes	--	Yes	--	\$11
Vermont	--	Yes	--	--	Yes	--	\$5
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	--	--	--	Yes	Yes	--	\$0
Washington	--	Yes	--	--	Yes	--	\$3
West Virginia	--	Yes	--	--	Yes	--	\$3
Wisconsin	--	Yes	--	--	Yes	--	\$5
Wyoming	--	Yes	--	--	Yes	--	\$5
Total	9	24	5	16	50	9	\$7

Direct Purchase states – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider.

Pharmacy Network (Rebate) states – These are ADAPs who pay retail pharmacies a pre-determined amount at the point of sale for drugs dispensed to ADAP clients. ADAP then bills drug manufacturers for the 340B Unit Rebate amount for the number of units dispensed.

Hybrid states – A direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs. The entity maintains a single drug inventory purchased at 340B prices. To secure the additional supplemental discounts negotiated by the ADAP Crisis Task Force, these ADAPs must submit rebate claims for any supplemental discount amounts.

Dual Purchaser – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider and bill drug manufacturers for the 340B Unit Rebate amount for the number of units dispensed for clients accessing an insurance plan (public or private).

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 23: ADAP Prescription Distribution, June 2011

State/Territory	Mail order delivered to client's home	Mail order delivered to client's clinic	Central pharmacy pick-up	Central pharmacy distribution	Client choice of pharmacy or mail order	Designated ADAP pharmacy(ies) for pick-up	Other
Alabama	--	--	--	Yes	--	--	--
Alaska	Yes	Yes	--	--	Yes	Yes	--
American Samoa	--	--	--	--	--	--	--
Arizona	Yes	Yes	Yes	--	--	Yes	--
Arkansas	Yes	Yes	Yes	Yes	--	Yes	--
California	Yes	--	--	--	--	Yes	--
Colorado	Yes	Yes	--	--	Yes	Yes	Yes
Connecticut	--	--	--	--	Yes	--	Yes
Delaware	Yes	--	Yes	--	Yes	--	--
District of Columbia	--	--	--	--	--	Yes	--
Federated States of Micronesia	--	--	--	--	--	--	--
Florida	--	--	--	Yes	--	--	--
Georgia	--	--	--	--	--	Yes	Yes
Guam	--	--	--	--	--	--	--
Hawaii	Yes	Yes	Yes	--	--	--	--
Idaho	--	Yes	--	--	--	--	--
Illinois	Yes	Yes	--	Yes	--	--	--
Indiana	--	--	--	--	Yes	--	--
Iowa	Yes	Yes	Yes	--	--	--	--
Kansas	--	--	--	--	--	--	Yes
Kentucky	Yes	Yes	--	Yes	Yes	Yes	--
Louisiana	--	--	--	--	--	Yes	--
Maine	--	--	--	--	Yes	--	--
Marshall Islands	--	--	--	--	--	--	--
Maryland	--	--	--	--	--	--	Yes
Massachusetts	--	--	--	--	Yes	--	--
Michigan	--	--	--	--	Yes	Yes	--
Minnesota	--	--	--	--	Yes	--	--
Mississippi	--	--	--	--	--	--	Yes
Missouri	--	--	--	--	Yes	--	--
Montana	Yes	Yes	Yes	Yes	--	Yes	--
Nebraska	Yes	--	Yes	Yes	--	--	Yes
Nevada	--	--	--	--	--	Yes	--
New Hampshire	Yes	--	--	--	Yes	--	--
New Jersey	--	--	--	--	Yes	--	Yes
New Mexico	Yes	Yes	--	--	--	--	Yes
New York	--	--	--	--	--	Yes	Yes
North Carolina	Yes	Yes	Yes	Yes	Yes	Yes	--
North Dakota	--	--	--	--	Yes	--	--
Northern Mariana Islands	--	--	--	--	--	--	--
Ohio	Yes	Yes	--	--	--	--	--
Oklahoma	Yes	Yes	--	--	--	Yes	--
Oregon	Yes	--	--	--	--	Yes	Yes
Pennsylvania	--	--	--	--	--	--	Yes
Puerto Rico	--	--	--	Yes	--	--	--
Republic of Palau	--	--	--	--	--	--	--
Rhode Island	Yes	--	--	--	Yes	--	Yes
South Carolina	Yes	--	--	--	--	--	--
South Dakota	--	--	--	--	Yes	--	--
Tennessee	Yes	Yes	Yes	--	Yes	--	--
Texas	--	--	--	Yes	--	Yes	--
Utah	Yes	--	--	--	--	Yes	--
Vermont	--	--	--	--	Yes	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--
Virginia	--	--	--	Yes	--	Yes	Yes
Washington	--	--	--	--	Yes	--	--
West Virginia	--	--	--	--	Yes	--	--
Wisconsin	--	--	--	--	Yes	--	--
Wyoming	--	--	--	--	Yes	--	--
Total	22	15	9	11	23	19	14

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 24: Federal ADAP Funds Used and Clients Served Through Insurance Purchasing and Continuation, 2011

State/Territory	FY2011 Est. Expenditures	June 2011 Expenditures	June 2011 Clients Served
Alabama	\$300,000	\$53,885	70
Alaska	\$160,650	\$37,839	42
American Samoa	--	--	--
Arizona	\$2,800,000	\$186,926	440
Arkansas	\$500,000	\$48,428	73
California	\$49,000,000	\$1,429,166	8,779
Colorado	\$3,063,020	\$296,653	698
Connecticut	\$1,302,000	\$27,261	314
Delaware	\$108,086	\$8,319	23
District of Columbia	\$715,000	\$64,213	274
Federated States of Micronesia	--	--	--
Florida	\$8,666,282	\$208,333	316
Georgia	\$0	\$0	0
Guam	--	--	--
Hawaii	\$510,000	\$25,703	82
Idaho	\$0	\$0	--
Illinois	\$890,784	\$74,232	427
Indiana	\$9,345,901	\$544,642	1,800
Iowa	\$500,000	\$46,084	168
Kansas	--	\$276,566	368
Kentucky	--	--	--
Louisiana	\$1,236,518	\$130,997	473
Maine	\$196,729	\$18,978	47
Marshall Islands	--	--	--
Maryland	\$11,828,636	\$1,213,900	2,765
Massachusetts	\$15,951,259	\$1,206,726	4,074
Michigan	\$5,000,000	\$407,458	1,039
Minnesota	\$2,768,048	\$405,284	187
Mississippi	\$0	\$0	0
Missouri	\$2,900,000	\$226,352	604
Montana	\$101,840	\$6,137	16
Nebraska	\$200,000	\$18,952	90
Nevada	\$5,194	\$5,193	252
New Hampshire	\$394,669	\$68,249	61
New Jersey	\$6,020,000	\$250,108	94
New Mexico	\$260,000	\$243,676	608
New York	\$36,000,000	\$2,933,483	3,378
North Carolina	\$2,500,000	\$178,898	468
North Dakota	\$0	\$0	0
Northern Mariana Islands	--	--	--
Ohio	\$2,000,000	\$310,462	599
Oklahoma	\$1,604,040	\$149,509	492
Oregon	\$8,100,000	\$595,505	2,688
Pennsylvania	\$47,450,480	\$3,941,680	1,986
Puerto Rico	\$250,000	\$58,078	0
Republic of Palau	--	--	--
Rhode Island	\$0	\$0	0
South Carolina	\$2,000,000	\$230,678	720
South Dakota	\$0	\$0	0
Tennessee	\$7,500,000	\$639,807	1,193
Texas	\$6,000,000	\$243,837	1,352
Utah	\$500,000	\$75,392	106
Vermont	\$278,105	\$13,156	96
Virgin Islands (U.S.)	--	--	--
Virginia	\$804,540	\$49,003	156
Washington	\$23,649,566	\$4,728,566	2,939
West Virginia	\$589,000	\$52,353	122
Wisconsin	\$4,365,991	\$888,099	594
Wyoming	\$40,000	\$4,365	22
Total	\$268,356,338	\$22,623,131	41,095

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 25: ADAP Client Eligibility Requirements, as of June 30, 2011

State/Territory	Financial Eligibility as % of FPL ¹	Medical Eligibility ²	Asset Limits	State Residency Requirement	Other Requirement
Alabama	250% GR	--	--	Yes (Proof required)	--
Alaska	300% GR	--	--	Yes (Must be a resident for 30 days with intent to stay)	--
American Samoa	--	--	--	--	--
Arizona	300% GR	--	--	Yes (Proof required)	--
Arkansas	200% GR	CD4<500 and proof of medication adherence from clinician	--	Yes (Proof required)	--
California	400% GR	--	--	Yes (Proof required)	--
Colorado	400% GR	--	--	Yes (Proof required)	--
Connecticut	400% NET	--	--	Yes (Proof required)	--
Delaware	500% GR	--	\$10,000	Yes (Proof required)	--
District of Columbia	500% GR	--	--	Yes (Proof required)	--
Federated States of Micronesia	--	--	--	--	--
Florida	300% GR	--	--	Yes (Proof required)	--
Georgia	300% GR	CD4<500	\$10,000	Yes (Proof required)	--
Guam	200% NET	--	--	--	--
Hawaii	400% GR	--	--	Yes (Proof required)	Must be enrolled in case management services.
Idaho	200% GR	--	--	Yes (Proof required)	--
Illinois	300% GR	--	--	Yes (Proof required)	--
Indiana	300% GR	--	--	Yes (Proof required)	Must be enrolled in case management services.
Iowa	200% GR	--	\$10,000, not including major residence, household furnishings, and one vehicle	Yes (Proof required)	--
Kansas	300% GR	--	--	Yes (Proof required)	--
Kentucky	300% GR	CD4<250	\$10,000	Yes (Proof required)	Must be enrolled in case management services.
Louisiana	300% GR	--	\$4,000, not including one house and one vehicle	Yes (Proof required)	--
Maine	500% GR	--	--	Yes (Proof required)	--
Marshall Islands	--	--	--	--	--
Maryland	500% GR	--	--	Yes (Proof required)	--
Massachusetts	500% GR	--	--	Yes (Proof required)	--
Michigan	450% GR	--	--	Yes (Proof required)	--
Minnesota	300% GR	--	\$25,000	Yes (Proof required)	--
Mississippi	400% GR	CD4<350	--	Yes (Proof required)	--
Missouri	300% GR	--	--	Yes (Proof required)	Must be enrolled in case management services.
Montana	330% GR	--	--	Yes (Proof required)	--
Nebraska	200% GR	--	--	Yes (Proof required)	--
Nevada	400% GR	--	\$4,000	Yes (Proof required)	--
New Hampshire	300% GR	CD4<500	--	Yes (Proof required)	--
New Jersey	500% GR	--	--	Yes (Must be a resident for 30 days)	--
New Mexico	400% GR	--	\$9,999	Yes (Proof required)	--
New York	406% GR	--	\$25,000, not including federally recognized retirement accounts	Yes (Proof required)	--
North Carolina	300% GR	--	--	Yes (Proof required)	--
North Dakota	300% NET	--	--	Yes (Proof required)	--
Northern Mariana Islands	--	--	--	--	--
Ohio	300% GR	--	--	Yes (Proof required)	--
Oklahoma	200% GR	--	--	Yes (Proof required)	--
Oregon	200% GR	--	\$10,000, not including one vehicle and one house	Yes (Proof required)	--
Pennsylvania	337% GR	--	--	Yes (Proof required)	--
Puerto Rico	200% NET	--	--	Yes (Must be a resident for 60 days)	--
Republic of Palau	--	--	--	--	--
Rhode Island	400% GR	--	--	Yes (Proof required)	--
South Carolina	300% GR	--	--	Yes (Proof required)	--
South Dakota	300% GR	--	--	Yes (Proof required)	--
Tennessee	300% GR	--	\$8,000	Yes (Proof required)	--
Texas	200% GR	--	--	Yes (Proof required)	--
Utah	250% GR	--	\$5,000, not including one vehicle and one house	Yes (Proof required)	--
Vermont	200% NET	--	--	--	--
Virgin Islands (U.S.)	400% GR	CD4<350	--	Yes (Proof required)	--
Virginia	400% GR	--	--	Yes (Proof required)	--
Washington	300% GR	--	\$10,000	Yes (Proof required)	--
West Virginia	325% GR	--	--	Yes (Proof required)	--
Wisconsin	300% GR	--	--	Yes (Proof required)	--
Wyoming	332% GR	--	--	Yes (Proof required)	--
Total		6	13	52	4

¹The 2011 Federal Poverty Level (FPL) was \$10,830 (slightly higher in Alaska and Hawaii) for a household of one. GR=Gross income; NET=Net income.

²CD4=CD4 cell count; VL = Viral load.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 26: ADAP Client Enrollment Processes, as of June 30, 2011

State/Territory	Intake at Local ASOs, CBOs, and Local Health Department ¹	Intake at ADAP Office	Intake at Private Clinical Settings	Online Application	Application Over the Phone	Mailed Application	Enrollment via Other State Programs	Other Enrollment Processes
Alabama	--	--	Yes	--	--	Yes	--	Yes
Alaska	--	Yes	--	--	Yes	Yes	--	Yes
American Samoa	--	--	--	--	--	--	--	--
Arizona	--	--	--	--	--	Yes	--	--
Arkansas	--	--	Yes	--	--	--	--	--
California	Yes	--	--	--	--	--	--	--
Colorado	Yes	Yes	Yes	--	--	Yes	--	--
Connecticut	--	--	--	--	--	Yes	--	--
Delaware	Yes	--	--	--	--	--	--	--
District of Columbia	Yes	Yes	--	--	--	--	--	Yes
Federated States of Micronesia	--	--	--	--	--	--	--	--
Florida	Yes	Yes	--	--	--	--	--	--
Georgia	Yes	--	--	--	--	--	--	--
Guam	--	--	--	--	--	--	--	--
Hawaii	Yes	--	--	--	--	--	--	--
Idaho	Yes	--	--	--	--	--	--	--
Illinois	--	Yes	--	--	--	--	--	--
Indiana	Yes	--	--	--	--	--	--	--
Iowa	Yes	--	--	--	--	--	--	--
Kansas	Yes	--	--	--	--	--	--	--
Kentucky	Yes	--	Yes	Yes	Yes	Yes	--	--
Louisiana	Yes	Yes	Yes	--	--	Yes	--	--
Maine	Yes	--	Yes	--	--	Yes	--	--
Marshall Islands	--	--	--	--	--	--	--	--
Maryland	Yes	Yes	Yes	--	--	Yes	--	Yes
Massachusetts	Yes	Yes	Yes	--	--	Yes	--	Yes
Michigan	Yes	Yes	Yes	--	--	Yes	--	--
Minnesota	--	Yes	--	--	--	Yes	--	--
Mississippi	--	--	Yes	--	--	--	--	Yes
Missouri	Yes	--	--	--	--	--	--	--
Montana	Yes	--	--	--	--	Yes	--	--
Nebraska	Yes	Yes	Yes	--	--	Yes	--	--
Nevada	--	--	--	--	--	--	--	Yes
New Hampshire	Yes	--	Yes	--	--	Yes	--	--
New Jersey	Yes	Yes	Yes	--	--	Yes	--	--
New Mexico	--	--	--	--	--	--	--	Yes
New York	--	--	--	--	--	Yes	--	Yes
North Carolina	Yes	--	Yes	--	--	Yes	--	--
North Dakota	--	--	--	--	--	--	--	Yes
Northern Mariana Islands	--	--	--	--	--	--	--	--
Ohio	Yes	--	Yes	--	--	Yes	--	--
Oklahoma	--	--	--	--	--	--	--	Yes
Oregon	--	Yes	--	--	--	Yes	--	--
Pennsylvania	--	--	--	--	--	Yes	--	--
Puerto Rico	Yes	--	--	--	--	--	--	--
Republic of Palau	--	--	--	--	--	--	--	--
Rhode Island	--	Yes	Yes	--	--	Yes	--	--
South Carolina	--	--	--	--	--	Yes	--	Yes
South Dakota	--	Yes	Yes	--	--	Yes	Yes	Yes
Tennessee	Yes	--	--	--	--	--	--	--
Texas	--	--	--	--	--	Yes	--	Yes
Utah	Yes	Yes	--	--	--	Yes	--	--
Vermont	Yes	Yes	Yes	--	--	Yes	--	--
Virgin Islands (U.S.)	--	--	--	--	--	--	--	--
Virginia	Yes	--	--	Yes	Yes	Yes	--	Yes
Washington	--	--	--	--	--	Yes	--	Yes
West Virginia	Yes	Yes	Yes	--	Yes	Yes	--	--
Wisconsin	Yes	Yes	Yes	--	--	Yes	--	--
Wyoming	Yes	Yes	--	--	--	--	--	--
Total	32	20	20	2	4	31	1	16

¹ ASOs=AIDS Service Organizations; CBOs=Community-Based Organizations.

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 data, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 27: ADAP Management Poli

State/Territory	Client Cost-Sharing	Overall Program Enrollment Cap	Drug Specific Enrollment Cap	Maximum Cost Per Client
Alabama	--	Yes (1,900)		
Alaska	--			
American Samoa				
Arizona	--			
Arkansas	--			
California	Yes			
Colorado				
Connecticut	--			
Delaware	Yes			
District of Columbia				
Federated States of Micronesia				
Florida	--			
Georgia			Yes (Fuzeon)	
Guam				
Hawaii	--			
Idaho	--	Yes (125)	Yes (Fuzeon)	
Illinois	--		Yes (Fuzeon and Valcyte)	Yes (\$2,000 per month)
Indiana	--	Yes (1,960)		
Iowa	--			
Kansas				
Kentucky	Yes			
Louisiana	--	Yes (3,281)		
Maine	--			
Marshall Islands				
Maryland				
Massachusetts	--			
Michigan	--			
Minnesota	--			
Mississippi				
Missouri	--			
Montana	--			
Nebraska	--			
Nevada	--			
New Hampshire	--			
New Jersey	--			
New Mexico	--			
New York	--			
North Carolina	--			
North Dakota	--		Yes (Fuzeon)	
Northern Mariana Islands				
Ohio	--			
Oklahoma	--			
Oregon	Yes			
Pennsylvania	--			
Puerto Rico	--			
Republic of Palau				
Rhode Island	--			
South Carolina	--			
South Dakota	--			
Tennessee	--			
Texas	--			
Utah	--			
Vermont	--			
Virgin Islands (U.S.)				
Virginia	--			
Washington	Yes		Yes (Fuzeon)	
West Virginia				
Wisconsin	--			
Wyoming	--	Yes (125)	--	
Total	5	5	5	1

Step therapy - The practice of beginning drug therapy for a medical condition with the most cost-effective and safest drug therapy and progressing to other more costly or risky therapy, on

Note: 52 ADAPs reported data. American Samoa, Federated States of Micronesia, Guam, Northern Mariana Islands, Republic of Palau, and the U.S. Virgin Islands did not report FY2011 dat

cies in Place, as of June 30, 2011

Maximum Number of Prescriptions Per Client Per Month	Drug(s) with Prior Authorization	Drug(s) with Clinical Criteria	Drug(s) with Required Resistance Testing	Other ADAP Program Practices/Restrictions
	Fuzeon, Procrit, Selzentry	Procrit, Fuzeon, Selzentry	Procrit	
	Fuzeon, Pedinterferon Alfa, Ribavirin, Valcyte	Aptivus and Mepron		
	Crestor, Fuzeon, Nexum, Noxafil, Prevacid, Selzentry, Tricor, Vfend, Zetia			
	Fuzeon, Methadone, Selzentry, Somatropin, Sporanox	Bupropion, Capreomycin, Caspofungin, Cycloserine, Dextroamphetamine, Ethionamide, Fentanyl patch, Imipenem/Cilastatin, Itraconazole, Lansoprazole, Linezolid, Methadone, Methylphenidate, Moxifloxacin, Nadralone, Omeprazole, Paclitaxel, Para-aminosalicylate, Selzentry, Somatropin, Testosterone, Valacyclovir, Valganciclovir, Voriconazole		
	Serostim	Serostim		
	Somatropin, Subutex, Suboxone	Somatropin, Subutex, Suboxone		
	Fuzeon and Selzentry		Fuzeon	
Yes (4 antiretrovirals)			Selzentry	
	Fuzeon, Pegasys, PEG-Intron, Ribavirin	Baraclude		
	Fuzeon		Selzentry	
Yes (5 antiretrovirals plus a reduced dose of Norvir per month)	Fuzeon, Mepron, Valcyte		Fuzeon	
	Fuzeon			
	Fuzeon		Selzentry	
	Aptivus, Fuzeon, Intelence			
			Selzentry	
	Copegus, Epogen, Neupogen, Pegasys, PEG-Intron, Procrit, Oxandrin, Rebetol			
	Actos, Avandia, Epogen, Fentanyl, Neupogen, Oxycontin	Selzentry		
			Selzentry	
	Aptivus, Amphotercin, Epogen, Fuzeon, Intelence, Neurontin, Selzentry, Testosterone, Vfend	Aptivus and Fuzeon	Aptivus and Selzentry	Step therapy
	Fuzeon, Isentress, Selzentry		Selzentry	
	Edurant		All second line antiretrovirals	
	Amikin, Diflucan, Epogen, Famvir, Ganciclovir, Megace, Mepron, Neupogen, Sporanox, Valcyte, Vfend			
	Aptivus, Atonaquone, Epotin Alpha, Filgrastin, Fuzeon, Immune Globulin Rho, Opreluekin, Sargramostim, Selzentry	Aptivus, Atonaquone, Epotin Alpha, Filgrastin, Fuzeon, Immune Globulin Rho, Opreluekin, Sargramostim, Selzentry		
	Selzentry			
	Fuzeon and Selzentry	Fuzeon	Selzentry	
			Selzentry	
	Copegus, Fuzeon, PEG-Intron, Rebetol, Selzentry			
	Epizcom, Trizivir, Ziagen			
			Selzentry	
Yes (4 antiretrovirals per month)			Selzentry	
	Foscavir, Fuzeon, Neupogen, Selzentry, Valcyte, Vistide		Selzentry	
	Aptivus, Dapsone, Fuzeon, Intelence, Prednisone, Selzentry, Voriconazole			
	Foscavir and Fuzeon		Selzentry	
	Imiquimod, Isentress, Lyrica			Step therapy
3	28	10	17	2

ily if necessary. The aims are to control costs and minimize risks. Also called step protocol. Step therapy does not apply to antiretrovirals

sa, but their federal ADAP earmark and ADAP supplemental awards were known and incorporated. Marshall Islands did not receive a federal ADAP earmark award in FY2011.

Table 28: HIV/AIDS Antiretroviral and Opportunistic Infection Medications

FDA-Approved Antiretroviral Medications	
GENERIC NAME	BRAND NAME
Multi-Class Combination Products	
efavirenz, emtricitabine, and tenofovir disoproxil fumarate	Atripla
rilpivirine, emtricitabine, and tenofovir disoproxil fumarate	Complera
NRTIs	
abacavir sulfate, ABC	Ziagen
abacavir, zidovudine, and lamivudine	Trizivir
abacavir and lamivudine	Epzicom
didanosine, dideoxyinosine, ddI	Videx
emtricitabine, FTC	Emtriva
lamivudine and zidovudine	Combivir
lamivudine, 3TC	Epivir
stavudine, d4T	Zerit
tenofovir, disoproxil fumarate, TDF	Viread
tenofovir disoproxil fumarate and emtricitabine	Truvada
zalcitabine, dideoxycytidine, ddC	Hivid ¹
zidovudine, azidothymidine, AZT, ZDV	Retrovir
NNRTIs	
delavirdine, DLV	Rescriptor
efavirenz, EFV	Sustiva
etravirine	Intelence
nevirapine, NVP	Viramune
rilpivirine	Edurant
Protease Inhibitors	
amprenavir, APV	Agenerase ²
atazanavir sulfate, ATV	Reyataz
darunavir	Prezista
fosamprenavir calcium, FOS-APV	Lexiva
indinavir, IDV	Crixivan
lopinavir and ritonavir, LPV/RTV	Kaletra
nelfinavir mesylate, NFV	Viracept
ritonavir, RTV	Norvir
saquinavir	Fortovase ³
saquinavir mesylate, SQV	Invirase
tipranavir, TPV	Aptivus
Fusion Inhibitors	
enfuvirtide, T-20	Fuzeon
Entry Inhibitors - CCR5 Co-Receptor Antagonist	
maraviroc	Selzentry
HIV Integrase Strand Transfer Inhibitors	
raltegravir	Isentress

¹ The sale and distribution of Hivid (zalcitabine, dideoxycytidine, ddC) was discontinued as of December 2006.

² The manufacturer of Agenerase (amprenavir) discontinued the sale and distribution of the drug in capsule form, used for adult dosing, after 2004 and is instead manufacturing fosamprenavir (Lexiva), a "prodrug" of Agenerase (a prodrug is an inactive precursor of a drug, converted into its active form in the body). Agenerase is still available in pediatric dosing.

³ Fortovase (saquinavir soft-gel) is no longer marketed.

Source: FDA, "Drugs Used in the Treatment of HIV Infection": <http://www.fda.gov/oashi/aids/virals.html>. Also see: DHHS, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," November 24, 2008: <http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1>.

"A1" Medications for the Prevention & Treatment of Opportunistic Infections (Highly Recommended) ¹	
GENERIC NAME	BRAND NAME
acyclovir	Zovirax
amphotericin B	Fungizone
azithromycin	Zithromax
cidofovir	Vistide
clarithromycin	Biaxin
clindamycin	Cleocin
ethambutol	--
famciclovir	Famvir
fluconazole	Diflucan
flucytosine	Ancobon
foscarnet	Foscavir
ganciclovir	Cytovene
isoniazid (INH)	Lanizid, Nydravid
itraconazole	Sporonox
leucovorin calcium	Wellcovorin
liposomal amphotericin B	--
peg-interferon alfa-2a	PEG-Intron
peg-interferon alfa-2b	--
pentamidine	Nebupent
prednisone	Deltasone, Liquid Pred, Metocorten, Orasone, Panasol, Prednicen-M, Sterapred
probenecid	--
pyrazinamide (PZA)	--
pyrimethamine	Daraprim, Fansidar
ribavirin	Virazole, Rebetol, Copegus
rifabutin	Mycobutin
rifampin (RIF)	Rifadin, Rimactane
sulfadiazine (oral generic)	Microsulfon
trimethoprim- sulfamethoxazole (TMP/SMX)	Bactrim, Septra
valacyclovir	Valtrex
valganciclovir	Valcyte

¹ "A" = "should always be offered"; "1" = "evidence from at least one properly randomized, controlled trial"

Sources: CDC, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." *MMWR*, 51 (No. RR08), 1-46; 2002; CDC, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." *MMWR*, 53 (No. RR15), 1-112; 2004. Also see: DHHS, "Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents," November 24, 2008:

<http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=211&ClassID=4>.

GLOSSARY

340B Drug Discount Program – The federal 340B Drug Discount Program, authorized under the Veterans Health Care Act of 1992, enables ADAPs to purchase drugs at or below the statutorily defined 340B ceiling price.

AIDS Drug Assistance Program (ADAP) - A state administered program authorized under Part B (formerly Title II) of the Title XXVI of the Public Health Service Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009 (Ryan White Program) that provides Food and Drug Administration (FDA) approved medications to low-income individuals with HIV disease who have limited or no coverage from private insurance or Medicaid. ADAPs may also purchase insurance and provide adherence monitoring and outreach under the flexibility policy.

ADAP Crisis Task Force – A group of state ADAP and AIDS directors, convened by NASTAD, that negotiates with the manufacturers of HIV antiretrovirals and other high-cost medications to secure supplemental discounts/rebates benefitting all ADAPs.

ADAP Earmark - The amount of federal Ryan White Program, Part B dollars specifically designated by Congress through the annual appropriations process to ADAP for the federal fiscal year.

ADAP Supplemental Drug Treatment Grant – ADAP Supplemental grants are used for the purchase of medications by states and territories with demonstrated severe need to increase access to HIV/AIDS related medications. These grants must be used to expand ADAP formularies, target resources to reflect the changes in the epidemic, and enhance the ADAP's ability to remove eligibility restrictions. States must meet HRSA eligibility criteria in order to apply for ADAP Supplemental funds. The overall supplemental amount is mandated by law to be five percent of the congressionally appropriated ADAP earmark.

Back-billing – In some instances, ADAP covers an individual's prescription costs but later determines there is another payer source, for example, state Medicaid. Once it is certain that another payer should have covered a client's previous claims, the ADAP can request reimbursement for expenditures previously incurred or "back bill." Another scenario for back billing is when individuals apply and are eligible for Medicaid. Their eligibility coverage dates back three months PRIOR to the application date. ADAP covers the individual while they wait for their Medicaid eligibility determination and then "back-bills" Medicaid for any drugs or services they paid for during the interim wait time (see also pay and chase).

Co-payment - Some ADAPs pay the co-payments for ADAP formulary drugs, which can be a cost-effective way to help clients access medications through existing insurance coverage. In those states where ADAPs largely use their funding to purchase or maintain health insurance coverage, co-payments accounted for a much greater share of expenditures. Co-payments are a set amount an individual must pay upon receiving medical services or prescriptions. For example, there may be a \$10 co-payment required each time a prescription is purchased at a retail pharmacy.

Cost-recovery - Reimbursement from third party entities such as private insurers and Medicaid.

Cost-sharing – The payment of a premium or fee by an enrolled ADAP client to the ADAP as a portion of the cost for medications and/or services received.

Deductible - The amount a health insurance beneficiary must pay before a third party payer begins to provide coverage for health services. Amounts can change from year to year. Some ADAPs pay this cost for eligible clients.

Direct Purchase States – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider.

Dual Eligible – Individuals who are eligible for both Medicare and Medicaid.

Dual Purchaser – ADAPs using this model centrally purchase and dispense medications through their own pharmacy or a single contract pharmacy services provider and also bill drug manufacturers for the 340B Unit Rebate Amount for the number of units dispensed for clients accessing an insurance plan (public or private).

Formulary - ADAP drug list that establishes the number of drugs available within a therapeutic class for purposes of drug purchasing, dispensing and/or reimbursement. Effective July 1, 2007, all ADAPs were required to include at least one drug from each antiretroviral drug class. The minimum formulary requirement does not apply to multi-class combination products (not considered a unique class of drugs), drugs for preventing and treating opportunistic infections (OIs), hepatitis C treatments, or drugs for other HIV-related conditions (e.g., depression, hypertension, and diabetes).

- **Closed/restricted formulary** – allows only those drug products listed to be dispensed or reimbursed.
- **Open formulary** – covers all FDA-approved drugs prescribed by a physician with no restrictions or with restrictions such as higher patient cost-sharing requirements for certain drugs.
- **Tiered formulary** – also referred to as “step therapy” and is a cost containment measure that categorizes medications for a particular condition based upon their cost. For example, a tier one medication would be one that is lowest cost and recommended to be used first, unless there are medical restrictions for doing so. Tier two would be a different medication that is prescribed for the same condition as the tier one drug but is more expensive. Step therapy or tiered formularies are most commonly used by ADAPs with medications prescribed for depression, respiratory problems and opportunistic infections.

Hybrid states – A direct purchase state that utilizes an existing entity (e.g., University Hospital) to purchase and distribute ADAP drugs. The entity maintains a single drug inventory purchased at 340B prices. To secure the additional supplemental discounts negotiated by the ADAP Crisis Task Force, these ADAPs must submit rebate claims for any supplemental discount amounts.

Insurance Continuation - The payment of all or some combination of insurance premiums, co-pays, or deductibles for clients who have existing insurance policies through their current employment, Consolidated Omnibus Budget Reconciliation Act (COBRA) or other supplemental programs. HRSA allows ADAP funds to be used for insurance continuation with certain restrictions.

Insurance Purchasing - The purchase of new insurance policies through the insurance industry market, state high risk insurance pools or Pre-existing Condition Insurance Plans (PCIPs).

Part A funding - Provided to metropolitan jurisdictions, some of whom make local decisions to allocate funds to ADAPs.

Part B “base” - Formula-based funding to states (other than that earmarked for ADAP); some states choose to allocate some of this funding to ADAPs, but are not required to do so.

Part B supplemental funding – Funding to states with “unmet need;” some states choose to allocate some of this funding to ADAPs, but are not required to do so.

Patient Assistance Programs (PAPs) - Programs through which many pharmaceutical manufacturers provide free or greatly subsidized medications to indigent patients. To see information on pharmaceutical company co-payment assistance and patient assistance programs, please visit the Positively Aware [website](#) or the Fair Pricing Coalition's [website](#).

Rebate states – ADAPs who pay retail pharmacies a pre-determined amount at the point of sale for drugs dispensed to ADAP clients. ADAP then bills drug manufacturers for the 340B Unit Rebate Amount for the number of units dispensed.

The Ryan White HIV/AIDS Treatment Modernization Act of 2009 - The Ryan White CARE Act, "Title XXVI of the PHS Act as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2009", or "Ryan White Program" is the single largest federal program designed specifically for people with HIV/AIDS. First enacted in 1990, it provides care and treatment to individuals and families affected by HIV/AIDS. The Ryan White Program has five parts - **Part A** (formerly Title I) funds eligible metropolitan areas and transitional grant areas, 75% of grant funds must be spent for core services; **Part B** (formerly Title II) funds States/Territories, 75% must be spent for core services; **Part C** (formerly Title III) funds early intervention services, 75% must be spent for core services; **Part D** (formerly Title IV) grants support services for women, infants, children and youth and **Part F** comprises Special Projects of National Significance, AIDS Education & Training Centers (AETCs), Dental Programs and the Minority AIDS Initiative.

State funding - General revenue support from state budgets. States are not required to provide funding to their ADAPs (except in limited cases of matching requirements), although many have historically done so either over a sustained period of time or at critical junctures to address gaps in funding. Such funding is, for the most part, dependent on individual state decisions and budgets; even where states are required to provide a match of federal Part B Ryan White funds, they are not required to put this funding toward ADAP. The only exception to this is the ADAP supplemental, where states must provide a 1:4 match (or seek a waiver of the requirement, if eligible to do so).

True Out of Pocket Expenditures (TrOOP) – This is the amount of money that a Medicare Part D enrolled client will have to pay from their own money to reach the "catastrophic limit" making Part D the primary payer for medications. Payments for drugs, co-payments, and coinsurance made by the beneficiary, friends, family members, State Pharmacy Assistance Programs, charities and the Medicare low-income subsidy (LIS) count towards TrOOP costs. Payments for premiums, drugs not on plan formularies, costs incurred by the ADAP and payments by other types of insurance are not counted as TrOOP costs.